BSE Healthcare

Up
35095.19
-223.00 (-0.63%)
15:16 Feb 29
38.80

RSI

RSI is mid-range

51.20

MFI

MFI is mid-range

1.0

Beta 1Year

Average volatility

16

50Day SMA Rs

Price below SMA-50

16.8

200Day SMA Rs

Price below SMA-200

29 Feb-2024
  • 29-Feb-2024 14:37:17

    BIOCON: RS 136.99CR BSE BLOCK TRADE; FOR ~5059601 SHARES, AT RS 270.75

    BIOCON, 276.45 1.99
  • 29-Feb-2024 10:17:10

    RAINBOW CHILDRENS MEDICARE LTD: Rs. 29.05 Crores NSE Block Trade; for ~ 206150 Shares, at Rs. 1409.40

    RAINBOW, 1,352.60 -5.36
  • 29-Feb-2024 07:10:21

    DR. REDDYS LAB: COS MEXICO UNIT RECEIVES TAX LITIGATION ORDER FROM MEXICAN FEDERAL COURT

    DRREDDY, 6,425.55 -0.04
28 Feb-2024
  • 28-Feb-2024 17:09:08

    ADVANCED ENZYME TECHNOLOGIES: CO SAYS COURT GRANTED UNIT ADVANCED SUPPLEMENTARY TECHNOLOGIES CLAIMS AGAINST WORLD NUTRITION -- COURT ALSO GRANTED WNIS CLAIMS AGAINST UNIT FOR JUDGMENT OF $3.2M

    ADVENZYMES, 385.95 0.39
  • 28-Feb-2024 15:13:49

    ALKEM LAB: CLOSURE OF US FDA INSPECTION AT CO’S API MANUFACTURING FACILITY LOCATED AT MANDVA -- THE INSPECTION HAS BEEN CLASSIFIED AS VAI

    ALKEM, 5,138.55 2.97
  • 28-Feb-2024 12:46:21

    BAJAJ HEALTHCARE: CO WILL UNDERTAKE DEVELOPMENT, SUPPLY OF THESE API MOLECULES, EXCLUSIVELY TO BE MANUFACTURED FOR ITS CLIENTELE

    BAJAJHCARE, 334.95 -6.48
  • 28-Feb-2024 12:44:26

    BAJAJ HEALTHCARE: CO ENTERING INTO DEFINITIVE CDMO AGREEMENT FOR 15 APIS WITH UK/EU CUSTOMERS

    BAJAJHCARE, 334.95 -6.48
  • 28-Feb-2024 12:33:31

    ASTER DM HEALTHCARE: CO UNIT ACQUIRED 20.40% STAKE IN AASRAYA HEALTHCARE LLP

    ASTERDM, 471.55 -2.74
27 Feb-2024
  • 27-Feb-2024 16:27:00

    GLAND PHARMA: CO HAS INFORMED THE EXCHANGE REGARDING APPOINTMENT OF PRESIDENT FOR PHIXEN S.A.S. (CENEXI); THE WHOLLY-OWNED STEP-DOWN SUBSIDIARY OF CO

    GLAND, 1,764.45 -2.07
  • 27-Feb-2024 15:14:15

    PIRAMAL PHARMA LTD: Rs. 27.28 Crores NSE Block Trade; for ~ 2007109 Shares, at Rs. 135.90

    PPLPHARMA, 131.75 1.19
  • 27-Feb-2024 10:58:51

    MAX HEALTHCARE INSTITUTE LTD: RS. 93.34 CRORES NSE BLOCK TRADE; FOR ~ 1124479 SHARES, AT RS. 830.05

    MAXHEALTH, 791.15 -7.09
  • 27-Feb-2024 09:00:30

    SUNPHARMA: RS 102.18CR BSE BLOCK TRADE; FOR ~656286 SHARES, AT RS 1556.94 (PRE-OPEN BLOCK)

    SUNPHARMA, 1,579.75 0.37
26 Feb-2024
  • 26-Feb-2024 20:01:03

    SIGACHI INDUSTRIES: CO AND IMASS INVESTMENT UAE BASED CO TO ENTER THE GROWING UAE FOOD AND PHARMA MARKET

    SIGACHI, 83.50 -0.77
  • 26-Feb-2024 19:34:24

    WOCKHARDT: CO TO LAUNCH A QIP OF RS 400 CRORE -- QIP PRICE LIKELY TO BASED ON 10-DAY AVERAGE PRICE - NDTV

    WOCKPHARMA, 603.85 3.67
  • 26-Feb-2024 18:06:03

    CIPLA: CO GETS APPROVAL TO INTRODUCE ZEMDRI INJECTION IN INDIA - RTRS

    CIPLA, 1,477.55 0.04
  • 26-Feb-2024 14:16:23

    ALKEM LABS: CO CATEGORICALLY DENY THESE ALLEGATIONS AND RUMOURS AS PUBLISHED IN ARTICLES -" INCOME TAX FINDS LARGE-SCALE TAX EVASION OF 1000 CR BY CO "

    ALKEM, 5,138.55 2.97
  • 26-Feb-2024 12:21:15

    European Markets Are Heading For A Lower Open Monday As Global Investors Look Ahead To More Inflation Data This Week; European Futures; DAX (-0.17%); CAC (-0.14%); FTSE (-0.25%)

    ALKEM, 5,138.55 2.97
  • 26-Feb-2024 12:12:15

    ALKEM LABS: INCOME TAX FINDS LARGE-SCALE TAX EVASION OF 1000 CR BY CO - INDIA TODAY

    ALKEM, 5,138.55 2.97
  • 26-Feb-2024 10:43:51

    SHILPA MEDICARE: EUROPE APPROVAL FOR VARENICLINE TABLETS, 0.5MG AND 1MG -- THIS TABLET HAS US SALES OF 57M USD

    SHILPAMED, 414.80 1.01
24 Feb-2024
  • 24-Feb-2024 18:08:11

    MAX HEALTHCARE: CO BOARD GIVES IN-PRINCIPLE APPROVAL FOR ACQUISITION OF LAND PARCEL IN UTTAR PRADESH WORTH RS 167 CRORE.

    MAXHEALTH, 791.15 -7.09
  • 24-Feb-2024 18:06:18

    PIRAMAL PHARMA: U.S. FDA CONCLUDES PRE-APPROVAL INSPECTION OF PIRAMALPHARMAS U.S.-BASED FACILITY WITH 2 OBSERVATIONS, ISSUES FORM-483

    PPLPHARMA, 131.75 1.19
  • 24-Feb-2024 18:03:47

    ZYDUS LIFESCIENCES: CO RECEIVES WHO PREQUALIFICATION APPROVAL FOR API, FORMULATION OF MILTEFOSINE.

    ZYDUSLIFE, 943.80 1.20
23 Feb-2024
  • 23-Feb-2024 21:02:24

    THEMIS MEDICARE: CO TO MEET INSTITUTIONAL INVESTOR LUCKY SECURITIES ON 29 FEB

    THEMISMED, 237.85 -0.19
  • 23-Feb-2024 20:36:52

    BIOCON: CO HAS ISSUED CORPORATE GUARANTEE ON BEHALF OF UNIT BIOCON GENERICS INC -- CORPORATE GUARANTEE OF $20M, VALID FOR 5 YEARS

    BIOCON, 276.45 1.99
  • 23-Feb-2024 18:31:54

    SANOFI INDIA: CO DECLARED AN INTERIM DIVIDEND OF 50 RUPEES

    SANOFI, 8,611.25 -2.64
  • 23-Feb-2024 18:31:49

    SANOFI INDIA: Q3 EBITDA 1.87B RUPEES VS 1.67B (YOY) -- Q3 EBITDA MARGIN 27.01% VS 24.84% (YOY)

    SANOFI, 8,611.25 -2.64
  • 23-Feb-2024 18:31:40

    SANOFI INDIA: Q3 REVENUE 6.94B RUPEES VS 6.7B (YOY); 7.15B (QOQ)

    SANOFI, 8,611.25 -2.64
  • 23-Feb-2024 18:31:34

    SANOFI INDIA: Q3 SL NET PROFIT 1.38B RUPEES VS 1.3B (YOY); 1.5B (QOQ)

    SANOFI, 8,611.25 -2.64
  • 23-Feb-2024 17:44:56

    NARAYANA HRUDAYALAYA: CO ALLOTTED 7.26 ACRES OF LAND IN NEW TOWN, KOLKATA -- LAND ALLOTED FOR SETTING UP A HEALTHCARE FACILITY

    NH, 1,350.00 -1.05
  • 23-Feb-2024 16:50:22

    SUVEN PHARMACEUTICALS: CO SAYS NO FORM 483 HAS BEEN ISSUED AS A RESULT OF THE INSPECTION BY USFDA

    SUVENPHAR, 631.05 -1.80
  • 23-Feb-2024 16:50:16

    SUVEN PHARMACEUTICALS: CO SAYS COMPLETION OF PRE-APPROVAL INSPECTIONS (PAI) AND GOOD MANUFACTURING PRACTICES (GMP) INSPECTIONS BY USFDA -- API FACILITIES IN PASHAMYLARA COMPLETED PRE- APPROVAL INSPECTIONS AND GOOD MANUFACTURING PRACTICES INSPECTIONS

    SUVENPHAR, 631.05 -1.80
  • 23-Feb-2024 16:49:50

    ALEMBIC PHARMACEUTICALS: CO FULLY RESUMED ITS MANUFACTURING OPERATIONS AT ITS MANUFACTURING FACILITY AT NAMTHANG

    APLLTD, 1,017.90 -1.05
  • 23-Feb-2024 12:50:05

    PIRAMAL PHARMA: CO EXEC SAYS REDUCED DEBT TO EQUITY TO AROUND 3.1X AS OF LAST QUARTER -- GROSS DEBT ON BOOKS IS AROUND RUPEES 4000 CR RUPEES - CNBC TV18

    PPLPHARMA, 131.75 1.19
  • 23-Feb-2024 09:30:44

    WOCKHARDT: CO TO RAISE AROUND RUPEES 1600 CR THROUGH QIP - ZEE BUSINESS

    WOCKPHARMA, 603.85 3.67
22 Feb-2024
  • 22-Feb-2024 20:23:10

    MOREPEN LABORATORIES: CO APPROVED RAISING OF FUNDS WORTH UPTO 3.5B RUPEES VIA QIP

    MOREPENLAB, 49.45 0.92
  • 22-Feb-2024 20:19:08

    MOREPEN LABORATORIES: CO APPROVED RAISING OF FUNDS WORTH UPTO 3.5B RUPEES

    MOREPENLAB, 49.45 0.92
  • 22-Feb-2024 14:26:55

    PROCTER & GAMBLE HEALTH LTD: Rs. 31.08 Crores NSE Block Trade; for ~ 61076 Shares, at Rs. 5088.45

    PGHL, 5,080.00 -0.18
  • 22-Feb-2024 10:13:55

    MANKIND PHARMA LTD: Rs. 25.63 Crores NSE Block Trade; for ~ 116496 Shares, at Rs. 2200.30

    MANKIND, 2,138.50 4.14
21 Feb-2024
  • 21-Feb-2024 22:16:49

    JB CHEMICALS: CO EYES $100 MILLION REVENUE FROM CONTRACT MANUFACTURING IN 3-5 YEARS - CNBCTV18

    JBCHEPHARM, 1,564.45 -2.23
  • 21-Feb-2024 19:01:50

    NATCO PHARMA : CO AIMS TO DELIVER SIGNIFICANT PRODUCTS IN THE COMING MONTHS TO DRIVE GROWTH AND PROFITABILITY IN THE U.S. MARKET -- CO IS ACTIVELY SEEKING A LARGE ACQUISITION IN EMERGING MARKETS TO STRENGTHEN ITS PORTFOLIO

    NATCOPHARM, 995.00 1.17
  • 21-Feb-2024 10:01:15

    JB CHEM: CO EXEC SAYS OPHTHALMOLOGY IS A GROWING MARKET, GROWING AT 14% PER ANNUM - CNBC TV 18

    JBCHEPHARM, 1,564.45 -2.23
  • 21-Feb-2024 09:19:44

    POLY MEDICURE: RS 200.1CR BSE BLOCK TRADE; FOR ~1290951 SHARES, AT RS 1550

    POLYMED, 1,560.90 -1.66
20 Feb-2024
  • 20-Feb-2024 20:27:25

    MAX HEALTHCARE INSTITUTE: CO SAYS COMPLETION OF ACQUISITION OF 100% EQUITY STAKE IN ALEXIS MULTI-SPECIALITY HOSPITAL

    MAXHEALTH, 791.15 -7.09
  • 20-Feb-2024 14:56:09

    SUN PHARMA: CO HAS ENTERED INTO AN AGREEMENT WITH SURGIMATIX, INC, CO HAS AGREED TO ACQUIRE 16.33% SHARES OF SURGIMATIX, INC -- COST OF ACQUISITION IS USD 3.05M

    SUNPHARMA, 1,579.75 0.37
  • 20-Feb-2024 14:44:39

    MARKSANS PHARMA: CO WOULD LIKE TO GIVE A SLIGHTLY LONGER OUTLOOK THAN JUST 12 MONTHS, BUT OBVIOUSLY OUR FIRST TARGET WAS TO CROSS INR2000 CRORES, WHICH YOU RIGHTLY SAID WE ARE TRENDING WAY ABOVE THAT TARGET OF INR 2000 CRORES

    MARKSANS, 151.95 -0.49
  • 20-Feb-2024 14:40:35

    MARKSANS PHARMA: CO HAVE SET OUT A TARGET TO COME VERY CLOSE TO, OUR NEXT TARGET IS INR 3000 CRORES WITHIN THE NEXT TWO YEARS

    MARKSANS, 151.95 -0.49
  • 20-Feb-2024 11:07:19

    BIOCON: CO INCLUDED IN S&P GLOBAL SUSTAINABILITY YEARBOOK 2024 -- S&P GLOBAL ESG SCORE AT 63 INDUCTED IN DOW JONES SUSTAINABILITY EMERGING MARKETS INDEX FOR 3RD YEAR IN A ROW

    BIOCON, 276.45 1.99
16 Feb-2024
  • 16-Feb-2024 20:34:54

    BLISS GVS PHARMA: CO APPROVED AN INTERNAL RESTRUCTURING OF FOREIGN SUBSIDIARIES OF CO

    BLISSGVS, 126.45 2.47
  • 16-Feb-2024 14:19:24

    ZYDUS LIFE: CO RECEIVES FINAL APPROVAL FROM THE USFDA FOR ISOSORBIDE MONONITRATE EXTENDED - RELEASE, TABLETS -- TABLETS HAS US SALES OF 47M USD

    ZYDUSLIFE, 943.80 1.20
  • 16-Feb-2024 13:05:49

    LUPIN: CO RECEIVES APPROVAL FROM U.S. FDA FOR MINZOYA (LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS, USP AND FERROUS BISGLYCINATE TABLETS) -- THIS MEDICINE HAD ESTIMATED ANNUAL SALES OF USD 42 MILLION IN THE U.S.

    LUPIN, 1,622.05 0.35
  • 16-Feb-2024 12:56:29

    AUROBINDO PHARMA: CO SAYS USFDA INSPECTION AT SYNTHETIC PEPTIDE API FACILITY WAS CONCLUDED WITH ZERO OBSERVATIONS

    AUROPHARMA, 1,028.10 -0.04
  • 16-Feb-2024 12:45:52

    DISHMAN CARBOGEN: CO SAYS ENERGY COSTS FOR EUROPEAN UNITS COMING DOWN - CONCALL

    DCAL, 255.60 2.40
  • 16-Feb-2024 12:45:19

    DISHMAN CARBOGEN: CO SAYS AHMEDABAD UNIT CLEARANCE TO DRIVE ORDERS FROM EU CUSTOMERS - CONCALL

    DCAL, 255.60 2.40
  • 16-Feb-2024 12:44:40

    DISHMAN CARBOGEN: CO SAYS FRENCH FACILITY SHOULD BREAK EVEN AND/OR TURN PROFITABLE IN FY25 - CONCALL

    DCAL, 255.60 2.40
  • 16-Feb-2024 12:44:33

    DISHMAN CARBOGEN: CO SAYS TARGET 20-25% RETURN ON CAPITAL EMPLOYED IN NEAR TERM, SALES GROWTH WILL BE IN THE 10-15% RANGE - CONCALL

    DCAL, 255.60 2.40
  • 16-Feb-2024 12:44:02

    DISHMAN CARBOGEN: CO SAYS OVERALL MARGINS WILL IMPROVE IN FY25 - CONCALL

    DCAL, 255.60 2.40
14 Feb-2024
  • 14-Feb-2024 21:23:12

    GLENMARK PHARMA: CO SAYS Q3 API SALES 4.13B RUPEES, UP 9.8% (YOY)

    GLENMARK, 925.95 1.62
  • 14-Feb-2024 21:21:15

    GLENMARK PHARMA: CO HAS AN EXCEPTIONAL ITEM OF 767M RUPEES

    GLENMARK, 925.95 1.62
  • 14-Feb-2024 21:21:07

    GLENMARK PHARMA: Q3 CONS NET LOSS 4.7B RUPEES VS PROFIT 1.67B (YOY); EST 2.73B - LOSS 2B (QOQ) -- Q3 REVENUE 24.6B RUPEES VS 33.9B (YOY); 31.61B (QOQ)

    GLENMARK, 925.95 1.62
  • 14-Feb-2024 21:20:28

    DISHMAN CARBOGEN AMCIS: Q3 EBITDA 407M RUPEES VS 1.14B (YOY) -- Q3 EBITDA MARGIN 6.25% VS 17.83% (YOY)

    DCAL, 255.60 2.40
  • 14-Feb-2024 21:20:22

    DISHMAN CARBOGEN AMCIS: Q3 CONS NET LOSS 596M RUPEES VS PROFIT 469M (YOY); LOSS 409M (QOQ) -- Q3 REVENUE 6.5B RUPEES VS 6.4B (YOY); 5.86B (QOQ)

    DCAL, 255.60 2.40
  • 14-Feb-2024 20:20:20

    NARAYANA HRUDAYALAYA: Q3 EBITDA 2.97B RUPEES VS 2.66B (YOY) -- Q3 EBITDA MARGIN 24.67% VS 23.57% (YOY)

    NH, 1,350.00 -1.05
  • 14-Feb-2024 20:20:15

    NARAYANA HRUDAYALAYA: Q3 CONS NET PROFIT 1.88B RUPEES VS 1.54B (YOY); 2.27B (QOQ) -- Q3 REVENUE 12.04B RUPEES VS 11.28B (YOY); 13.05B (QOQ)

    NH, 1,350.00 -1.05
  • 14-Feb-2024 19:48:31

    GUFIC BIOSCIENCES: Q3 EBITDA 365M RUPEES VS 334M (YOY) -- Q3 EBITDA MARGIN 18.07% VS 18.81% (YOY)

    GUFICBIO, 313.55 1.32
  • 14-Feb-2024 19:48:25

    GUFIC BIOSCIENCES: Q3 SL NET PROFIT 222M RUPEES VS 203M (YOY); 232M (QOQ) -- Q3 REVENUE 2.02B RUPEES VS 1.8B (YOY); 2.15B (QOQ)

    GUFICBIO, 313.55 1.32
  • 14-Feb-2024 16:52:18

    GLAND PHARMA: Q3 EBITDA 3.56B RUPEES VS 3.5B (YOY) -- Q3 EBITDA MARGIN 23.07% VS 35% (YOY)

    GLAND, 1,764.45 -2.07
  • 14-Feb-2024 16:52:13

    GLAND PHARMA: Q3 CONS NET PROFIT 1.92B RUPEES VS 2.3B (YOY); 1.94B (QOQ) -- Q3 REVENUE 15.4B RUPEES VS 9.4B (YOY); 13.73B (QOQ)

    GLAND, 1,764.45 -2.07
  • 14-Feb-2024 14:36:26

    WOCKHARDT: Q3 REVENUE 7B RUPEES VS 6.99B (YOY)

    WOCKPHARMA, 603.85 3.67
  • 14-Feb-2024 14:36:24

    WOCKHARDT: Q3 EBITDA 370M RUPEES VS 450M (YOY) -- Q3 EBITDA MARGIN 5.28% VS 6.44% (YOY)

    WOCKPHARMA, 603.85 3.67
  • 14-Feb-2024 14:36:00

    WOCKHARDT: Q3 CONS NET LOSS 830M RUPEES VS LOSS 960M (YOY)

    WOCKPHARMA, 603.85 3.67
  • 14-Feb-2024 14:26:02

    IPCA LAB: CO EXEC SAYS CO HAD REDUCED BRANDED BIZ GROWTH GUIDANCE EVEN IN Q2FY24 - CNBC TV18

    IPCALAB, 1,191.35 0.26
  • 14-Feb-2024 14:25:32

    IPCA LAB: CO EXEC SAYS DOMESTIC BUSINESS GROWTH IS IN A LOWER RANGE OF GUIDANCE OF 12-14% - CNBC TV18

    IPCALAB, 1,191.35 0.26
  • 14-Feb-2024 14:25:24

    IPCA LAB: CO EXEC SAYS DOMESTIC BIZ 9MFY24 REVENUE GROWTH AT 12% - CNBC TV18

    IPCALAB, 1,191.35 0.26
  • 14-Feb-2024 14:07:16

    NATCO PHARMA: Q3 EBITDA 2.68B RUPEES VS 1.05B (YOY) -- Q3 EBITDA MARGIN 35.34% VS 21.5% (YOY)

    NATCOPHARM, 995.00 1.17
  • 14-Feb-2024 14:07:04

    NATCO PHARMA: Q3 REVENUE 7.6B RUPEES VS 4.93B (YOY)

    NATCOPHARM, 995.00 1.17
  • 14-Feb-2024 14:06:27

    NATCO PHARMA: Q3 CONS NET PROFIT 2.13B RUPEES VS 623M (YOY)

    NATCOPHARM, 995.00 1.17
  • 14-Feb-2024 13:41:08

    IPCA LABORATORIES: Q3 REVENUE 20.5B RUPEES VS 15.5B (YOY)

    IPCALAB, 1,191.35 0.26
  • 14-Feb-2024 13:40:47

    IPCA LABORATORIES: Q3 EBITDA 3.31B RUPEES VS 2.16B (YOY) -- Q3 EBITDA MARGIN 16.14% VS 13.96% (YOY)

    IPCALAB, 1,191.35 0.26
  • 14-Feb-2024 13:40:04

    IPCA LABORATORIES: Q3 CONS NET PROFIT 1.8B RUPEES VS 1.1B (YOY)

    IPCALAB, 1,191.35 0.26
  • 14-Feb-2024 11:49:25

    AUROBINDO PHARMA LTD: Rs. 15.69 Crores NSE Block Trade; for ~ 156850 Shares, at Rs. 1000.00

    AUROPHARMA, 1,028.10 -0.04
13 Feb-2024
  • 13-Feb-2024 21:52:16

    SEQUENT SCIENTIFIC: Q3 EBITDA 221M RUPEES VS 103.4M (YOY) -- Q3 EBITDA MARGIN 6.72% VS 2.75% (YOY)

    SEQUENT, 128.70 -2.76
  • 13-Feb-2024 21:52:10

    SEQUENT SCIENTIFIC: Q3 CONS NET PROFIT 83M RUPEES VS LOSS 88.7M (YOY); LOSS 84M (QOQ) -- Q3 REVENUE 3.29B RUPEES VS 3.75B (YOY); 3.46B (QOQ)

    SEQUENT, 128.70 -2.76
  • 13-Feb-2024 15:59:05

    ERIS LIFESCIENCES: Q3 EBITDA 1.76B RUPEES VS 1.4B (YOY) -- Q3 EBITDA MARGIN 36.09% VS 32.42% (YOY)

    ERIS, 883.75 1.31
  • 13-Feb-2024 15:58:59

    ERIS LIFESCIENCES: Q3 CONS NET PROFIT 1.02B RUPEES VS 1B (YOY); 1.2B (QOQ) -- Q3 REVENUE 4.8B RUPEES VS 4.2B (YOY); 5.05B (QOQ)

    ERIS, 883.75 1.31
  • 13-Feb-2024 15:23:57

    LUPIN: CO LAUNCHES BROMFENAC OPHTHALMIC SOLUTION -- SOLUTION HAS US SALES OF 15M USD

    LUPIN, 1,622.05 0.35
  • 13-Feb-2024 14:36:29

    MARKSANS PHARMA: Q3 EBITDA 1.33B RUPEES VS 766M (YOY) -- Q3 EBITDA MARGIN 22.69% VS 15.97% (YOY)

    MARKSANS, 151.95 -0.49
  • 13-Feb-2024 14:35:40

    MARKSANS PHARMA: Q3 REVENUE 5.86B RUPEES VS 4.8B (YOY)

    MARKSANS, 151.95 -0.49
  • 13-Feb-2024 14:35:18

    MARKSANS PHARMA: Q3 CONS NET PROFIT 832M RUPEES VS 634M (YOY)

    MARKSANS, 151.95 -0.49
12 Feb-2024
  • 12-Feb-2024 22:06:23

    MANKIND PHARMA: CO WANTS TO ENTER EXPORT MARKET OF NICHE PRODUCTS - CNBCTV18

    MANKIND, 2,138.50 4.14
  • 12-Feb-2024 17:06:22

    GLAXOSMITHKLINE PHARMA: CO HAS AN EXCEPTIONAL ITEM LOSS OF 1.63B RUPEES

    GLAXO, 2,176.10 1.02
  • 12-Feb-2024 17:06:16

    GLAXOSMITHKLINE PHARMA: Q3 EBITDA 2.18B RUPEES VS 2.3B (YOY) -- Q3 EBITDA MARGIN 27.08% VS 28.51% (YOY)

    GLAXO, 2,176.10 1.02
  • 12-Feb-2024 17:06:11

    GLAXOSMITHKLINE PHARMA: Q3 CONS NET PROFIT 457M RUPEES VS 1.7B (YOY); 2.17B (QOQ) -- Q3 REVENUE 8.05B RUPEES VS 8B (YOY); 9.57B (QOQ)

    GLAXO, 2,176.10 1.02
  • 12-Feb-2024 14:42:04

    AUROBINDO PHARMA: CO RECEIVES USFDA APPROVAL FOR DEFLAZACORT TABLETS -- TABLETS HAS US SALES OF 67M USD

    AUROPHARMA, 1,028.10 -0.04
  • 12-Feb-2024 14:36:26

    AMI ORGANICS: Q3 EBITDA 235M RUPEES VS 308M (YOY) -- Q3 EBITDA MARGIN 14.55% VS 20.21% (YOY)

    AMIORG, 1,112.30 -1.35
  • 12-Feb-2024 14:36:00

    AMI ORGANICS: Q3 SL NET PROFIT 157M RUPEES VS 223M (YOY) -- Q3 REVENUE 1.6B RUPEES VS 1.55B (YOY)

    AMIORG, 1,112.30 -1.35
  • 12-Feb-2024 11:33:33

    SYNGENE INTERNATIONAL LTD: Rs. 24.27 Crores NSE Block Trade; for ~ 323768 Shares, at Rs. 749.65

    SYNGENE, 706.60 -0.32
10 Feb-2024
  • 10-Feb-2024 18:39:31

    THEMIS MEDICARE: Q3 EBITDA 81M RUPEES VS 153M (YOY) -- Q3 EBITDA MARGIN 9.77% VS 17.20% (YOY)

    THEMISMED, 237.85 -0.19
  • 10-Feb-2024 18:39:11

    THEMIS MEDICARE: Q3 CONS NET PROFIT 74M RUPEES VS 133M (YOY) -- Q3 REVENUE 825M RUPEES VS 888M (YOY)

    THEMISMED, 237.85 -0.19
  • 10-Feb-2024 18:29:40

    AUROBINDO PHARMA: Q3 EBITDA 16.83B RUPEES VS 10.3B (YOY) -- Q3 EBITDA MARGIN 23.15% VS 16.09% (YOY)

    AUROPHARMA, 1,028.10 -0.04
  • 10-Feb-2024 18:28:55

    AUROBINDO PHARMA: Q3 CONS NET PROFIT 9.4B RUPEES VS 4.9B (YOY) -- Q3 REVENUE 72.71B RUPEES VS 63.88B (YOY)

    AUROPHARMA, 1,028.10 -0.04
  • 10-Feb-2024 18:23:57

    AUROBINDO PHARMA: CO HAS APPROVED THE SECOND INTERIM DIVIDEND OF RUPEES 1.50 PER EQUITY SHARE

    AUROPHARMA, 1,028.10 -0.04
  • 10-Feb-2024 12:59:58

    ADVANCED ENZYME TECH: Q3 EBITDA 538M RUPEES VS 416M (YOY) -- Q3 EBITDA MARGIN 33.41% VS 29.34% (YOY)

    ADVENZYMES, 385.95 0.39
  • 10-Feb-2024 12:59:20

    ADVANCED ENZYME TECH: Q3 CONS NET PROFIT 418M RUPEES VS 294M (YOY) -- Q3 REVENUE 1.61B RUPEES VS 1.42B (YOY)

    ADVENZYMES, 385.95 0.39
  • 10-Feb-2024 12:32:55

    DIVIS LAB: Q3 EBITDA 5B RUPEES VS 4.1B (YOY) -- Q3 EBITDA MARGIN 26.90% VS 23.95% (YOY)

    DIVISLAB, 3,490.00 -0.81
  • 10-Feb-2024 12:18:01

    DIVIS LAB: Q3 CONS NET PROFIT 3.58B RUPEES VS 3.06B (YOY) -- Q3 REVENUE 18.55B RUPEES VS 17.08B (YOY))

    DIVISLAB, 3,490.00 -0.81
  • 10-Feb-2024 12:06:56

    DR.REDDYS: CO SAYS USFDA CONCLUDES INSPECTION AT COS HYDERABAD FACILITY, CLASSIFIES AS VOLUNTARY ACTION INDICATED (VAI)

    DRREDDY, 6,425.55 -0.04
09 Feb-2024
  • 09-Feb-2024 14:42:35

    PFIZER: Q3 EBITDA 1.52B RUPEES VS 2.04B (YOY) -- Q3 EBITDA MARGIN 28.25% VS 32.72% (YOY)

    PFIZER, 4,601.45 0.89
  • 09-Feb-2024 14:42:17

    PFIZER: Q3 SL NET PROFIT 1.3B RUPEES VS 1.51B (YOY) -- Q3 REVENUE 5.4B RUPEES VS 6.22B (YOY)

    PFIZER, 4,601.45 0.89
  • 09-Feb-2024 13:17:51

    ALKEM LAB: CO FIXES FEB.17 AS RECORD DATE FOR THE PURPOSE OF INTERIM DIVIDEND

    ALKEM, 5,138.55 2.97
  • 09-Feb-2024 13:08:50

    ALKEM LAB: CO DECLARED DIVIDEND 35 RUPEES PER SHARE

    ALKEM, 5,138.55 2.97
  • 09-Feb-2024 13:08:18

    ALKEM LABORATORIES: Q3 EBITDA 7.08B RUPEES VS 5.99B (YOY); EST 6.1B -- Q3 EBITDA MARGIN 21.29% VS 19.7% (YOY); EST 19%

    ALKEM, 5,138.55 2.97
  • 09-Feb-2024 13:07:44

    ALKEM LABORATORIES: Q3 REVENUE 33B RUPEES VS 30.4B (YOY)

    ALKEM, 5,138.55 2.97
  • 09-Feb-2024 13:07:14

    ALKEM LABORATORIES: Q3 CONS NET PROFIT 5.9B RUPEES VS 4.5B (YOY); EST 4.80B

    ALKEM, 5,138.55 2.97
  • 09-Feb-2024 13:05:45

    ZYDUS LIFESCIENCES: CO FIXES FEB.23 AS RECORD DATE FOR THE PURPOSE OF BUYBACK

    ZYDUSLIFE, 943.80 1.20
  • 09-Feb-2024 13:02:38

    ZYDUS LIFESCIENCES: CO APPROVED SHARE BUYBACK AT THE PRICE OF RUPEES 1005 PER SHARE VIA TENDER OFFER ROUTE

    ZYDUSLIFE, 943.80 1.20
  • 09-Feb-2024 12:58:38

    ZYDUS LIFESCIENCES: Q3 EBITDA 11.02B RUPEES VS 9.6B (YOY) -- Q3 EBITDA MARGIN 24.47% VS 22.46% (YOY)

    ZYDUSLIFE, 943.80 1.20
  • 09-Feb-2024 12:58:11

    ZYDUS LIFESCIENCES: Q3 CONS NET PROFIT 7.9B RUPEES VS 6.23B (YOY) -- Q3 REVENUE 45B RUPEES VS 42.5B (YOY)

    ZYDUSLIFE, 943.80 1.20
  • 09-Feb-2024 12:48:45

    CAPLIN POINT LABORATORIES: Q3 EBITDA 1.42B RUPEES VS 1.1B (YOY) -- Q3 EBITDA MARGIN 32.67% VS 29.40% (YOY)

    CAPLIPOINT, 1,479.90 1.91
  • 09-Feb-2024 12:48:05

    CAPLIN POINT LABORATORIES: Q3 CONS NET PROFIT 1.17B RUPEES VS 975M (YOY) -- Q3 REVENUE 4.3B RUPEES VS 3.72B (YOY)

    CAPLIPOINT, 1,479.90 1.91
  • 09-Feb-2024 11:06:45

    GLENMARK LIFE SCIENCES LTD: Rs. 43.50 Crores NSE Block Trade; for ~ 500530 Shares, at Rs. 869.00

    GLS, 869.45 -0.84
  • 09-Feb-2024 11:01:58

    MAX HEALTHCARE: RS. 134.71 CRORES NSE BLOCK TRADE; FOR ~ 1553291 SHARES, AT RS. 867.25

    MAXHEALTH, 791.15 -7.09
  • 09-Feb-2024 10:44:46

    MAX HEALTHCARE: RS. 209.45 CRORES NSE BLOCK TRADE; FOR ~ 2410249 SHARES, AT RS. 869.00

    MAXHEALTH, 791.15 -7.09
  • 09-Feb-2024 10:39:11

    MAX HEALTHCARE: CO SAYS COST OF ACQUISITION 3.72B RUPEES

    MAXHEALTH, 791.15 -7.09
  • 09-Feb-2024 10:35:34

    MAX HEALTHCARE: CO UPDATED REGARDING EXECUTION OF PURCHASE AGREEMENT FOR ACQUISITION OF 100% STAKE IN ALEXIS MULTI-SPECIALITY HOSPITAL

    MAXHEALTH, 791.15 -7.09
  • 09-Feb-2024 08:10:32

    BIOCON: CO UNIT PARTNERS WITH SANDOZ AUSTRALIA FOR BIOSIMILARS TRASTUZUMAB AND BEVACIZUMAB

    BIOCON, 276.45 1.99
  • 09-Feb-2024 07:56:00

    BIOCON: CO SAYS CRL DID NOT IDENTIFY ANY OUTSTANDING SCIENTIFIC ISSUES ON THE DOSSIER -- CRL INFORMS NEED FOR COMPLETION OF PRE-APPROVAL INSPECTION OF BBEVACIZUMAB MANUFACTURING FACILITY

    BIOCON, 276.45 1.99
08 Feb-2024
  • 08-Feb-2024 21:09:08

    HIKAL: Q3 EBITDA 648M RUPEES VS 746M (YOY) -- Q3 EBITDA MARGIN 14.47% VS 13.81% (YOY)

    HIKAL, 281.45 0.43
  • 08-Feb-2024 21:09:00

    HIKAL: Q3 CONS NET PROFIT 161M RUPEES VS 264M (YOY); 126M (QOQ) -- Q3 REVENUE 4.47B RUPEES VS 5.4B (YOY); 4.34B (QOQ)

    HIKAL, 281.45 0.43
  • 08-Feb-2024 20:44:19

    ASTRAZENECA PHARMA: Q3 EBITDA 151M RUPEES VS 356M (YOY) -- Q3 EBITDA MARGIN 4.92% VS 14.83% (YOY)

    ASTRAZEN, 5,535.50 0.42
  • 08-Feb-2024 20:44:13

    ASTRAZENECA PHARMA: Q3 SL NET PROFIT 158M RUPEES VS 293M (YOY); 524M (QOQ) -- Q3 REVENUE 3.06B RUPEES VS 2.4B (YOY); 3B (QOQ)

    ASTRAZEN, 5,535.50 0.42
  • 08-Feb-2024 19:59:28

    SMS PHARMACEUTICALS: CO APPROVED RAISING OF FUNDS THROUGH ISSUE OF CONVERTIBLE EQUITY WARRANTS UP TO 1.14 BLN RUPEES

    SMSPHARMA, 149.80 -3.01
  • 08-Feb-2024 19:58:05

    ASTER DM HEALTHCARE: PROPOSED DIVIDEND TO SHAREHOLDERS IN RANGE OF 110 RUPEES TO 120 RUPEES PER SHARE

    ASTERDM, 471.55 -2.74
  • 08-Feb-2024 19:57:59

    ASTER DM HEALTHCARE: CO RECEIVED REQUISITE MAJORITY OF SHAREHOLDER VOTES TOWARDS SEPARATION OF GCC BUSINESS FROM INDIAN OPERATIONS -- DESIROUS TO CONSIDER DISTRIBUTING 70- 80 PERCENT OF UPFRONT CONSIDERATION OF $903 MLN AS A DIVIDEND TO ITS SHAREHOLDERS

    ASTERDM, 471.55 -2.74
  • 08-Feb-2024 19:57:12

    SMS PHARMA: Q3 EBITDA 289M RUPEES VS 183M (YOY) -- Q3 EBITDA MARGIN 17.88% VS 12.27% (YOY)

    SMSPHARMA, 149.80 -3.01
  • 08-Feb-2024 19:57:05

    SMS PHARMA: Q3 SL NET PROFIT 122M RUPEES VS 50M (YOY); 120M (QOQ) -- Q3 REVENUE 1.6B RUPEES VS 1.49B (YOY); 1.66B (QOQ)

    SMSPHARMA, 149.80 -3.01
  • 08-Feb-2024 19:56:44

    ASTER DM HEALTHCARE: Q3 EBITDA 5.64B RUPEES VS 4.49B (YOY) -- Q3 EBITDA MARGIN 15.20% VS 14.06% (YOY)

    ASTERDM, 471.55 -2.74
  • 08-Feb-2024 19:56:38

    ASTER DM HEALTHCARE: Q3 CONS NET PROFIT 1.79B RUPEES VS 1.39B PROFIT (YOY); 308M LOSS (QOQ) -- Q3 REVENUE 37.11B RUPEES VS 31.9B (YOY); 33.17B (QOQ)

    ASTERDM, 471.55 -2.74
  • 08-Feb-2024 19:56:25

    BIOCON: CO SAYS CFO INDRANIL SEN RESIGNS

    BIOCON, 276.45 1.99
  • 08-Feb-2024 19:55:58

    BIOCON: Q3 EBITDA 9.27B RUPEES VS 6.44B (YOY) -- Q3 EBITDA MARGIN 23.44% VS 21.91% (YOY)

    BIOCON, 276.45 1.99
  • 08-Feb-2024 19:55:52

    BIOCON: Q3 CONS NET PROFIT 6.6B RUPEES VS 418M LOSS (YOY); 1.26B PROFIT (QOQ) -- Q3 REVENUE 39.54B RUPEES VS 29.41B (YOY); 34.62B (QOQ)

    BIOCON, 276.45 1.99
  • 08-Feb-2024 19:45:38

    GLOBAL HEALTH: CO APPROVED APPOINTMENT OF YOGESH KUMAR GUPTA AS CFO

    MEDANTA, 1,357.70 -5.86
  • 08-Feb-2024 19:42:58

    SHILPA MEDICARE: CO TO ISSUE SECURITIES VIA QIP -- CO TO ISSUE SECURITIES WORTH UP TO 5B RUPEES

    SHILPAMED, 414.80 1.01
  • 08-Feb-2024 19:31:13

    NEULAND LABORATORIES: Q3 EBITDA 1.21B RUPEES VS 541M (YOY) -- Q3 EBITDA MARGIN 30.87% VS 20.09% (YOY)

    NEULANDLAB, 7,149.90 0.67
  • 08-Feb-2024 19:31:08

    NEULAND LABORATORIES: Q3 CONS NET PROFIT 814M RUPEES VS 305M (YOY); 892M (QOQ) -- Q3 REVENUE 3.93B RUPEES VS 2.69B (YOY); 4.2B (QOQ)

    NEULANDLAB, 7,149.90 0.67
  • 08-Feb-2024 17:44:18

    GLOBAL HEALTH: Q3 EBITDA 2.12B RUPEES VS 1.6B (YOY) -- Q3 EBITDA MARGIN 25.47% VS 23.04% (YOY)

    MEDANTA, 1,357.70 -5.86
  • 08-Feb-2024 17:44:12

    GLOBAL HEALTH: Q3 CONS NET PROFIT 1.23B RUPEES VS 806M (YOY); 1.25B (QOQ) -- Q3 REVENUE 8.33B RUPEES VS 6.94B (YOY); 8.44B (QOQ)

    MEDANTA, 1,357.70 -5.86
  • 08-Feb-2024 17:43:45

    HEALTHCARE GLOBAL ENTERPRISES: Q3 EBITDA 786M RUPEES VS 755M (YOY) -- Q3 EBITDA MARGIN 16.77% VS 17.81% (YOY)

    HCG, 361.75 -0.65
  • 08-Feb-2024 17:43:39

    HEALTHCARE GLOBAL ENTERPRISES: Q3 CONS NET PROFIT 57M RUPEES VS 75M (YOY); 136M (QOQ) -- Q3 REVENUE 4.69B RUPEES VS 4.24B (YOY); 4.86B (QOQ)

    HCG, 361.75 -0.65
  • 08-Feb-2024 17:43:31

    SHILPA MEDICARE: Q3 EBITDA 659M RUPEES VS 312.8M (YOY) -- Q3 EBITDA MARGIN 23.02% VS 11.92% (YOY)

    SHILPAMED, 414.80 1.01
  • 08-Feb-2024 17:43:26

    SHILPA MEDICARE: Q3 CONS NET PROFIT 46M RUPEES VS 66.19M LOSS (YOY); 16M PROFIT (QOQ) -- Q3 REVENUE 2.86B RUPEES VS 2.62B (YOY); 3.2B(QOQ)

    SHILPAMED, 414.80 1.01
  • 08-Feb-2024 14:42:12

    APOLLO HOSPITALS: CO DECLARED INTERIM DIVIDEND OF RUPEES 6 PER EQUITY SHARE

    APOLLOHOSP, 6,102.65 -4.08
  • 08-Feb-2024 14:37:44

    APOLLO HOSPITALS ENTERPRISE: Q3 EBITDA 6.13B RUPEES VS 5.05B (YOY); EST 6.01B -- Q3 EBITDA MARGIN 12.65% VS 11.85% (YOY); EST 12.6%

    APOLLOHOSP, 6,102.65 -4.08
  • 08-Feb-2024 14:36:46

    APOLLO HOSPITALS ENTERPRISE: Q3 REVENUE 48.5B RUPEES VS 42.63B (YOY)

    APOLLOHOSP, 6,102.65 -4.08
  • 08-Feb-2024 14:36:23

    APOLLO HOSPITALS ENTERPRISE: Q3 CONS NET PROFIT 2.45B RUPEES VS 1.53B (YOY); EST 2.56B

    APOLLOHOSP, 6,102.65 -4.08
  • 08-Feb-2024 14:28:33

    ZYDUS LIFESCIENCES: CO RECEIVES FINAL APPROVALS FROM THE USFDA FOR DEXAMETHASONE TABLETS -- TABLETS HAS US SALES OF 6M USD

    ZYDUSLIFE, 943.80 1.20
  • 08-Feb-2024 12:24:46

    LINCOLN PHARMA: Q3 EBITDA 297M RUPEES VS 268M (YOY) -- Q3 EBITDA MARGIN 20.25% VS 20% (YOY)

    LINCOLN, 685.50 -0.33
  • 08-Feb-2024 12:24:08

    LINCOLN PHARMA: Q3 SL NET PROFIT 280M RUPEES VS 216M (YOY) -- Q3 REVENUE 1.5B RUPEES VS 1.33B (YOY)

    LINCOLN, 685.50 -0.33
  • 08-Feb-2024 10:48:40

    NARAYANA HRUDAYALAYA LTD: Rs. 19.51 Crores NSE Block Trade; for ~ 141062 Shares, at Rs. 1383.00

    NH, 1,350.00 -1.05
  • 08-Feb-2024 09:00:37

    MANKIND PHARMA: RS 1272.67CR NSE BLOCK TRADE; FOR ~6039183 SHARES, AT RS 2107.35 (PRE-OPEN BLOCK)

    MANKIND, 2,138.50 4.14
07 Feb-2024
  • 07-Feb-2024 21:27:27

    LUPIN: Q3 EBITDA 9.50B RUPEES VS 5.33B (YOY); EST 8.36B -- Q3 EBITDA MARGIN 18.70% VS 12.32% (YOY); EST 17%

    LUPIN, 1,622.05 0.35
  • 07-Feb-2024 21:27:22

    LUPIN: Q3 CONS NET PROFIT 6.13B RUPEES VS 1.53B (YOY); EST 4.08B - 4.9B (QOQ) -- Q3 REVENUE 50.8B RUPEES VS 43.2B (YOY); 50.4B (QOQ)

    LUPIN, 1,622.05 0.35
  • 07-Feb-2024 21:08:37

    FORTIS HEALTHCARE: Q3 EBITDA 2.91B RUPEES VS 2.9B (YOY) -- Q3 EBITDA MARGIN 17.31% VS 18.5% (YOY)

    FORTIS, 408.55 -3.07
  • 07-Feb-2024 21:08:31

    FORTIS HEALTHCARE: Q3 CONS NET PROFIT 1.34B RUPEES VS 1.4B (YOY); 1.84B (QOQ) -- Q3 REVENUE 16.80B RUPEES VS 15.6B (YOY); 17.7B (QOQ)

    FORTIS, 408.55 -3.07
  • 07-Feb-2024 19:55:39

    SUPRIYA LIFESCIENCE: Q3 EBITDA 415M RUPEES VS 140M (YOY) -- Q3 EBITDA MARGIN 29.62% VS 13.32% (YOY)

    SUPRIYA, 344.00 0.85
  • 07-Feb-2024 19:55:32

    SUPRIYA LIFESCIENCE: Q3 SL NET PROFIT 298M RUPEES VS 95.18M (YOY); 239M (QOQ) -- Q3 REVENUE 1.4B RUPEES VS 1.05B (YOY); 1.4B (QOQ)

    SUPRIYA, 344.00 0.85
  • 07-Feb-2024 19:52:32

    SUPRIYA LIFESCIENCE: CO APPROVED CAPITAL EXPENDITURE PLAN AT AMBERNATH SITE FOR CDMO FACILITY

    SUPRIYA, 344.00 0.85
  • 07-Feb-2024 17:25:14

    MANKIND PHARMA: BLOCK DEAL ALERT - PROMOTERS TO SELL 1.62% STAKE OR 64.9 LAKH SHARES -- PROMOTERS TO SELL SHARES WORTH 1330 CR VIA BLOCK DEALS -- FLOOR PRICE FOR BLOCK DEAL AT 2050 -- IIFL BROKER TO DEAL - CNBC AWAAZ, CITING SOURCES

    MANKIND, 2,138.50 4.14
  • 07-Feb-2024 17:19:14

    PIRAMAL PHARMA: CO SAYS US FDA CONDUCTED PRE-APPROVAL INSPECTION INSPECTION OF COS RIVERVIEW (USA) FACILITY FROM 29TH JAN TO 6TH FEB -- CO SAYS ON CONCLUSION OF INSPECTION, A FORM-483 WAS ISSUED WITH 3 OBSERVATIONS

    PPLPHARMA, 131.75 1.19
  • 07-Feb-2024 15:18:46

    MANKIND PHARMA: CO SAYS POST COMPLETION OF SALE, AGGREGATE PROMOTER, PROMOTER GROUP STAKE IN CO WOULD BE 74.88%

    MANKIND, 2,138.50 4.14
  • 07-Feb-2024 14:36:14

    FDC: Q3 EBITDA 838M RUPEES VS 492M (YOY) -- Q3 EBITDA MARGIN 18.29% VS 12.03% (YOY)

    FDC, 434.85 -2.36
  • 07-Feb-2024 14:35:58

    FDC: Q3 REVENUE 4.6B RUPEES VS 4.1B (YOY)

    FDC, 434.85 -2.36
  • 07-Feb-2024 14:35:25

    FDC: Q3 CONS NET PROFIT 792M RUPEES VS 407M (YOY)

    FDC, 434.85 -2.36
  • 07-Feb-2024 14:24:46

    SHALBY: Q3 EBITDA 423M RUPEES VS 340M (YOY) -- Q3 EBITDA MARGIN 19.59% VS 16.77% (YOY)

    SHALBY, 269.25 -3.67
  • 07-Feb-2024 14:23:29

    SHALBY: Q3 CONS NET PROFIT 191M RUPEES VS 152.86M (YOY) -- Q3 REVENUE 2.16B RUPEES VS 2B (YOY)

    SHALBY, 269.25 -3.67
  • 07-Feb-2024 13:38:29

    KOPRAN: Q3 EBITDA 257M RUPEES VS 123M (YOY) -- Q3 EBITDA MARGIN 16.18% VS 7.8% (YOY)

    KOPRAN, 245.70 -0.73
  • 07-Feb-2024 13:37:47

    KOPRAN: Q3 CONS NET PROFIT 158M RUPEES VS 69M (YOY) -- Q3 REVENUE 1.59B RUPEES VS 1.58B (YOY)

    KOPRAN, 245.70 -0.73
  • 07-Feb-2024 13:33:47

    DR. REDDYS: CO SAYS US RECALL OF TACROLIMUS IN DECEMBER WAS PRECAUTIONARY

    DRREDDY, 6,425.55 -0.04
  • 07-Feb-2024 11:29:25

    DR.REDDYS LABORATORIES LTD: Rs. 50.93 Crores NSE Block Trade; for ~ 82666 Shares, at Rs. 6161.10

    DRREDDY, 6,425.55 -0.04
  • 07-Feb-2024 10:56:52

    PROCTER & GAMBLE HEALTH LTD: Rs. 11.60 Crores NSE Block Trade; for ~ 21394 Shares, at Rs. 5424.00

    PGHL, 5,080.00 -0.18
06 Feb-2024
  • 06-Feb-2024 20:01:54

    IOL CHEM AND PHARMA: CO DECLARED INTERIM DIVIDEND OF 5 RUPEES PER SHARE

    IOLCP, 402.80 1.10
  • 06-Feb-2024 20:01:48

    IOL CHEM AND PHARMA: Q3 EBITDA 442M RUPEES VS 432M (YOY) -- Q3 EBITDA MARGIN 8.51% VS 8.27% (YOY)

    IOLCP, 402.80 1.10
  • 06-Feb-2024 20:01:41

    IOL CHEM AND PHARMA: Q3 EBITDA 442M RUPEES VS 432M (YOY) -- Q3 EBITDA MARGIN 8.51% VS 8.27% (YOY)

    IOLCP, 402.80 1.10
  • 06-Feb-2024 20:01:35

    IOL CHEM AND PHARMA: Q3 SL NET PROFIT 232M RUPEES VS 241M (YOY) -- Q3 REVENUE 5.2B RUPEES VS 5.23B (YOY)

    IOLCP, 402.80 1.10
  • 06-Feb-2024 19:53:58

    ASTER DM HEALTHCARE: CO SAYS UNIT MALABAR INSTITUTE OF MEDICAL SCIENCES TO ACQUIRE 26% STAKE IN USOLAR ASSETCO TWO -- DEAL FOR 40M RUPEES

    ASTERDM, 471.55 -2.74
  • 06-Feb-2024 19:48:06

    SUN PHARMA: CO SAYS SUBSIDIARY COMPANY WITH THE NAME SUN PHARMA MIDDLE EAST FZ-LLC (UAE) IS SET UP AS A WHOLLY-OWNED SUBSIDIARY OF SUN PHARMA (NETHERLANDS) B.V -- SPME FZ-LLC IS SET UP AS AN ENTITY TO EXPAND THE BUSINESS OF THE CO IN UAE

    SUNPHARMA, 1,579.75 0.37
  • 06-Feb-2024 18:28:04

    INDRAPRASTHA MEDICAL CORP: Q3 EBITDA 475M RUPEES VS 383M (YOY) -- Q3 EBITDA MARGIN 15.54% VS 13.77% (YOY)

    INDRAMEDCO, 180.00 -2.99
  • 06-Feb-2024 18:27:57

    INDRAPRASTHA MEDICAL CORP: Q3 SL NET PROFIT 294M RUPEES VS 209M (YOY) -- Q3 REVENUE 3.06B RUPEES VS 2.78B (YOY)

    INDRAMEDCO, 180.00 -2.99
  • 06-Feb-2024 18:24:25

    SHILPA MEDICARE: CO SAYS EUROPE (EMA) INSPECTION OF BIO-ANALYTICAL LABORATORY, UNIT 7 -- CO SAYS INTEGRATED EMA INSPECTION CLOSED WITH ISSUANCE OF INSPECTION REPORT STATING SATISFACTORY COMPLIANCE TO GCP

    SHILPAMED, 414.80 1.01
  • 06-Feb-2024 18:23:19

    PROCTER & GAMBLE HEALTH: CO DECLARED FIRST INTERIM DIVIDEND OF 200 RUPEES PER SHARE (INCLUDING ONE-TIME SPECIAL DIVIDEND OF RS 150)

    PGHL, 5,080.00 -0.18
  • 06-Feb-2024 18:23:14

    PROCTER & GAMBLE HEALTH: Q3 EBITDA 1.02B RUPEES VS 1.09B (YOY) -- Q3 EBITDA MARGIN 32.79% VS 35.12% (YOY)

    PGHL, 5,080.00 -0.18
  • 06-Feb-2024 18:23:07

    PROCTER & GAMBLE HEALTH: Q3 SL NET PROFIT 721M RUPEES VS 768M (YOY) -- Q3 REVENUE 3.1B RUPEES VS 3.09B (YOY)

    PGHL, 5,080.00 -0.18
  • 06-Feb-2024 17:46:25

    J B CHEMICALS AND PHARMA: CO APPROVED APPOINTMENT OF NARAYAN SARAF AS CHIEF FINANCIAL OFFICER

    JBCHEPHARM, 1,564.45 -2.23
  • 06-Feb-2024 17:20:35

    LUPIN: BROMFENAC OPHTHALMIC SOLUTION, 0.075% IS INDICATED FOR THE TREATMENT OF POSTOPERATIVE INFLAMMATION AND PREVENTION OF OCULAR PAIN IN PATIENTS UNDERGOING CATARACT SURGERY

    LUPIN, 1,622.05 0.35
  • 06-Feb-2024 17:20:24

    LUPIN: CO RECEIVES APPROVAL FROM U.S. FDA FOR BROMFENAC OPHTHALMIC SOLUTION, 0.075% -- BROMFENAC OPHTHALMIC SOLUTION 0.075% (RLD BROMSITE®) HAD ESTIMATED ANNUAL SALES OF USD 15 MILLION IN THE U.S. (IQVIA MAT DECEMBER 2023)

    LUPIN, 1,622.05 0.35
  • 06-Feb-2024 16:36:31

    J.B.CHEMICALS & PHARMACEUTICALS: CO DECLARED AN INTERIM DIVIDEND OF 5.5 RUPEES PER SHARE

    JBCHEPHARM, 1,564.45 -2.23
  • 06-Feb-2024 16:36:26

    J.B.CHEMICALS & PHARMACEUTICALS: Q3 EBITDA 2.23B RUPEES VS 1.75B (YOY) -- Q3 EBITDA MARGIN 26.42% VS 22.05% (YOY)

    JBCHEPHARM, 1,564.45 -2.23
  • 06-Feb-2024 16:36:21

    J.B.CHEMICALS & PHARMACEUTICALS: Q3 CONS NET PROFIT 1.34B RUPEES VS 1.06B (YOY) -- Q3 REVENUE 8.44B RUPEES VS 7.93B (YOY)

    JBCHEPHARM, 1,564.45 -2.23
  • 06-Feb-2024 16:34:30

    BIOCON: CO RECEIVED TENTATIVE APPROVAL OF ITS ANDA FOR DASATINIB TABLETS FROM US FDA

    BIOCON, 276.45 1.99
  • 06-Feb-2024 12:47:47

    IOL CP: CO SAYS THIS WILL ENABLE THE COMPANY TO EXPORT LOSARTAN POTASSIUM IN EUROPEAN MARKET

    IOLCP, 402.80 1.10
  • 06-Feb-2024 12:47:14

    IOL CP: CO SAYS EUROPEAN DIRECTORATE FOR THE QUALITY OF MEDICINES & HEALTH CARE (EDQM) HAS ISSUED A CERTIFICATE OF SUITABILITY FOR LOSARTAN POTASSIUM

    IOLCP, 402.80 1.10
  • 06-Feb-2024 11:31:47

    MANKIND PHARMA LTD: Rs. 40.44 Crores NSE Block Trade; for ~ 194671 Shares, at Rs. 2077.25

    MANKIND, 2,138.50 4.14
  • 06-Feb-2024 11:16:51

    SUVEN LIFE SCIENCES: CO ANNOUNCES RANDOMIZATION OF FIRST PATIENT IN PHASE-2 POC CLINICAL TRIAL OF ROPANICANT (SUVN-911) FOR THE TREATMENT OF MODERATE TO SEVERE MAJOR DEPRESSIVE DISORDER STUDY IN USA

    SUVEN, 102.50 0.89
05 Feb-2024
  • 05-Feb-2024 21:05:43

    TORRENT PHARMA: SUPERNUS WINS INFRINGEMENT AND VALIDITY CASE ON TROKENDI XR® AGAINST TORRENT

    TORNTPHARM, 2,668.55 2.12
  • 05-Feb-2024 18:58:53

    ZYDUS LIFESCIENCES: BOARD MEETING ON FEB 9 TO CONSIDER A PROPOSAL FOR BUYBACK OF FULLY PAID-UP EQUITY SHARES OF THE CO

    ZYDUSLIFE, 943.80 1.20
  • 05-Feb-2024 18:12:57

    ARTEMIS MEDICARE SERVICES: Q3 EBITDA 317M RUPEES VS 257M (YOY) -- Q3 EBITDA MARGIN 15.07% VS 14.15% (YOY)

    ARTEMISMED, 169.55 -3.22
  • 05-Feb-2024 18:12:51

    ARTEMIS MEDICARE SERVICES: Q3 SL NET PROFIT 115M RUPEES VS 108M (YOY) -- Q3 REVENUE 2.1B RUPEES VS 1.81B (YOY)

    ARTEMISMED, 169.55 -3.22
  • 05-Feb-2024 18:07:02

    SUVEN PHARMA: Q3 EBITDA 651M RUPEES VS 1.47B (YOY) -- Q3 EBITDA MARGIN 29.64% VS 41.47% (YOY)

    SUVENPHAR, 631.05 -1.80
  • 05-Feb-2024 18:06:55

    SUVEN PHARMA: Q3 CONS NET PROFIT 467M RUPEES VS 1.1B (YOY) -- Q3 REVENUE 2.2B RUPEES VS 3.5B (YOY)

    SUVENPHAR, 631.05 -1.80
  • 05-Feb-2024 14:48:31

    VIJAYA DIAGNOSTIC CENTRE: Q3 EBITDA 523M RUPEES VS 443M (YOY) -- Q3 EBITDA MARGIN 39.42% VS 39.15% (YOY)

    VIJAYA, 643.90 -1.92
  • 05-Feb-2024 14:48:13

    VIJAYA DIAGNOSTIC CENTRE: Q3 REVENUE 1.33B RUPEES VS 1.13B (YOY)

    VIJAYA, 643.90 -1.92
  • 05-Feb-2024 14:48:08

    VIJAYA DIAGNOSTIC CENTRE: Q3 CONS NET 258M PROFIT RUPEES VS 164M (YOY)

    VIJAYA, 643.90 -1.92
  • 05-Feb-2024 14:24:18

    ALEMBIC PHARMA: CO SAYS API BUSINESS REMAINS ON A STRONG FOOTING MOVING FORWARD

    APLLTD, 1,017.90 -1.05
  • 05-Feb-2024 14:14:33

    UNICHEM LAB: Q3 CONS PROFIT BEFORE EXCEPTIONAL ITEM 160M RUPEES VS LOSS 613M (YOY)

    UNICHEMLAB, 517.95 0.21
  • 05-Feb-2024 14:13:31

    UNICHEM LAB: Q3 EBITDA GAIN 381M RUPEES VS LOSS 427M (YOY) -- Q3 EBITDA MARGIN 8.77%

    UNICHEMLAB, 517.95 0.21
  • 05-Feb-2024 14:12:45

    UNICHEM LAB: Q3 REVENUE4.3B RUPEES VS 3.02B (YOY)

    UNICHEMLAB, 517.95 0.21
  • 05-Feb-2024 14:12:26

    UNICHEM LAB: Q3 CONS NET PROFIT 840M RUPEES VS LOSS 639M (YOY)

    UNICHEMLAB, 517.95 0.21
  • 05-Feb-2024 14:11:41

    ALEMBIC PHARMA: Q3 EBITDA 2.66B RUPEES VS 2.49B (YOY); EST 2.37B -- Q3 EBITDA MARGIN 16.34% VS 16.47% (YOY); EST 14.4%

    APLLTD, 1,017.90 -1.05
  • 05-Feb-2024 14:11:21

    ALEMBIC PHARMA: Q3 REVENUE 16.3B RUPEES VS 15.09B (YOY)

    APLLTD, 1,017.90 -1.05
  • 05-Feb-2024 14:10:56

    ALEMBIC PHARMA: Q3 CONS NET PROFIT 1.8B RUPEES VS 1.22B (YOY); EST 1.40B

    APLLTD, 1,017.90 -1.05
  • 05-Feb-2024 13:08:30

    BIOCON: ORAL CANCER TASK FORCES CONSENSUS GUIDELINES FOR HEAD & NECK CANCER RECOGNIZED AMONG 13 WORLDWIDE CLINICAL PRACTICE GUIDELINES

    BIOCON, 276.45 1.99
  • 05-Feb-2024 11:58:02

    SEQUENT SCIENTIFIC: CO APPROVED DIVESTMENT OF ITS SHAREHOLDING AND BENEFICIAL INTEREST IN UNIT

    SEQUENT, 128.70 -2.76
02 Feb-2024
  • 02-Feb-2024 21:54:35

    JAGSONPAL PHARMA: Q3 EBITDA 34M RUPEES VS 86.34M (YOY) -- Q3 EBITDA MARGIN 7.19% VS 14.36% (YOY)

    JAGSNPHARM, 305.05 0.74
  • 02-Feb-2024 21:54:23

    JAGSONPAL PHARMA: Q3 SL NET PROFIT 39.63M RUPEES VS 77.85M (YOY) -- Q3 REVENUE 472.34M RUPEES VS 601.4M (YOY)

    JAGSNPHARM, 305.05 0.74
  • 02-Feb-2024 17:07:16

    AUROBINDO PHARMA: CO SAYS DECIDED TO TEMPORARILY STOP MANUFACTURING ON CERTAIN LINES -- CO SAYS DONT FORESEE ANY MATERIAL IMPACT ON BUSINESS

    AUROPHARMA, 1,028.10 -0.04
  • 02-Feb-2024 17:07:10

    AUROBINDO PHARMA: CO SAYS WILL BE RESPONDING TO THESE OBSERVATIONS WITHIN STIPULATED TIME

    AUROPHARMA, 1,028.10 -0.04
  • 02-Feb-2024 17:07:01

    AUROBINDO PHARMA: CO SAYS COMPLETION OF US FDA INSPECTION AT UNIT III OF EUGIA PHARMA SPECIALITIES -- INSPECTION CLOSED WITH 9 OBSERVATIONS

    AUROPHARMA, 1,028.10 -0.04
  • 02-Feb-2024 14:27:21

    JUBILANT PHARMOVA: Q3 EBITDA 2.18B RUPEES VS 1.5B (YOY) -- Q3 EBITDA MARGIN 13.09% VS 9.52% (YOY)

    JUBLPHARMA, 568.00 1.44
  • 02-Feb-2024 14:26:09

    JUBILANT PHARMOVA: Q3 CONS NET PROFIT 660M RUPEES VS LOSS 157M (YOY) -- Q3 REVENUE 16.8B RUPEES VS 15.52B (YOY)

    JUBLPHARMA, 568.00 1.44
  • 02-Feb-2024 14:01:28

    TORRENT PHARMACEUTICALS: Q3 REVENUE 27.3B RUPEES VS 24.9B (YOY)

    TORNTPHARM, 2,668.55 2.12
  • 02-Feb-2024 13:57:15

    TORRENT PHARMACEUTICALS: Q3 EBITDA 8.7B RUPEES VS 7.24B (YOY); EST 8.52B -- Q3 EBITDA MARGIN 31.81% VS 29.06% (YOY); EST 30.6%

    TORNTPHARM, 2,668.55 2.12
  • 02-Feb-2024 13:55:05

    TORRENT PHARMACEUTICALS: CO APPROVED DIVIDEND OF 22 RUPEES PER SHARE

    TORNTPHARM, 2,668.55 2.12
  • 02-Feb-2024 13:54:32

    TORRENT PHARMACEUTICALS: Q3 CONS NET PROFIT 4.4B RUPEES VS 2.92B (YOY); EST 3.63B

    TORNTPHARM, 2,668.55 2.12
  • 02-Feb-2024 12:21:50

    HESTER BIOSCIENCES: Q3 EBITDA 101M RUPEES VS 188M (YOY) -- Q3 EBITDA MARGIN 15.08% VS 25.03% (YOY)

    HESTERBIO, 1,394.95 -0.58
  • 02-Feb-2024 12:20:54

    HESTER BIOSCIENCES: Q3 CONS NET PROFIT 40M RUPEES VS 112M (YOY) -- Q3 REVENUE 670M RUPEES VS 749M (YOY)

    HESTERBIO, 1,394.95 -0.58
  • 02-Feb-2024 09:33:15

    MAX HEALTHCARE: RS. 94.87 CR NSE BLOCK TRADE; FOR ~ 1231773 SHARES, AT RS. 770.20

    MAXHEALTH, 791.15 -7.09
01 Feb-2024
  • 01-Feb-2024 17:48:41

    RPG LIFE SCIENCES: Q3 EBITDA 379M RUPEES VS 292M (YOY) -- Q3 EBITDA MARGIN 24.66% VS 22.37% (YOY)

    RPGLIFE, 1,513.95 -1.78
  • 01-Feb-2024 17:48:35

    RPG LIFE SCIENCES: Q3 SL NET PROFIT 265M RUPEES VS 191.1M (YOY) -- Q3 REVENUE 1.54B RUPEES VS 1.3B (YOY)

    RPGLIFE, 1,513.95 -1.78
  • 01-Feb-2024 17:38:28

    THYROCARE TECHNOLOGIES: Q3 EBITDA 308M RUPEES VS 280M (YOY) -- Q3 EBITDA MARGIN 22.80% VS 21.84% (YOY)

    THYROCARE, 696.25 2.24
  • 01-Feb-2024 17:38:21

    THYROCARE TECHNOLOGIES: Q3 CONS NET PROFIT 153M RUPEES VS 147M (YOY) -- Q3 REVENUE 1.35B RUPEES VS 1.28B (YOY)

    THYROCARE, 696.25 2.24
  • 01-Feb-2024 16:14:21

    PANACEA BIOTEC: OAI CLASSIFICATION IMPLIES, INTER‐ ALIA, THAT THE USFDA EXPECTS FURTHER CORRECTIVE ACTIONS AND MAY WITHHOLD APPROVAL OF ANY PENDING PRODUCT APPLICATIONS OR SUPPLEMENTS IN WHICH THIS FACILITY IS LISTED TILL THE OUTSTANDING OBSERVATIONS ARE RESOLVED

    PANACEABIO, 152.40 0.33
  • 01-Feb-2024 16:14:14

    PANACEA BIOTEC: CO UNIT GOT USFDA COMMUNICATION INDICATING INSPECTION CLASSIFICATION AS OFFICIAL ACTION INDICATED

    PANACEABIO, 152.40 0.33
  • 01-Feb-2024 15:16:30

    LUPIN: CO RECEIVES APPROVAL FROM USFDA FOR DRONEDARONE TABLETS -- TABLETS HAS US SALES OF 510M USD

    LUPIN, 1,622.05 0.35
  • 01-Feb-2024 13:30:28

    DR. LAL PATH LABS: CO RECOMENDED DIVIDEND 12 RUPEES/SHARE

    LALPATHLAB, 2,350.60 1.62
  • 01-Feb-2024 13:30:08

    DR. LAL PATH LABS: Q3 EBITDA 1.4B RUPEES VS 1.13B (YOY) -- Q3 EBITDA MARGIN 26.09% VS 23.52% (YOY)

    LALPATHLAB, 2,350.60 1.62
  • 01-Feb-2024 13:29:29

    DR. LAL PATH LABS: Q3 CONS NET PROFIT 813M RUPEES VS 528M (YOY) -- Q3 REVENUE 5.4B RUPEES VS 4.9B (YOY)

    LALPATHLAB, 2,350.60 1.62
  • 01-Feb-2024 12:59:30

    AUROBINDO PHARMA: CO CLARIFIES ON NEWS ITEM APPEARED IN TV -- CO SAYS AFTER THE INSPECTION IS CONCLUDED, CO INTIMATES THE STOCK EXCHANGES REGARDING THE OUTCOME

    AUROPHARMA, 1,028.10 -0.04
  • 01-Feb-2024 10:34:01

    AUROBINDO PHARMA: COS UNIT NO. 4 INSPECTION UNDERWAY - CNBC TV18

    AUROPHARMA, 1,028.10 -0.04
31 Jan-2024
  • 31-Jan-2024 20:30:55

    MANKIND PHARMA: Q3 EBITDA 6.06B RUPEES VS 4.37B (YOY) -- Q3 EBITDA MARGIN 23.27% VS 20.90% (YOY)

    MANKIND, 2,138.50 4.14
  • 31-Jan-2024 20:30:49

    MANKIND PHARMA: Q3 CONS NET PROFIT 4.66B RUPEES VS 2.9B (YOY); 5.01B (QOQ) -- Q3 REVENUE 26B RUPEES VS 21B (YOY); 27.1B (QOQ)

    MANKIND, 2,138.50 4.14
  • 31-Jan-2024 19:44:51

    DISHMAN CARBOGEN AMCIS: CO SAYS GOT ATTESTATION OF INSPECTION FROM EUROPEAN DIRECTORATE FOR QUALITY OF MEDICINES & HEALTHCARE AUTHORITY

    DCAL, 255.60 2.40
  • 31-Jan-2024 17:40:56

    SASTASUNDAR VENTURES: Q3 CONS NET LOSS 7M RUPEES VS LOSS 234M (YOY) -- Q3 REVENUE 3.7B RUPEES VS 2.81B (YOY)

    SASTASUNDR, 345.80 -1.00
  • 31-Jan-2024 17:33:58

    GLENMARK PHARMACEUTICALS: CO SAYS ABROCITINIB WILL BE CO‐MARKETED UNDER BRAND NAMES JABRYUS AND CIBINQO BY GLENMARK AND PFIZER RESPECTIVELY

    GLENMARK, 925.95 1.62
  • 31-Jan-2024 17:33:51

    GLENMARK PHARMACEUTICALS: GLENMARK PARTNERS WITH PFIZER TO LAUNCH ABROCITINIB IN INDIA -- DEVELOPED BY PFIZER, ABROCITINIB HAS RECEIVED MARKETING AUTHORIZATION FROM CDSCO, US FDA AND EMA

    GLENMARK, 925.95 1.62
  • 31-Jan-2024 16:25:38

    AJANTA PHARMA: CO DECLARED 2ND INTERIM DIVIDEND FOR THE YEAR FY 2024 OF 26 RUPEES PER SHARE

    AJANTPHARM, 2,232.70 7.08
  • 31-Jan-2024 16:25:32

    AJANTA PHARMA: Q3 EBITDA 3.14B RUPEES VS 1.69B (YOY) -- Q3 EBITDA MARGIN 28.42% VS 17.39% (YOY)

    AJANTPHARM, 2,232.70 7.08
  • 31-Jan-2024 16:25:26

    AJANTA PHARMA: Q3 CONS NET PROFIT 2B RUPEES VS 1.34B (YOY) -- Q3 REVENUE 11.05B RUPEES VS 9.72B (YOY)

    AJANTPHARM, 2,232.70 7.08
  • 31-Jan-2024 14:18:25

    MOREPEN LABORATORIES: Q3 EBITDA 506M RUPEES VS 205M (YOY) -- Q3 EBITDA MARGIN 11.37% VS 5.89% (YOY)

    MOREPENLAB, 49.45 0.92
  • 31-Jan-2024 14:17:56

    MOREPEN LABORATORIES: Q3 REVENUE 4.44B RUPEES VS 3.48B (YOY)

    MOREPENLAB, 49.45 0.92
  • 31-Jan-2024 14:17:24

    MOREPEN LABORATORIES: Q3 CONS NET PROFIT 320M RUPEES VS 90M (YOY)

    MOREPENLAB, 49.45 0.92
  • 31-Jan-2024 14:16:12

    SUN PHARMA INDUSTRIES: Q3 EBITDA 34.8B RUPEES VS 30B (YOY); EST 31.97B -- Q3 EBITDA MARGIN 28.08% VS 26.7% (YOY); EST 26.2%

    SUNPHARMA, 1,579.75 0.37
  • 31-Jan-2024 14:14:28

    SUN PHARMA INDUSTRIES: Q3 REVENUE 124B RUPEES VS 112.41B (YOY)

    SUNPHARMA, 1,579.75 0.37
  • 31-Jan-2024 14:14:15

    SUN PHARMA INDUSTRIES: Q3 NET PROFIT 25.2B RUPEES VS 21.66B (YOY); EST 23.8B

    SUNPHARMA, 1,579.75 0.37
  • 31-Jan-2024 13:47:48

    VIMTA LABS: Q3 EBITDA 218M RUPEES VS 214M (YOY)

    VIMTALABS, 507.80 1.33
  • 31-Jan-2024 13:46:58

    VIMTA LABS: Q3 REVENUE 817M RUPEES VS 774M (YOY)

    VIMTALABS, 507.80 1.33
  • 31-Jan-2024 13:46:19

    VIMTA LABS: Q3 CONS NET PROFIT 101M RUPEES VS 102M (YOY)

    VIMTALABS, 507.80 1.33
  • 31-Jan-2024 13:14:34

    MAX HEALTHCARE: CO PLANS RUPEES 600 CRORES LOAN AGREEMENT WITH GUJARMAL MODI HOSPITAL FOR EXPANSION OF MAX SMART SUPER SPECIALITY HOSPITAL

    MAXHEALTH, 791.15 -7.09
  • 31-Jan-2024 13:11:06

    MAX HEALTHCARE: CO RECEIVES APPROVAL TO ACQUIRE 3.6% ADDITIONAL EQUITY STAKE IN SANDHYA HYDRO POWER PROJECTS, STRENGTHENING ITS TOTAL HOLDING TO 5.8%

    MAXHEALTH, 791.15 -7.09
  • 31-Jan-2024 13:06:00

    MAX HEALTHCARE INSTITUTE: Q3 EBITDA 3.86B RUPEES VS 3.13B (YOY) -- Q3 EBITDA MARGIN 28.90% VS 27.50% (YOY)

    MAXHEALTH, 791.15 -7.09
  • 31-Jan-2024 13:05:19

    MAX HEALTHCARE INSTITUTE: Q3 CONS NET PROFIT 2.9B RUPEES VS 2.2B (YOY) -- Q3 REVENUE 13.4B RUPEES VS 11.41B (YOY)

    MAXHEALTH, 791.15 -7.09
  • 31-Jan-2024 11:55:16

    POLY MEDICURE: Q3 EBITDA 902M RUPEES VS 714M (YOY) -- Q3 EBITDA MARGIN 26.57% VS 25.06% (YOY)

    POLYMED, 1,560.90 -1.66
  • 31-Jan-2024 11:53:49

    POLY MEDICURE: Q3 CONS NET PROFIT 650M RUPEES VS 500M (YOY) -- Q3 REVENUE 3.4B RUPEES VS 2.84B (YOY)

    POLYMED, 1,560.90 -1.66
  • 31-Jan-2024 09:17:16

    AUROBINDO PHARMA: RS. 322.59 CR NSE BLOCK TRADE; FOR ~ 2807682 SHARES, AT RS. 1148.95

    AUROPHARMA, 1,028.10 -0.04
30 Jan-2024
  • 30-Jan-2024 21:07:01

    PIRAMAL PHARMA: Q3 EBITDA 2.69B RUPEES VS 873.3M (YOY) -- Q3 EBITDA MARGIN 13.72% VS 5.09% (YOY)

    PPLPHARMA, 131.75 1.19
  • 30-Jan-2024 21:06:53

    PIRAMAL PHARMA: Q3 CONS NET PROFIT 101M RUPEES VS LOSS 901.8M (YOY); PROFIT 50.2M (QOQ) -- Q3 REVENUE 19.58B RUPEES VS 17.2B (YOY); 19.11B (QOQ)

    PPLPHARMA, 131.75 1.19
  • 30-Jan-2024 20:53:20

    AARTI DRUGS: TOTAL INVESTMENT REQUIREMENT 1.5-2B RUPEES -- FACILITY WILL HAVE TOTAL OPERATIONAL CAPACITY OF 24,000 MTPA

    AARTIDRUGS, 497.90 -0.56
  • 30-Jan-2024 20:53:13

    AARTI DRUGS: CO SAYS INITIATING COMMERCIAL PRODUCTION OF DERMATOLOGY PRODUCT AT FACILITY IN TARAPUR, MAHARASHTRA

    AARTIDRUGS, 497.90 -0.56
  • 30-Jan-2024 20:15:54

    LAURUS LABS: CO SAYS IS SEEING GOOD RFPS FLOW FROM BIG PHARMA AND LEADING BIOTECHS AND EXPECTS ITS CDMO GROWTH POTENTIAL TO ACCELERATE IN THE COMING YEARS -- CO HAS A TOTAL OF 61 PRODUCTS IN ITS R&D PIPELINE

    LAURUSLABS, 407.00 0.48
  • 30-Jan-2024 20:15:44

    LAURUS LABS: CO SAYS EXCITED ABOUT ITS ENTRY INTO THE CELL AND GENE THERAPY SPACE

    LAURUSLABS, 407.00 0.48
  • 30-Jan-2024 19:36:24

    GUFIC BIOSCIENCES: CO GRANTED PATENT OF ADDITION FOR FREEZE DRIED PARENTERAL COMPOSITION OF OMADACYCLINE TOSYLATE -- CO GOT PATENT FOR 20 YEARS

    GUFICBIO, 313.55 1.32
  • 30-Jan-2024 18:06:48

    DR REDDYS LABORATORIES: CO EXEC SAYS NO MATERIAL IMPACT FROM RED SEA CRISIS, HAVE BEEN ABLE TO DIVERT ROUTES

    DRREDDY, 6,425.55 -0.04
  • 30-Jan-2024 17:42:13

    GLENMARK PHARMA: CO AND ICHNOS COLLABORATE TO ACCELERATE INNOVATION IN CANCER TREATMENT -- THIS ALLIANCE BRINGS TOGETHER DRUG INNOVATION CAPABILITIES OF GLENMARK AND ICHNOS TO DEVELOP CUTTING‐EDGE THERAPIES FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES AND SOLID TUMORS

    GLENMARK, 925.95 1.62
  • 30-Jan-2024 16:30:22

    DR REDDYS LABORATORIES: CO APPROVED INVESTMENT IN AURIGENE ONCOLOGY LIMITED UP TO 6.5B RUPEES

    DRREDDY, 6,425.55 -0.04
  • 30-Jan-2024 16:04:22

    DR.REDDYS LAB: Q3 EBITDA 20.23B RUPEES VS 19.66B (YOY); EST 19.72B -- Q3 EBITDA MARGIN 27.96% VS 29.04% (YOY); EST 28.6%

    DRREDDY, 6,425.55 -0.04
  • 30-Jan-2024 16:04:15

    DR.REDDYS LAB: Q3 CONS NET PROFIT 13.81B RUPEES VS 12.5B (YOY); EST 12.94B - 14.8B (QOQ) -- Q3 REVENUE 72.37B RUPEES VS 67.7B (YOY); 69.03B (QOQ)

    DRREDDY, 6,425.55 -0.04
  • 30-Jan-2024 13:24:54

    STRIDES PHARMA: CO SAYS AIMING FOR AN EBITDA OF ₹7B – ₹7.5B -- CO FURTHER SAYS CONTINUING BUSINESS REVENUES TO GROW AT 15% YOY

    STAR, 784.50 0.25
  • 30-Jan-2024 13:23:20

    STRIDES PHARMA: CO SAYS PLEASED TO ANNOUNCE THE SUCCESSFUL DIVESTMENT OF SINGAPORE FACILITY, THEREBY OPTIMISING OUR MANUFACTURING NETWORK

    STAR, 784.50 0.25
  • 30-Jan-2024 13:23:05

    STRIDES PHARMA SCIENCE: CO SAYS PERFORMANCE PREDOMINANTLY DRIVEN BY OUR US OPERATIONS, WHICH RECORDED ITS HIGHEST-EVER REVENUE OF $67 MILLION IN THE QUARTER

    STAR, 784.50 0.25
  • 30-Jan-2024 13:21:48

    STRIDES PHARMA SCIENCE: CO SAYS NET DEBT TO EBITDA IMPROVED TO 3.0X, TRENDING AHEAD ON NET DEBT TO EBITDA TARGET < 3X FOR FY24

    STAR, 784.50 0.25
  • 30-Jan-2024 13:21:29

    STRIDES PHARMA SCIENCE: Q3 EBITDA 1.94B RUPEES VS 1.2B (YOY) -- Q3 EBITDA MARGIN 18.68% VS 13.8% (YOY)

    STAR, 784.50 0.25
  • 30-Jan-2024 13:20:33

    STRIDES PHARMA SCIENCE: Q3 CONS NET PROFIT 497M RUPEES VS LOSS 800M (YOY) -- Q3 REVENUE 10.4B RUPEES VS 8.7B (YOY)

    STAR, 784.50 0.25
  • 30-Jan-2024 13:19:00

    STRIDES PHARMA SCIENCE: Q3 CONS NET PROFIT BEFORE EXCEPTIONAL ITEM 720M RUPEES VS PROFIT 240M (YOY)

    STAR, 784.50 0.25
  • 30-Jan-2024 13:00:14

    SUVEN LIFE SCIENCES: Q3 SL NET LOSS 48M RUPEES VS LOSS 66M (YOY)

    SUVEN, 102.50 0.89
  • 30-Jan-2024 12:37:16

    LUPIN: CO DIGITAL HEALTH INTRODUCES DIGITAL THERAPEUTICS CERTIFICATE FOR CARDIOLOGISTS IN INDIA IN COLLABORATION WITH THE AMERICAN COLLEGE OF CARDIOLOGY

    LUPIN, 1,622.05 0.35
  • 30-Jan-2024 09:37:20

    ZYDUS LIFESCIENCES: CO SAYS WITH THIS LAUNCH, ZYDUS BRINGS BOTH ACCESS TO A CRITICAL THERAPY AND ALSO MAKES IT AFFORDABLE AT A COST OF RS. 6995 PER MONTH

    ZYDUSLIFE, 943.80 1.20
  • 30-Jan-2024 09:36:14

    ZYDUS LIFESCIENCES: CO LAUNCHES REXIGO, THE ORAL ONCE-A-DAY PILL FOR ADVANCED PROSTATE CANCER PATIENTS IN INDIA

    ZYDUSLIFE, 943.80 1.20
29 Jan-2024
  • 29-Jan-2024 18:26:50

    DR REDDYS LABORATORIES: BARCLAYS RAISES TARGET PRICE TO $80 FROM $75

    DRREDDY, 6,425.55 -0.04
  • 29-Jan-2024 11:13:28

    DIVIS LAB: Rs 35.85cr NSE Block Trade; for ~100274 shares, at Rs 3575

    DIVISLAB, 3,490.00 -0.81
  • 29-Jan-2024 09:11:19

    AMI ORGANICS: COS UNIT COMMENCES COMMERCIAL OPERATIONS FOR LITHIUM-ION BATTERY CELL PRODUCTS

    AMIORG, 1,112.30 -1.35
25 Jan-2024
  • 25-Jan-2024 18:52:49

    STRIDES PHARMA SCIENCE: STRIDES RECEIVES USFDA APPROVAL FOR PREGABALIN CAPSULES -- PREGABALIN CAPSULES HAS A MARKET SIZE OF ~US$248M PER IQVIA; PRODUCT WILL BE MANUFACTURED AT THE CO’S FACILITY IN PUDUCHERRY

    STAR, 784.50 0.25
  • 25-Jan-2024 17:51:48

    NEULAND LABORATORIES: CO APPROVED CAPITAL EXPENDITURE OF 172M RUPEES FOR ACQUISITION OF LAND PARCEL

    NEULANDLAB, 7,149.90 0.67
  • 25-Jan-2024 16:55:41

    LAURUS LABS: LAURUS LABS ENTERS INTO JOINT VENTURE AGREEMENT WITH KRKA, SLOVENIA

    LAURUSLABS, 407.00 0.48
  • 25-Jan-2024 16:55:33

    LAURUS LABS: CO TO ESTABLISH A JOINT VENTURE COMPANY IN HYDERABAD -- NEWLY FOUNDED CO SHALL BE UP TO INDIAN RUPEES EQUIVALENT TO 50M EUROS -- JV WILL ENABLE PRODUCTION OF FINISHED PRODUCTS FOR NEW MARKETS

    LAURUSLABS, 407.00 0.48
  • 25-Jan-2024 16:37:38

    CIPLA: CO CEO SAYS Q3 SAW SOME IMPACT FROM RED SEA CRISIS, EXPECT SOME OF IT IN Q4 TOO

    CIPLA, 1,477.55 0.04
  • 25-Jan-2024 14:47:20

    SYNGENE INTERNATIONAL: CO SAYS BIOTECH SECTOR FACES SLOWDOWN IN US FUNDING, LEADING TO ADJUSTED REVENUE GROWTH PROJECTIONS IN NEAR TERM

    SYNGENE, 706.60 -0.32
  • 25-Jan-2024 14:44:20

    ZYDUS LIFESCIENCES: CO RECEIVES FINAL APPROVAL FROM THE USFDA FOR GABAPENTIN TABLETS (ONCE-DAILY), 300 MG AND 600 MG -- TABLETS HAS US SALES OF 85M USD

    ZYDUSLIFE, 943.80 1.20
  • 25-Jan-2024 14:33:19

    SYNGENE INTERNATIONAL: Q3 EBITDA 2.3B RUPEES VS 2.3B (YOY) -- Q3 EBITDA MARGIN 27.12% VS 29.39% (YOY)

    SYNGENE, 706.60 -0.32
  • 25-Jan-2024 14:32:17

    SYNGENE INTERNATIONAL: Q3 REVENUE 8.53B RUPEES VS 7.86B (YOY)

    SYNGENE, 706.60 -0.32
  • 25-Jan-2024 14:32:12

    SYNGENE INTERNATIONAL: Q3 CONS NET PROFIT 1.1B RUPEES VS 1.09B (YOY)

    SYNGENE, 706.60 -0.32
  • 25-Jan-2024 10:11:44

    FORTIS HEALTHCARE: Rs 94.7cr BSE Block Trade; for ~2212583 shares, at Rs 428 (MULTIPLE BLOCKS)

    FORTIS, 408.55 -3.07
  • 25-Jan-2024 09:10:52

    GLENMARK PHARMA: CO ANNOUNCE THE SIGNING OF A LICENSE AGREEMENT FOR KN035 FOR MULTIPLE GEOGRAPHIES AROUND THE WORLD WITH JIANGSU ALPHAMAB BIOPHARMACEUTICALS, 3D MEDICINES

    GLENMARK, 925.95 1.62
24 Jan-2024
  • 24-Jan-2024 19:24:36

    SHILPA MEDICARE: CO SAYS ARBITRATOR DIRECTED CO TO PAY TO CELLTRION, INC DAMAGES FOR BREACH OF A CONTRACT IN SUM OF $3.06M

    SHILPAMED, 414.80 1.01
  • 24-Jan-2024 18:15:36

    RAINBOW CHILDRENS: Q3 EBITDA 1.18B RUPEES VS 1.07B (YOY) -- Q3 EBITDA MARGIN 35.19% VS 34.82% (YOY)

    RAINBOW, 1,352.60 -5.36
  • 24-Jan-2024 18:15:30

    RAINBOW CHILDRENS: Q3 CONS NET PROFIT 621M RUPEES VS 579M (YOY); 629M (QOQ) -- Q3 REVENUE 3.36B RUPEES VS 3B (YOY); 3.33B (QOQ)

    RAINBOW, 1,352.60 -5.36
  • 24-Jan-2024 16:29:41

    AARTI DRUGS: CO DECLARED INTERIM DIVIDEND OF 1 RUPEES PER SHARE

    AARTIDRUGS, 497.90 -0.56
  • 24-Jan-2024 16:29:33

    AARTI DRUGS: Q3 EBITDA 701M RUPEES VS 706M (YOY) -- Q3 EBITDA MARGIN 11.58% VS 10.64% (YOY)

    AARTIDRUGS, 497.90 -0.56
  • 24-Jan-2024 16:29:27

    AARTI DRUGS: Q3 CONS NET PROFIT 367M RUPEES VS 369M (YOY); (QOQ) -- Q3 REVENUE 6.06B RUPEES VS 6.64B (YOY); 6.4B (QOQ)

    AARTIDRUGS, 497.90 -0.56
  • 24-Jan-2024 15:30:29

    LAURUS LABS: Q3 EBITDA 1.8B RUPEES VS 4.03B (YOY); EST 2.82B -- Q3 EBITDA MARGIN 15.18% VS 26.15% (YOY); EST 20.6%

    LAURUSLABS, 407.00 0.48
  • 24-Jan-2024 15:26:43

    LAURUS LABS: Q3 REVENUE 12B RUPEES VS 15.4B (YOY)

    LAURUSLABS, 407.00 0.48
  • 24-Jan-2024 15:26:15

    LAURUS LABS: Q3 CONS NET PROFIT 231M RUPEES VS 2.03B (YOY); EST 1.08B

    LAURUSLABS, 407.00 0.48
  • 24-Jan-2024 11:08:13

    LUPIN: CO TO CONSIDER Q3 RESULTS ON FEB 7

    LUPIN, 1,622.05 0.35
23 Jan-2024
  • 23-Jan-2024 19:35:59

    DISHMAN CARBOGEN AMCIS: CO SAYS BAVLA SITE HAS BEEN DECLARED GMP COMPLIANT BY JAPANESE PHARMACEUTICALS AND MEDICAL DEVICES AGENCY

    DCAL, 255.60 2.40
  • 23-Jan-2024 17:49:46

    GLENMARK LIFE SCIENCES: CO SIGNED MULTI-YEAR DEFINITIVE AGREEMENT TO SUPPLY APIS FOR AN INNOVATORS PRODUCT, WHICH IS EXPECTED TO COMMERCIALIZE IN FY25

    GLS, 869.45 -0.84
  • 23-Jan-2024 17:37:28

    GLENMARK LIFE SCIENCES: Q3 EBITDA 1.73B RUPEES VS 1.5B (YOY) -- Q3 EBITDA MARGIN 30.13% VS 28.10% (YOY)

    GLS, 869.45 -0.84
  • 23-Jan-2024 17:37:19

    GLENMARK LIFE SCIENCES: Q3 SL NET PROFIT 1.19B RUPEES VS 1B (YOY); 1.2B (QOQ) -- Q3 REVENUE 5.73B RUPEES VS 5.4B (YOY); 6B (QOQ)

    GLS, 869.45 -0.84
  • 23-Jan-2024 16:28:24

    LUPIN: CO RECEIVES TENTATIVE APPROVAL FROM U.S. FDA FOR RIVAROXABAN TABLETS USP -- RIVAROXABAN TABLETS USP (RLD XARELTO®) HAD ESTIMATED ANNUAL SALES OF USD 8,249 MILLION IN THE U.S. (IQVIA MAT NOV 2023)

    LUPIN, 1,622.05 0.35
  • 23-Jan-2024 14:47:05

    CIPLA: COS UNITS INCORPORATE MEXICIP S.A. DE C.V. IN MEXICO, ADVANCING PRESENCE IN PHARMA INDUSTRY

    CIPLA, 1,477.55 0.04
  • 23-Jan-2024 12:24:48

    INDOCO REMEDIES: Q3 EBITDA 629M RUPEES VS 620M (YOY) -- Q3 EBITDA MARGIN 13.69% VS 15.54% (YOY)

    INDOCO, 349.00 -0.60
  • 23-Jan-2024 12:23:23

    INDOCO REMEDIES: Q3 CONS NET PROFIT 163M RUPEES VS 281M (YOY) -- Q3 REVENUE 4.6B RUPEES VS 4.1B (YOY)

    INDOCO, 349.00 -0.60
  • 23-Jan-2024 12:18:38

    GRANULES INDIA: Q3 EBITDA 2.5B RUPEES VS 2.3B (YOY) -- Q3 EBITDA MARGIN 22% VS 20% (YOY)

    GRANULES, 464.50 0.98
  • 23-Jan-2024 12:17:50

    GRANULES INDIA: Q3 CONS NET PROFIT 1.26B RUPEES VS 1.24B (YOY) -- Q3 REVENUE 11.55B RUPEES VS 11.5B (YOY)

    GRANULES, 464.50 0.98
22 Jan-2024
  • 22-Jan-2024 21:11:31

    CIPLA: Q3 EBITDA 17.47B RUPEES VS 14.08B (YOY) -- Q3 EBITDA MARGIN 26.45% VS 24.23% (QOQ)

    CIPLA, 1,477.55 0.04
  • 22-Jan-2024 21:11:25

    CIPLA: Q3 CONS NET PROFIT 10.55B VS 8B (YOY); 11B (QOQ) -- Q3 REVENUE 65B RUPEES VS 57B (YOY); 66B (QOQ)

    CIPLA, 1,477.55 0.04
  • 22-Jan-2024 16:28:33

    PFIZER: CO NAMES AMIT AGARWAL AS CFO

    PFIZER, 4,601.45 0.89
20 Jan-2024
  • 20-Jan-2024 12:59:28

    ASTRAZENECA PHARMA: CO RECEIVES PERMISSION TO IMPORT PHARMACEUTICAL FORMULATIONS OF NEW DRUG FOR SALE OR FOR DISTRIBUTION IN FORM CT-20 FROM CENTRAL DRUGS STANDARD CONTROL ORGANISATION FOR ANDEXANET ALFA POWDER FOR SOLUTION FOR INFUSION 200 MG

    ASTRAZEN, 5,535.50 0.42
19 Jan-2024
  • 19-Jan-2024 17:42:13

    FORTIS HEALTHCARE: CO UNIT RECEIVED A NOTICE FROM ANTI-CORRUPTION BRANCH, GOVT OF NATIONAL CAPITAL TERRITORY OF DELHI -- NOTICE REGARDING ALLEGED ANOMALIES IN DIAGNOSTICS TEST IN AAM AADMI MOHALLA CLINIC AND OTHER ISSUES

    FORTIS, 408.55 -3.07
  • 19-Jan-2024 16:52:02

    SIGACHI INDUSTRIES: Q3 EBITDA 226M RUPEES VS 149M (YOY) -- Q3 EBITDA MARGIN 20.36% VS 21.67% (YOY)

    SIGACHI, 83.50 -0.77
  • 19-Jan-2024 16:51:57

    SIGACHI INDUSTRIES: Q3 CONS NET PROFIT 161M RUPEES VS 98M (YOY); 151.4M (QOQ) -- Q3 REVENUE 1.11B RUPEES VS 688M (YOY); 992M (QOQ)

    SIGACHI, 83.50 -0.77
  • 19-Jan-2024 15:23:59

    STRIDES PHARMA SCIENCE: INVESTOR MUKUL AGARWAL NAME APPEARS WITH STAKE OF 1.5% IN CO DURING Q3

    STAR, 784.50 0.25
  • 19-Jan-2024 12:57:01

    LUPIN: Rs. 22.20 Cr NSE Block Trade; for ~ 154967 Shares, at Rs. 1432.60

    LUPIN, 1,622.05 0.35
  • 19-Jan-2024 12:30:15

    SHILPA MEDICARE: CO SAYS AMIFAMPRIDINE TABLETS HAS SALES OF 20M USD IN EUROPE

    SHILPAMED, 414.80 1.01
  • 19-Jan-2024 12:29:11

    SHILPA MEDICARE: CO RECEIVED MARKETING AUTHORIZATION FROM GERMANY, EU FOR AMIFAMPRIDINE TABLETS, 10 MG UNDER NATIONAL PROCEDURE -- TABLETS HAS A SALE OF 20M USD IN EUROPE

    SHILPAMED, 414.80 1.01
  • 19-Jan-2024 09:46:04

    GLENMARK LIFE: CO SAYS THE ESTIMATED COMMERCIAL VALUE OF THIS PROJECT IS EXPECTED TO BE AROUND $5M

    GLS, 869.45 -0.84
  • 19-Jan-2024 09:45:14

    GLENMARK LIFE: CO SIGNS MASTER SUPPLY AGREEMENT WITH A LEADING JAPANESE INNOVATOR PHARMACEUTICAL CO TO MANUFACTURE AND SUPPLY API IN THE THERAPEUTIC AREA OF URINARY ANTI-SPASMODIC

    GLS, 869.45 -0.84
  • 19-Jan-2024 08:18:54

    ZYDUS LIFESCIENCES: CO AND SYNTHON ENTER INTO AN EXCLUSIVE LICENSING AND SUPPLY AGREEMENT FOR PALBOCICLIB TABLETS (GENERIC VERSION OF IBRANCE) FOR THE US MARKET

    ZYDUSLIFE, 943.80 1.20
18 Jan-2024
  • 18-Jan-2024 19:55:07

    ALEMBIC PHARMACEUTICALS: CO HAS AGREED TO INVEST USD 1.0M IN THE FORM OF PROMISSORY NOTES ISSUED BY RIGIMMUNE, INC

    APLLTD, 1,017.90 -1.05
  • 18-Jan-2024 17:46:59

    DR REDDYS LABORATORIES: CO SAYS DOES NOT COMMENT ON MARKET SPECULATIONS -- CO CLARIFIES TO NEWS REPORT DR REDDYS LABORATORIES EYES MEGA BRAND IN UK

    DRREDDY, 6,425.55 -0.04
  • 18-Jan-2024 17:29:30

    ALEMBIC PHARMACEUTICALS: BOARD MEETING ON FEB 5 TO CONSIDER Q3 RESULTS

    APLLTD, 1,017.90 -1.05
  • 18-Jan-2024 17:17:27

    LUPIN: CO RECEIVES APPROVAL FROM U.S. FDA FOR FEBUXOSTAT TABLETS -- TABLETS HAS ESTIMATED ANNUAL SALES OF USD 27 MILLION IN THE U.S. (IQVIA MAT NOVEMBER 2023)

    LUPIN, 1,622.05 0.35
  • 18-Jan-2024 16:21:42

    SHALBY: CO TO ACQUIRE MAJORITY STAKE IN PK HEALTHCARE -- DEAL FOR 1.02B RUPEES

    SHALBY, 269.25 -3.67
  • 18-Jan-2024 14:21:28

    INDOCO REMEDIES: CO SAYS PRE APPROVAL INSPECTION (PAI) WAS CONDUCTED FOR TWO DRUG PRODUCT APPLICATIONS (ANDAS) FILED FROM THIS FACILITY, FOR WHICH APPROVALS ARE EXPECTED SOON

    INDOCO, 349.00 -0.60
  • 18-Jan-2024 14:17:31

    INDOCO REMEDIES: CO RECEIVES EIR INDICATING A SUCCESSFUL CLOSURE OF THE INSPECTION OF GOA PLANT - I

    INDOCO, 349.00 -0.60
  • 18-Jan-2024 12:57:32

    MAX HEALTHCARE INSTITUTE LTD: RS. 312.95 CRORES NSE BLOCK TRADE; FOR ~ 4391910 SHARES, AT RS. 712.55

    MAXHEALTH, 791.15 -7.09
17 Jan-2024
  • 17-Jan-2024 15:24:13

    NATCO PHARMA: CO INVESTS AROUND USD 2M IN CELLOGEN THERAPEUTICS PRIVATE LTD

    NATCOPHARM, 995.00 1.17
  • 17-Jan-2024 14:45:10

    LAURUS LABS: BOARD MEETING ON JAN 24 TO CONSIDER Q3 RESULTS

    LAURUSLABS, 407.00 0.48
  • 17-Jan-2024 13:22:28

    SUN PHARMA: BAYER AND CO SIGN MARKETING AND DISTRIBUTION AGREEMENT FOR SECOND BRAND OF FINERENONE IN INDIA

    SUNPHARMA, 1,579.75 0.37
  • 17-Jan-2024 11:55:27

    DR. LAL PATHLABS: Rs. 24.84 Cr NSE Block Trade; for ~ 102846 Shares, at Rs. 2414.90

    LALPATHLAB, 2,350.60 1.62
  • 17-Jan-2024 11:38:21

    AUROBINDO PHARMA: COS SUBSIDIARY, CURATEQ BIOLOGICS, RECEIVES FAVORABLE RECOMMENDATION FOR MARKETING AUTHORIZATION OF BIOSIMILAR TRASTUZUMAB FROM CDSCOS SEC

    AUROPHARMA, 1,028.10 -0.04
16 Jan-2024
  • 16-Jan-2024 17:33:08

    DR REDDYS LAB: CO IN TALKS TO BUY NICOTINELL BRAND FROM HALEON - SKY NEWS

    DRREDDY, 6,425.55 -0.04
15 Jan-2024
  • 15-Jan-2024 20:22:57

    ASTER DM HEALTHCARE: CO SAYS DESIROUS TO CONSIDER DISTRIBUTION OF 70% TO 80% OF UPFRONT CONSIDERATION OF $903M, AS DIVIDEND TO ITS SHAREHOLDERS IN THE RANGE OF INR 110/- TO INR 120/- PER SHARE

    ASTERDM, 471.55 -2.74
  • 15-Jan-2024 16:27:15

    ASTER DM HEALTHCARE: CO BOARD WAS BRIEFED THAT THERE HAS BEEN SATISFACTORY PROGRESS ON CONDITIONS PRECEDENT FOR DEAL -- AFFINITY, ALPHA GCC AIMING TO COMPLETE DEAL SOON

    ASTERDM, 471.55 -2.74
  • 15-Jan-2024 16:27:09

    ASTER DM HEALTHCARE: CO TO DISCUSS PROGRESS OF TRANSACTION FOR SEGREGATION OF COMPANYS GCC BUSINESS

    ASTERDM, 471.55 -2.74
  • 15-Jan-2024 16:27:02

    ASTER DM HEALTHCARE: CO SAYS DESIROUS TO CONSIDER DISTRIBUTION OF 70% TO 80% OF UPFRONT CONSIDERATION OF $903M, AS DIVIDEND TO ITS SHAREHOLDERS

    ASTERDM, 471.55 -2.74
  • 15-Jan-2024 16:26:48

    SUN PHARMA: BOARD MEETING ON JAN 31 TO CONSIDER Q3 RESULTS -- CO TO CONSIDER AND APPROVE DECLARATION OF INTERIM DIVIDEND; IF ANY

    SUNPHARMA, 1,579.75 0.37
  • 15-Jan-2024 14:50:13

    SUN PHARMA: Rs. 20.02 Cr NSE Block Trade; for ~ 150298 Shares, at Rs. 1331.85

    SUNPHARMA, 1,579.75 0.37
  • 15-Jan-2024 13:51:36

    MAX HEALTHCARE INSTITUTE: Rs. 18.36 Cr NSE Block Trade; for ~ 251316 Shares, at Rs. 730.75

    MAXHEALTH, 791.15 -7.09
  • 15-Jan-2024 11:58:33

    JB CHEMICALS & PHARMA: Rs. 33.20 Cr NSE Block Trade; for ~ 198573 Shares, at Rs. 1672

    JBCHEPHARM, 1,564.45 -2.23
  • 15-Jan-2024 10:48:48

    METROPOLIS HEALTHCARE: Rs. 15.50 Cr NSE Block Trade; for ~ 100011 Shares, at Rs. 1550

    METROPOLIS, 1,602.35 -0.19
  • 15-Jan-2024 10:00:25

    BIOCON: CO INITIATES TALKS FOR POTENTIAL STAKE SALE IN BIOSIMILAR ARM & SYNGENE-- CO TO USE PROCEEDS TO REDUCE DEBT: ET SOURCE

    BIOCON, 276.45 1.99
12 Jan-2024
  • 12-Jan-2024 20:02:57

    ALKEM LABORATORIES: CO SAYS INCIDENT RESULTED IN A FRAUDULENT TRANSFER OF FUNDS OF ABOUT 520M RUPEES

    ALKEM, 5,138.55 2.97
  • 12-Jan-2024 20:02:50

    ALKEM LABORATORIES: CO SAYS CYBER SECURITY INCIDENT WHICH COMPROMISED BUSINESS EMAIL IDS OF CERTAIN EMPLOYEES AT ONE OF CO’S SUBSIDIARIES -- CO SAYS TAKEN NECESSARY STEPS, FILED COMPLAINTS WITH CONCERNED GOVT AND REGULATORY AUTHORITIES IN MATTER

    ALKEM, 5,138.55 2.97
  • 12-Jan-2024 19:53:42

    ASTER DM HEALTHCARE: ASTER HEALTH ACADEMY UNIT, CORPORATE UNIT TO CONTINUE OPERATING UNDER DM MEDCITY

    ASTERDM, 471.55 -2.74
  • 12-Jan-2024 16:35:54

    ZYDUS LIFE SCIENCES: INDIA INVESTOR SUMMIT - ZYDUS LIFE SCIENCES EXEC SAYS CO TO INVEST 50B RUPEES FOR BIOTECH PRODUCTS, MEDICAL DEVICES INITIATIVES, AND HOSPITALS

    ZYDUSLIFE, 943.80 1.20
  • 12-Jan-2024 12:54:33

    CIPLA: Rs. 26.50 Cr NSE Block Trade; for ~ 202246 Shares, at Rs. 1310.35

    CIPLA, 1,477.55 0.04
  • 12-Jan-2024 12:34:04

    GLAXOSMITHKLINE PHARMA: Rs. 29.77 Cr NSE Block Trade; for ~ 132102 Shares, at Rs. 2253.35

    GLAXO, 2,176.10 1.02
  • 12-Jan-2024 12:25:05

    PIRAMAL PHARMA: Rs. 28.93 Cr NSE Block Trade; for ~ 2027008 Shares, at Rs. 142.70

    PPLPHARMA, 131.75 1.19
11 Jan-2024
  • 11-Jan-2024 18:00:12

    SHALBY: CO SIGNS MOU WITH KAUSHALYA, THE SKILL UNIVERSITY OF THE GOVERNMENT OF GUJARAT -- THIS MOU SIGNIFIES OUR COMMITMENT TO COLLABORATIVELY ORGANIZE DIVERSE HEALTHCARE SKILL ENHANCEMENT INITIATIVES IN THE UPCOMING YEARS

    SHALBY, 269.25 -3.67
  • 11-Jan-2024 15:31:09

    STRIDES PHARMA: CO UPDATED REGARDING DIVESTMENT OF ITS 100% SHAREHOLDING IN ERIS PHARMA GMBH, GERMANY (ERIS) TO A THIRD PARTY -- DEAL FOR 200000 EUROS

    STAR, 784.50 0.25
  • 11-Jan-2024 15:04:02

    RAINBOW CHILDRENS: Rs. 22.14 Cr NSE Block Trade; for ~ 170398 Shares, at Rs. 1299.25

    RAINBOW, 1,352.60 -5.36
  • 11-Jan-2024 11:57:39

    UNICHEM LABORATORIES: CO TO RECIEVES OF ANDA APPROVAL FROM USFDA FOR UNICHEM’S DOXAZOSIN TABLETS

    UNICHEMLAB, 517.95 0.21
  • 11-Jan-2024 10:02:08

    IPCA LAB: Rs. 22.85 Cr NSE Block Trade; for ~ 201563 Shares, at Rs. 1133.65

    IPCALAB, 1,191.35 0.26
10 Jan-2024
  • 10-Jan-2024 19:25:09

    MANKIND PHARMA: CO SAYS GOING AHEAD - BUILD ALTERNATIVE CHANNELS OF GROWTH INCLUDING E-COMMERCE AND OTHER CONTEMPORARY TRADE CHANNELS; ~5% IN FY23 -- CONTINUE TO DEVELOP DIGITAL PLATFORMS TO ENHANCE DOCTOR ENGAGEMENT MEDICAL CONTENT; LAUNCH OF NEXT GENERATION AI BASED SALES FORCE AUTOMATION TOOL

    MANKIND, 2,138.50 4.14
  • 10-Jan-2024 19:25:07

    MANKIND PHARMA: CO SAYS GOING AHEAD - BUILD ALTERNATIVE CHANNELS OF GROWTH INCLUDING E-COMMERCE AND OTHER CONTEMPORARY TRADE CHANNELS; ~5% IN FY23 -- CONTINUE TO DEVELOP DIGITAL PLATFORMS TO ENHANCE DOCTOR ENGAGEMENT MEDICAL CONTENT; LAUNCH OF NEXT GENERATION AI BASED SALES FORCE AUTOMATION TOOL

    MANKIND, 2,138.50 4.14
  • 10-Jan-2024 19:24:53

    MANKIND PHARMA: CO SAYS GOING AHEAD - INCREASE THE VALUE OF PRESCRIPTIONS IN EXISTING MARKETS OF STRENGTH BY EXPANDING MARKET COVERAGE; CVM MOVED FROM 62% IN FY21 TO 68% IN FY23 -- INCREASE PENETRATION IN METROS/TIER I CITIES BY ENGAGING KEY OPINION LEADERS, HOSPITAL TIE-UPS AND SPECIALTY DIVISION LAUNCHES (10 DIVISIONS LAUNCHED IN LAST 2 YEARS)

    MANKIND, 2,138.50 4.14
  • 10-Jan-2024 19:24:39

    MANKIND PHARMA: INVESTOR PRESENTATION - EXPORTS BUSINESS - FOCUS ON DIFFERENTIATED FILINGS, INCLUDING IN-LICENSING FOR KEY MARKETS -- CO SAYS IN ADDITION TO USA, CO IS EXPORTING TO MANY COUNTRIES INCLUDING SRI-LANKA, NEPAL, UGANDA, KENYA ETC.

    MANKIND, 2,138.50 4.14
  • 10-Jan-2024 19:24:33

    MANKIND PHARMA: INVESTOR PRESENTATION - FY23 ROBUST PERFORMANCE, REVENUE AT RUPEES 8,749 CR WITH 15% EBITDA MARGIN. STRATEGIC FOCUS ON CHRONIC SEGMENTS, STRONG CONSUMER HEALTHCARE BRANDS. STEADY FINANCIALS AND GROWTH STRATEGY OUTLINED IN PRESENTATION.

    MANKIND, 2,138.50 4.14
  • 10-Jan-2024 15:00:28

    AUROBINDO PHARMA: CO IS NOW EXPLORING A BIG BANG IPO OF ITS UNIT SPECIALITY GENERIC FIRM EUGIA PHARMA SPECIALITIES TO RAISE AROUND RUPEES 4,500CR IN 2024 - MC

    AUROPHARMA, 1,028.10 -0.04
  • 10-Jan-2024 14:49:09

    KIMS: CO NOW HOLDS 64.14% OF TOTAL PAID-UP EQUITY SHARE CAPITAL OF SARVEJANA HEALTHCARE

    KIMS, 2,254.35 -1.55
  • 10-Jan-2024 14:48:44

    KIMS: CO MADE FURTHER INVESTMENT BY ACQUIRING ADDITIONAL 5.04% STAKE IN SARVEJANA HEALTHCARE

    KIMS, 2,254.35 -1.55
  • 10-Jan-2024 12:51:45

    LUPIN: CO LAUNCHES VARENICLINE TABLETS IN THE UNITED STATES -- TABLETS HAS US SALES 412M USD

    LUPIN, 1,622.05 0.35
  • 10-Jan-2024 12:14:27

    ALKEM LABORATORIES: Rs. 16.51 Cr NSE Block Trade; for ~ 32505 Shares, at Rs. 5077.95

    ALKEM, 5,138.55 2.97
  • 10-Jan-2024 12:10:12

    GRANULES: CO TO CONSIDER Q3 RESULTS ON JAN.23

    GRANULES, 464.50 0.98
  • 10-Jan-2024 10:49:57

    NARAYANA HRUDAYALAYA: Rs. 24.99 Cr NSE Block Trade; for ~ 201300 Shares, at Rs. 1241.60

    NH, 1,350.00 -1.05
09 Jan-2024
  • 09-Jan-2024 17:28:03

    LUPIN: CO LAUNCHES BROMFENAC OPHTHALMIC SOLUTION, 0.07% IN THE UNITED STATES -- MEDICINE HAD ESTIMATED ANNUAL SALES OF USD 182 MILLION IN THE U.S.

    LUPIN, 1,622.05 0.35
08 Jan-2024
  • 08-Jan-2024 19:59:44

    METROPOLIS HEALTHCARE: CO SAYS CORE BUSINESS REVENUE GREW BY 12% (YOY) -- REVENUE GROWTH WAS LARGELY DRIVEN BY VOLUME GROWTH AT 9% -- B2C REVENUE GREW BY 14% (YOY) -- GROSS DEBT AS ON 31ST DECEMBER 2023 STOOD AT RUPEES 12.7 CRS.

    METROPOLIS, 1,602.35 -0.19
  • 08-Jan-2024 19:52:36

    METROPOLIS HEALTHCARE: CO SAYS COMPETITIVE INTENSITY IN B2C SEGMENT HAS BEEN REDUCING, COUPLED WITH A STEADY INCREASE IN PRICES -- CO IS POISED TO TAKE A PRICE RISE IN B2C SEGMENT IN Q4 ON A PAN INDIA BASIS

    METROPOLIS, 1,602.35 -0.19
  • 08-Jan-2024 19:52:26

    METROPOLIS HEALTHCARE: CO SAYS MARGINS FOR Q3FY24 ARE SLIGHTLY LOWER ON A (YOY) BASIS -- CO SAYS WITNESSED EARLY DOUBLE-DIGIT GROWTH IN REVENUES FOR ITS CORE BUSINESS IN Q3

    METROPOLIS, 1,602.35 -0.19
  • 08-Jan-2024 19:20:33

    AUROBINDO PHARMA: CO SAYS U.S. FOOD AND DRUG ADMINISTRATION HAD CONDUCTED INSPECTION AT UNIT VI-B, A FORMULATION MANUFACTURING FACILITY

    AUROPHARMA, 1,028.10 -0.04
  • 08-Jan-2024 19:20:26

    AUROBINDO PHARMA: CO UNIT RECEIVED ESTABLISHMENT INSPECTION REPORT CLASSIFYING FACILITY AS "VOLUNTARY ACTION INDICATED" -- CO SAYS CLASSIFICATION OF US FDA INSPECTION AT OUR UNIT VI-B, TELANGANA AS VAII AND RECEIPT OF EIR

    AUROPHARMA, 1,028.10 -0.04
  • 08-Jan-2024 17:44:05

    CIPLA: CIPLA (EU) LIMITED WILL SECURE A 35.2% STAKE IN JOINT VENTURE COMPANY -- GOAL OF JOINT VENTURE IS TO DEVELOP AND COMMERCIALISE NOVEL CELL THERAPY PRODUCTS

    CIPLA, 1,477.55 0.04
  • 08-Jan-2024 17:42:23

    CIPLA: CO ANNOUNCES JOINT VENTURE IN THE UNITED STATES WITH KEMWELL BIOPHARMA AND MANIPAL EDUCATION & MEDICAL GROUP FOR GLOBAL DEVELOPMENT AND COMMERCIALISATION OF INNOVATIVE CELL THERAPY PRODUCTS

    CIPLA, 1,477.55 0.04
  • 08-Jan-2024 17:34:18

    CAPLIN POINT LABORATORIES: CAPLIN GROUP ANNOUNCES STRATEGIC INVESTMENT OF 7B RUPEES IN TAMIL NADU

    CAPLIPOINT, 1,479.90 1.91
  • 08-Jan-2024 12:07:57

    AUROBINDO PHARMA: Rs. 44.52 Cr NSE Block Trade; for ~ 400902 Shares, at Rs. 1110.40

    AUROPHARMA, 1,028.10 -0.04
  • 08-Jan-2024 11:53:24

    CAPLIN POINT LAB: CO GETS APPROVAL FROM USFDA FOR ANDA, TO CO UNIT FOR ONE OF ITS DRUG -- THIS DRUG HAS US SALES OF USD 36M

    CAPLIPOINT, 1,479.90 1.91
  • 08-Jan-2024 10:03:07

    SUPRIYA LIFESCIENCES: CO EXEC SAYS HAVE REGISTERED 10 APIS ALREADY, WILL ACHIEVE INCREMENTAL RUPEES 300 CR IN LATAM MARKET - CNBC TV18

    SUPRIYA, 344.00 0.85
  • 08-Jan-2024 10:01:53

    SUPRIYA LIFESCIENCES: CO EXEC SAYS EBITDA MARGIN WILL REMAIN SIMILAR TO FY23 LEVELS - CNBC TV18

    SUPRIYA, 344.00 0.85
  • 08-Jan-2024 10:00:46

    SUPRIYA LIFESCIENCES: CO EXEC SAYS CO EXPECT 15% GROWTH IN FY24 - CNBC TV18

    SUPRIYA, 344.00 0.85
05 Jan-2024
  • 05-Jan-2024 20:27:20

    STRIDES PHARMA SCIENCE: CO UNIT ACQUIRED ADDITIONAL STAKE IN NEVITON SOFTECH

    STAR, 784.50 0.25
  • 05-Jan-2024 17:37:53

    NARAYANA HRUDAYALAYA: NARAYANA HEALTH INSURANCE HAS BEEN GRANTED LICENSE BY INSURANCE REGULATORY AND DEVELOPMENT AUTHORITY OF INDIA -- LICENSE TO EXCLUSIVELY CARRY ON HEALTH INSURANCE BUSINESS

    NH, 1,350.00 -1.05
  • 05-Jan-2024 15:30:11

    LUPIN: Rs. 27.83 Cr NSE Block Trade; for ~ 200269 Shares, at Rs. 1389.70

    LUPIN, 1,622.05 0.35
  • 05-Jan-2024 14:55:07

    SUPRIYA LIFESCIENCE: CO CEO SAYS LOTE FACTORY ACHIEVES PERFECT COMPLIANCE WITH ZERO OBSERVATIONS IN BRAZILIAN GMP INSPECTION

    SUPRIYA, 344.00 0.85
  • 05-Jan-2024 14:52:43

    SUPRIYA LIFESCIENCES: CO SAYS THE CLEARANCE OF THIS AUDIT MARKS THE SUCCESSFUL REGISTRATION OF 8 APIS WITH CADIFA AND WILL FURTHER ENABLE SMOOTHER AND FASTER REGISTRATION OF THE CO’S OTHER APIS

    SUPRIYA, 344.00 0.85
  • 05-Jan-2024 14:51:54

    SUPRIYA LIFESCIENCES: CO RECEIVED GMP CERTIFICATION FROM ANVISA BRAZIL

    SUPRIYA, 344.00 0.85
  • 05-Jan-2024 13:56:13

    MANKIND PHARMA LTD: Rs. 31.19 Cr NSE Block Trade; for ~ 150984 Shares, at Rs. 2065.95

    MANKIND, 2,138.50 4.14
  • 05-Jan-2024 13:47:37

    MANKIND PHARMA LTD: RS. 66.36 CRORES NSE BLOCK TRADE; FOR ~ 322123 SHARES, AT RS. 2060.05

    MANKIND, 2,138.50 4.14
  • 05-Jan-2024 13:02:14

    ALEMBIC PHARMA: CO HAS RECEIVED 30 CR RUPEES AS COMPENSATION FROM INSURANCE COS FOR DAMAGES HAPPENED AT SIKKIM FACILITY

    APLLTD, 1,017.90 -1.05
  • 05-Jan-2024 11:55:48

    THEMIS MEDICARE: CO PROMOTER GROUP RELEASE PLEDGE OF 1.3CR SHARES OR 14.16% ON DEC 30

    THEMISMED, 237.85 -0.19
  • 05-Jan-2024 11:44:51

    CIPLA LTD: Rs. 24.18 Cr NSE Block Trade; for ~ 187943 Shares, at Rs. 1286.40

    CIPLA, 1,477.55 0.04
  • 05-Jan-2024 11:00:43

    TORRENT PHARMA: Rs. 17.69 Cr NSE Block Trade; for ~ 75500 Shares, at Rs. 2343.05

    TORNTPHARM, 2,668.55 2.12
  • 05-Jan-2024 10:49:57

    SUN PHARMA: Rs. 24.37 Cr NSE Block Trade; for ~ 188996 Shares, at Rs. 1289.55

    SUNPHARMA, 1,579.75 0.37
04 Jan-2024
  • 04-Jan-2024 16:49:34

    LUPIN: CO SAYS DAPAGLIFLOZIN AND SAXAGLIPTIN TABLETS ARE INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS -- DAPAGLIFLOZIN AND SAXAGLIPTIN TABLETS (RLD QTERN®) HAD ESTIMATED ANNUAL SALES OF USD 5 MILLION IN THE U.S. (IQVIA MAT NOVEMBER 2023).

    LUPIN, 1,622.05 0.35
  • 04-Jan-2024 16:47:25

    LUPIN: CO RECEIVES TENTATIVE APPROVAL FROM U.S. FDA FOR DAPAGLIFLOZIN AND SAXAGLIPTIN TABLETS -- CO SAYS THIS PRODUCT WILL BE MANUFACTURED AT LUPIN’S PITHAMPUR FACILITY IN INDIA

    LUPIN, 1,622.05 0.35
  • 04-Jan-2024 14:23:16

    RAINBOW CHILDRENS: CO HAS INAUGURATED A NEW 60 BEDS SPOKE HOSPITAL, LOCATED AT CENTRAL HYDERABAD, TELANGANA

    RAINBOW, 1,352.60 -5.36
  • 04-Jan-2024 10:55:18

    NARAYANA HRUDAYALAYA LTD: Rs. 15.29 Cr NSE Block Trade; for ~ 130454 Shares, at Rs. 1172.10

    NH, 1,350.00 -1.05
  • 04-Jan-2024 10:26:15

    LUPIN: CO EXEC ANTICIPATES ROBUST GROWTH: EXPECTS US SALES TO SURPASS USD 1B IN COMING YEARS, REPORTS LOW SINGLE-DIGIT (YOY) PRICE EROSION, AND SETS AGGRESSIVE 22-23% MARGIN TARGET - CNBC TV18

    LUPIN, 1,622.05 0.35
03 Jan-2024
  • 03-Jan-2024 16:35:13

    DR. REDDYS: CO ANNOUNCES THE ACQUISITION OF MENOLABS®, A LEADING WOMEN’S HEALTH AND DIETARY SUPPLEMENTS PORTFOLIO OF BRANDS

    DRREDDY, 6,425.55 -0.04
  • 03-Jan-2024 14:58:11

    DIVIS LABORATORIES: CO SAYS COURT DIRECTED CO TO DEPOSIT 10% OF AMOUNT THAT IS 8.2CR DEMANDED WITHIN A PERIOD OF 6 WEEKS

    DIVISLAB, 3,490.00 -0.81
  • 03-Jan-2024 14:25:22

    DR. REDDYS LAB: CO ANNOUNCES THE ACQUISITION OF MENOLABS, A LEADING WOMEN S HEALTH AND DIETARY SUPPLEMENTS PORTFOLIO OF BRANDS

    DRREDDY, 6,425.55 -0.04
02 Jan-2024
  • 02-Jan-2024 20:13:38

    NATCO PHARMA: CO COMPLETES TRANSITION OF DASH PHARMACEUTICALS INTO NATCO PHARMA U.S.A -- ALL PRODUCTS MARKETED BY DASH PHARMACEUTICALS TO TRANSITION TO NATCO PHARMA U.S.A LABEL

    NATCOPHARM, 995.00 1.17
  • 02-Jan-2024 19:56:31

    SUN PHARMA: CO ACQUIRED 100% OF SHARES OF LIBRA MERGER, A COMPANY INCORPORATED IN ISRAEL -- COST OF ACQUISITION NIS 10

    SUNPHARMA, 1,579.75 0.37
  • 02-Jan-2024 13:39:40

    STRIDES PHARMA: Rs 99.63cr BSE Block Trade; for ~1509501 shares, at Rs 660

    STAR, 784.50 0.25
01 Jan-2024
  • 01-Jan-2024 19:23:01

    ALEMBIC PHARMA: CO GETS APPROVAL FROM USFDA FOR 8 MEDICINES DURING Q3

    APLLTD, 1,017.90 -1.05
  • 01-Jan-2024 08:31:05

    Dr. Reddys Lab: Acquires Preferred A-1 Shares of Edity Therapeutics for $1.9715 per Share

    DRREDDY, 6,425.55 -0.04
  • 01-Jan-2024 08:29:56

    Hikal: Gujarat Pollution Control Board Directs Payment of INR 174.5M

    HIKAL, 281.45 0.43
  • 01-Jan-2024 06:40:24

    ASTER DM HEALTHCARE: CO UNIT ENTERS BUSINESS TRANSFER AGREEMENT WITH ASSCPL FOR THE SALE OF SPECIFIED UNITS AT A LUMP SUM INDICATIVE CONSIDERATION OF RUPEES 3.8 CR TO RUPEES 5.25 CR

    ASTERDM, 471.55 -2.74
29 Dec-2023
  • 29-Dec-2023 17:05:24

    DR REDDYS LAB: CO ACQUIRED PREFERRED A-1 SHARES OF EDITY THERAPEUTICS LIMITED FOR $1.9715 PER PREFERRED A-1 SHARE EQUIVALENT TO 6.46% OF THE SHAREHOLDING OF EDITY

    DRREDDY, 6,425.55 -0.04
  • 29-Dec-2023 17:04:41

    HIKAL: CO SAYS GUJARAT POLLUTION CONTROL BOARD DIRECTING CO TO PAY 174.5M RUPEES

    HIKAL, 281.45 0.43
  • 29-Dec-2023 11:22:01

    BIOCON: CO UPDATED REGARDING COURT DECISION - SOME PATENTS FOR EYLEA TREATMENT INVALID, OTHERS VALID AND INFRINGED

    BIOCON, 276.45 1.99
28 Dec-2023
  • 28-Dec-2023 18:04:11

    AARTI DRUGS: CO SAYS NO IMPACT ON FINANCIAL, OPERATION OR OTHER ACTIVITIES OF CO

    AARTIDRUGS, 497.90 -0.56
  • 28-Dec-2023 18:04:04

    AARTI DRUGS: CO RECEIVED AN ADMINISTRATIVE WARNING LETTER ISSUED BY SEBI -- LETTER REGARDING NON-DISCLOSURE IN EVENT OF CLOSURE OF COS SARIGAM PLANT IN APRIL 2022

    AARTIDRUGS, 497.90 -0.56
27 Dec-2023
  • 27-Dec-2023 15:21:04

    LUPIN: CO RECEIVES APPROVAL FROM U.S. FDA FOR LOTEPREDNOL ETABONATEOPHTHALMIC SUSPENSION, 0.2% -- THIS MEDICINE HAS US SALES OF USD 29M

    LUPIN, 1,622.05 0.35
  • 27-Dec-2023 11:14:43

    AUROBINDO PHARMA: CO UNIT RECEIVES USFDA APPROVAL FOR POSACONAZOLE INJECTION -- THIS INJECTION HAS US SALES OF USD 25M

    AUROPHARMA, 1,028.10 -0.04
  • 27-Dec-2023 10:23:48

    CIPLA: Rs 71.67cr NSE Block Trade; for ~577533 shares, at Rs 1240.95

    CIPLA, 1,477.55 0.04
26 Dec-2023
  • 26-Dec-2023 21:10:18

    GLAXOSMITHKLINE PHARMA: CO SAYS RECEIVED ORDER DATED DEC 23 FROM ANDHRA PRADESH STATE GST AUTHORITIES DISALLOWING CERTAIN GST CREDITS

    GLAXO, 2,176.10 1.02
  • 26-Dec-2023 21:10:11

    GLAXOSMITHKLINE PHARMA: CO SAYS VISIT FOR SUPPRESS OF TRANSACTIONS RELATING TO SUPPLY OF GOODS AND / OR SERVICES UNDER GST -- CO SAYS NO IMPACT ON GSK

    GLAXO, 2,176.10 1.02
  • 26-Dec-2023 21:10:06

    GLAXOSMITHKLINE PHARMA: CO SAYS GST TAX OFFICERS VISITED CO CFAS PREMISES IN CHENNAI & HOSUR ON DEC 24 FOR INSPECTION OF GOODS AND DOCUMENTS

    GLAXO, 2,176.10 1.02
  • 26-Dec-2023 20:15:53

    SYNGENE INTERNATIONAL: BOARD MEETING ON JAN 25, 2024 TO CONSIDER Q3 RESULTS

    SYNGENE, 706.60 -0.32
  • 26-Dec-2023 19:20:06

    PFIZER: CO GOT ONE MORE ORDER FROM CGST & CX FOR DEMAND OF 7.7M RUPEES

    PFIZER, 4,601.45 0.89
  • 26-Dec-2023 19:19:07

    PFIZER: CO GOT ORDER FROM DEPUTY COMMISSIONER FOR TAX -- TOTAL DEMAND OF 16.7M RUPEES

    PFIZER, 4,601.45 0.89
  • 26-Dec-2023 16:07:34

    ZYDUS LIFESCIENCES: CO UNIT GOT INTIMATION UNDER SECTION 143(1) OF INCOME TAX ACT, 1961 DETERMINING DEMAND OF 2.85B RUPEES

    ZYDUSLIFE, 943.80 1.20
22 Dec-2023
  • 22-Dec-2023 16:55:43

    ZYDUS LIFESCIENCES: CO SAYS THERE ARE 4 DMFS OF THIS SITE UNDER APPROVAL WITH THE USFDA -- NO DATA INTEGRITY RELATED OBSERVATIONS -- NO REPEAT OBSERVATIONS FROM THE PREVIOUS INSPECTION

    ZYDUSLIFE, 943.80 1.20
  • 22-Dec-2023 16:55:34

    ZYDUS LIFESCIENCES: USFDA CONDUCTED AN INSPECTION AT THE API SITE SITUATED AT CHANGODAR, AHMEDABAD -- THE INSPECTION CLOSED WITH 6 OBSERVATIONS

    ZYDUSLIFE, 943.80 1.20
  • 22-Dec-2023 16:26:09

    BIOCON: FUJIFILM KYOWA KIRIN BIOLOGICS CONCLUDED EXCLUSIVE GLOBAL MARKETING LICENSE AGREEMENT WITH BIOCON BIOLOGICS LTD AFFILIATE -- BIOCON BIOLOGICS ACQUIRED GLOBAL BIOSIMILARS PORTFOLIO OF VIATRIS INCLUDING ADALIMUMAB

    BIOCON, 276.45 1.99
  • 22-Dec-2023 16:26:02

    BIOCON: BIOCON BIOLOGICS PARTNERS WITH SANDOZ FOR THE DISTRIBUTION OF “ADALIMUMAB BS SUBCUTANEOUS INJECTION [FKB]" IN JAPAN -- VIATRIS TO CONTINUE TO PROVIDE TRANSITION SUPPORT UNTIL SANDOZ WILL GRADUALLY ASSUME RESPONSIBILITIES FOR PRODUCT STARTING FEB, 2024

    BIOCON, 276.45 1.99
  • 22-Dec-2023 14:49:52

    TORRENT PHARMA: CO WITHDRAWS NON - BINDING BID FOR BUYOUT OF FOUNDERS STAKE IN CIPLA - ET NOW

    TORNTPHARM, 2,668.55 2.12
  • 22-Dec-2023 11:31:44

    LUPIN: CO UNIT HAS SIGNED AN ASSET PURCHASE AGREEMENT WITH SANOFI TO ACQUIRE A PORTFOLIO OF ESTABLISHED PRODUCTS IN EUROPE AND CANADA

    LUPIN, 1,622.05 0.35
21 Dec-2023
  • 21-Dec-2023 19:27:26

    SUVEN PHARMACEUTICALS: CO SAYS APPOINTMENT OF HIMANSHU AGARWAL AS CHIEF FINANCIAL OFFICER -- CO SAYS SUBBA RAO PARUPALLI WILL CEASE TO BE CFO

    SUVENPHAR, 631.05 -1.80
  • 21-Dec-2023 18:38:13

    VIJAYA DIAGNOSTIC CENTRE: CO SAYS COMPLETED ACQUISITION OF 100% STAKE IN P H DIAGNOSTIC CENTRE

    VIJAYA, 643.90 -1.92
  • 21-Dec-2023 17:03:01

    LUPIN: CO LAUNCHES SOFTOVAC LIQUIFIBRE, A FIRST-OF-ITS-KIND LIQUID FIBRE

    LUPIN, 1,622.05 0.35
  • 21-Dec-2023 15:12:01

    AMI ORGANICS: CO WILL ALSO SIGN AN MOU WITH GOVERNMENT OF GUJARAT FOR INVESTMENT AMOUNTING UP TO RUPEES 300CR

    AMIORG, 1,112.30 -1.35
  • 21-Dec-2023 15:10:48

    AMI ORGANICS: CO SIGNS MOU WITH A GLOBAL MANUFACTURER OF ELECTROLYTES

    AMIORG, 1,112.30 -1.35
  • 21-Dec-2023 11:31:55

    NATCO PHARMA: CO SAYS CO NAMED AS A DEFENDANT IN AN ANTITRUST LAWSUIT IN US BY LOUISIANA HEALTH SERVICE & INDEMNITY CO -- CO SAYS ALL CLAIMS AGAINST CO IN LITIGATION HAVE NOW BEEN DISMISSED

    NATCOPHARM, 995.00 1.17
  • 21-Dec-2023 11:25:21

    DR REDDYS LAB: CO TO CONSIDER Q3 RESULTS ON JAN 30

    DRREDDY, 6,425.55 -0.04
  • 21-Dec-2023 10:16:42

    SYNGENE INTERNATIONAL: Rs 25.98cr NSE Block Trade; for ~379185 shares, at Rs 685.05

    SYNGENE, 706.60 -0.32
  • 21-Dec-2023 09:16:22

    AMI ORGANICS: RS 447.18CR NSE BLOCK TRADE; FOR ~4341514 SHARES, AT RS 1030

    AMIORG, 1,112.30 -1.35
20 Dec-2023
  • 20-Dec-2023 22:08:49

    TARSONS PRODUCTS: CO TO ACQUIRE GERMAN MEDICAL DISTRIBUTORS NERBE FOR ABOUT €10-15 MILLION

    TARSONS, 467.00 -0.18
  • 20-Dec-2023 22:08:17

    TARSONS PRODUCTS: CO TO ACQUIRE GERMAN MEDICAL DISTRIBUTORS NERBE FOR ABOUT €10-15 MILLION

    TARSONS, 467.00 -0.18
  • 20-Dec-2023 21:41:04

    ASTRAZENECA PHARMA INDIA: CO SAYS WILL LAUNCH ENHERTU IN JAN 2024 IN INDIA -- TRASTUZUMAB DERUXTECAN (ENHERTU) IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED A PRIOR ANTI-HER2- BASED REGIMEN

    ASTRAZEN, 5,535.50 0.42
  • 20-Dec-2023 12:51:38

    AUROBINDO PHARMA: CO UNIT HAS NOW RECEIVED EIR CLASSIFYING THE ANDHRA FACILITY AS VOLUNTARY ACTION INDICATED

    AUROPHARMA, 1,028.10 -0.04
19 Dec-2023
  • 19-Dec-2023 12:59:18

    VIJAYA DIAGNOSTIC CENTRE: CO ACQUIRES P H DIAGNOSTIC CENTRE, FOR RUPEES 134.65 CR IN CASH

    VIJAYA, 643.90 -1.92
  • 19-Dec-2023 12:57:55

    VIJAYA DIAGNOSTICS: CO APPROVES ACQUISITION OF P H DIAGNOSTIC CENTRE, SECURING 100% STAKE AS A UNIT

    VIJAYA, 643.90 -1.92
  • 19-Dec-2023 12:42:28

    JB CHEMICALS: CO SECURES NOVARTIS OPHTHALMOLOGY BRANDS FOR USD 116M, SIGNS RUPEES 125 CR DISTRIBUTION DEAL FOR 3 YEARS

    JBCHEPHARM, 1,564.45 -2.23
  • 19-Dec-2023 12:40:10

    JB CHEMICALS: CO APPROVED PROMOTION AND DISTRIBUTION AGREEMENT WITH NOVARTIS HEALTHCARE

    JBCHEPHARM, 1,564.45 -2.23
  • 19-Dec-2023 12:39:11

    JB CHEMICALS: CO HAS APPROVED THE EXECUTION OF A TRADE MARK LICENSE AGREEMENT WITH NOVARTIS INNOVATIVE THERAPIES

    JBCHEPHARM, 1,564.45 -2.23
  • 19-Dec-2023 06:33:28

    PIRAMAL PHARMA: CO UNIT INAUGURATES EXPANDED ADC MANUFACTURING FACILITY IN GRANGEMOUTH, SCOTLAND, STRENGTHENING GLOBAL CAPACITY

    PPLPHARMA, 131.75 1.19
18 Dec-2023
  • 18-Dec-2023 19:05:57

    SUN PHARMA: CO ENTERED INTO AGREEMENT TO ACQUIRE STAKE 16.7% SHARES IN LYNDRA THERAPEUTICS, INC -- COST OF ACQUISITION OR PRICE AT WHICH USD 30M

    SUNPHARMA, 1,579.75 0.37
  • 18-Dec-2023 16:51:10

    BIOCON: BIOCON BIOLOGICS CONCLUDES INTEGRATION OF ACQUIRED BIOSIMILARS BUSINESS IN 120 COUNTRIES -- BIOCON BIOLOGICS IS NOW A FULLY INTEGRATED LAB TO MARKET BIOSIMILARS COMPANY

    BIOCON, 276.45 1.99
  • 18-Dec-2023 13:18:25

    SHALBY: COS UNIT MARS MEDICAL DEVICES APPROVED TO INVEST 200,000 PREFERENCE SHARES OF ITS SUBSIDIARY SHALBY GLOBAL TECHNOLOGIES PTE LTD

    SHALBY, 269.25 -3.67
  • 18-Dec-2023 12:41:53

    ZYDUS LIFESCIENCES: COS UNIT NOVELTECH INC, USA, INCORPORATED IN NEW JERSEY, HAS BEEN DISSOLVED W.E.F DEC.15

    ZYDUSLIFE, 943.80 1.20
15 Dec-2023
  • 15-Dec-2023 16:28:04

    LUPIN: CO RECEIVES TENTATIVE APPROVAL FROM U.S. FDA FOR SITAGLIPTIN TABLETS -- SITAGLIPTIN TABLETS (RLD JANUVIA®) HAD ESTIMATED ANNUAL SALES OF USD 5789.3M IN THE U.S. (IQVIA MAT OCTOBER 2023)

    LUPIN, 1,622.05 0.35
  • 15-Dec-2023 16:27:53

    LUPIN: CO RECEIVES APPROVAL FROM U.S. FDA FOR ALLOPURINOL TABLETS -- ALLOPURINOL TABLETS (RLD ZYLOPRIM®) HAD ESTIMATED ANNUAL SALES OF USD 88.1M IN THE U.S. (IQVIA MAT OCTOBER 2023)

    LUPIN, 1,622.05 0.35
  • 15-Dec-2023 12:51:14

    BIOCON: CO IS NEITHER EVALUATING ANY DIVESTMENT OPTIONS FOR ITS APIS BUSINESS NOR CONSULTING ANY BANKERS

    BIOCON, 276.45 1.99
  • 15-Dec-2023 11:33:17

    KIMS: Rs 19.37cr NSE Block Trade; for ~100116 shares, at Rs 1935

    KIMS, 2,254.35 -1.55
  • 15-Dec-2023 10:49:37

    AUROBINDO PHARMA: CO SUCCESSFULLY COMPLETES ACQUISITION OF MARKETING AND MANUFACTURING AUTHORIZATIONS FROM VIATRIS INC / PFIZER INC

    AUROPHARMA, 1,028.10 -0.04
  • 15-Dec-2023 10:42:48

    SMS PHARMA: CO PROMOTER RELEASE PLEDGE OF 12.6 LAKH SHARES OR 1.49% ON DEC 12

    SMSPHARMA, 149.80 -3.01
  • 15-Dec-2023 10:40:49

    SMS PHARMA: CO PROMOTER GROUP RELEASE PLEDGE OF 38 LAKH SHARES OR 4.49% ON DEC 12

    SMSPHARMA, 149.80 -3.01
  • 15-Dec-2023 09:17:46

    ZYDUS LIFESCIENCES: CO RECEIVES FINAL APPROVAL FROM THE USFDA FOR DARUNAVIR TABLETS 600 MG AND 800 MG, AND TENTATIVE APPROVAL FOR 75 MG AND 150 MG TABLETS

    ZYDUSLIFE, 943.80 1.20
  • 15-Dec-2023 07:24:38

    BIOCON: CO WEIGHS SALE OF $1.5B GENERIC API BUSINESS- ET

    BIOCON, 276.45 1.99
  • 15-Dec-2023 07:22:34

    BIOCON: CO WEIGHS SALE OF GENERIC API BUSINESS- ET

    BIOCON, 276.45 1.99
  • 15-Dec-2023 06:37:50

    CIPLA: CO EXPANDS PATIENT REACH TO REMOTEST TOWNS BY FURTHERING INVESTMENT IN GOAPPTIV -- CO TO HOLD 22.99% STAKE IN THE DIGITAL TECH COMPANY

    CIPLA, 1,477.55 0.04
14 Dec-2023
  • 14-Dec-2023 18:11:29

    AMI ORGANICS: CO ENTERED INTO DEFINITIVE AGREEMENT FOR MANUFACTURE OF TWO ADVANCED PHARMACEUTICAL INTERMEDIATES PRODUCT -- CO ENTERED INTO DEFINITIVE AGREEMENT WITH FERMION, UNIT OF ORION CORPORATION, FINLAND

    AMIORG, 1,112.30 -1.35
  • 14-Dec-2023 17:49:59

    AMI ORGANICS: CO SAYS COMMENCEMENT OF PRODUCTION IS SUBJECT TO RECEIPT OF NECESSARY REGULATORY APPROVALS

    AMIORG, 1,112.30 -1.35
  • 14-Dec-2023 17:49:53

    AMI ORGANICS: CO UNVEILS NEW MANUFACTURING FACILITY IN ANKLESHWAR, GUJARAT -- CO SAYS DEVELOPMENT IS A STRATEGIC PART OF THE CO’S COMMITMENT TO BOLSTERING ITS POSITION IN THE ADVANCED PHARMACEUTICAL INTERMEDIATES SEGMENT

    AMIORG, 1,112.30 -1.35
  • 14-Dec-2023 17:43:13

    DR. REDDY’S LAB: CO BECOMES FIRST INDIAN PHARMA COMPANY TO DEBUT ON THE DOW JONES SUSTAINABILITY WORLD INDEX -- CO ALSO SECURES ‘GOLD MEDAL’ STATUS FROM GLOBAL SUSTAINABILITY RATINGS AGENCY, ECOVADIS

    DRREDDY, 6,425.55 -0.04
  • 14-Dec-2023 16:31:45

    PANACEA BIOTEC: CO LAUNCHES EASYFOURPOL IN INDIA -- CO RECEIVES REGISTRATION OF VALGANCICLOVIR POWDER FOR ORAL SOLUTION IN GERMANY

    PANACEABIO, 152.40 0.33
  • 14-Dec-2023 14:10:55

    LUPIN: COS DIAGNOSTICS EXPANDS PRESENCE IN SOUTH INDIA WITH NEW REGIONAL REFERENCE LABORATORY IN CHENNAI

    LUPIN, 1,622.05 0.35
  • 14-Dec-2023 13:40:08

    ZYDUS LIFESCIENCES: CO RECEIVES FINAL APPROVAL FROM THE USFDA FOR CYCLOPHOSPHAMIDE CAPSULES USP, 25 MG AND 50 MG -- THIS CAPSULES HAS US SALES OF USD 6M

    ZYDUSLIFE, 943.80 1.20
  • 14-Dec-2023 11:03:15

    MAX HEALTHCARE: Rs 87.02cr NSE Block Trade; for ~1209802 shares, at Rs 719.3

    MAXHEALTH, 791.15 -7.09
13 Dec-2023
  • 13-Dec-2023 19:41:39

    CIPLA: CO SAYS CESSATION OF FACILITY DEMAND GUARANTEE ISSUED IN FAVOR OF FIRST RAND BANK, SOUTH AFRICA

    CIPLA, 1,477.55 0.04
  • 13-Dec-2023 17:02:31

    BIOCON: CO UNIT BICARA THERAPEUTICS INC. COMPLETED ITS $165M SERIES C FINANCING -- CO SAYS PROCEEDS OF FUNDING SHALL BE USED TO SUPPORT CONTINUED ADVANCEMENT OF BICARAS LEAD PRODUCT CANDIDATE, BCA101

    BIOCON, 276.45 1.99
  • 13-Dec-2023 13:03:04

    SUN PHARMA: CO SAYS ILUMETRIS CATEGORY B INCLUSION BOOSTS ACCESSIBILITY AND AFFORDABILITY FOR PATIENTS

    SUNPHARMA, 1,579.75 0.37
  • 13-Dec-2023 13:01:22

    SUN PHARMA: CO UPDATED REGARDING INCLUSION OF SPECIALTY PRODUCT ILUMETRI, (TILDRAKIZUMAB INJECTION) IN CATEGORY B OF CHINAS NATIONAL REIMBURSEMENT DRUG LIST

    SUNPHARMA, 1,579.75 0.37
  • 13-Dec-2023 11:13:59

    GRANULES INDIA: CO RECEIVED ANDA APPROVAL FOR PANTOPRAZOLE SODIUM DELAYED - RELEASE TABLETS -- THIS TABLETS HAVE US SALES OF USD 233M

    GRANULES, 464.50 0.98
12 Dec-2023
  • 12-Dec-2023 12:10:27

    MAX HEALTHCARE: Rs 36.93cr NSE Block Trade; for ~527151 shares, at Rs 700.65

    MAXHEALTH, 791.15 -7.09
  • 12-Dec-2023 10:49:40

    MANKIND PHARMA: Rs 28.24cr NSE Block Trade; for ~151369 shares, at Rs 1865.35

    MANKIND, 2,138.50 4.14
  • 12-Dec-2023 09:37:11

    APOLLO HOSPITAL: Rs 72.08cr NSE Block Trade; for ~130740 shares, at Rs 5513.55

    APOLLOHOSP, 6,102.65 -4.08
  • 12-Dec-2023 09:18:59

    MANKIND PHARMA: RS 543.34CR NSE BLOCK TRADE; FOR ~2965320 SHARES, AT RS 1832.3

    MANKIND, 2,138.50 4.14
  • 12-Dec-2023 09:18:02

    MANKIND PHARMA: RS 2304.92CR NSE BLOCK TRADE; FOR ~12579360 SHARES, AT RS 1832.3

    MANKIND, 2,138.50 4.14
  • 12-Dec-2023 09:16:32

    MANKIND PHARMA: RS 2675.44CR BSE BLOCK TRADE; FOR ~14528592 SHARES, AT RS 1841.5

    MANKIND, 2,138.50 4.14
  • 12-Dec-2023 09:06:46

    TORRENT PHARMA: CO WAS ISSUED A FORM 483 WITH 5 PROCEDURAL OBSERVATIONS

    TORNTPHARM, 2,668.55 2.12
  • 12-Dec-2023 09:05:17

    TORRENT PHARMA: CO SAYS USFDA CONDUCTED PRE-APPROVAL INSPECTION AT ORAL-ONCOLOGY ORAL MANUFACTURING FACILITY

    TORNTPHARM, 2,668.55 2.12
11 Dec-2023
  • 11-Dec-2023 22:11:12

    MANKIND PHARMA: BLOCK DEAL ALERT - MANKIND HOLDERS SEEK TO RAISE UPTO $678M VIA BLOCK -- MANKIND SHARES OFFERED AT 1785.65 RUPEES APIECE FLOOR PRICE - CNBC AWAAZ, CITING SOURCES

    MANKIND, 2,138.50 4.14
  • 11-Dec-2023 18:59:06

    MANKIND PHARMA: DISCOUNT OF UPTO 7% OFFERED ON DEAL -- KOTAK BROKER TO DEAL, FURTHER DETAILS TO BE UPDATED SHORTLY - CNBC AWAAZ, CITING SOURCES

    MANKIND, 2,138.50 4.14
  • 11-Dec-2023 18:58:07

    MANKIND PHARMA: BLOCK DEAL ALERT - 3 PRIVATE INVESTORS TO SELL NEARLY 5-6% STAKE IN CO VIA BLOCK DEALS -- BLOCK DEAL FOR STAKE WORTH RS 3000-4000 CRORES - CNBC AWAAZ, CITING SOURCES

    MANKIND, 2,138.50 4.14
  • 11-Dec-2023 13:52:51

    AJANTA PHARMA: Rs 98.46cr BSE Block Trade; for ~519480 shares, at Rs 1895.35

    AJANTPHARM, 2,232.70 7.08
  • 11-Dec-2023 11:57:40

    WOCKHARDT: CO ANNOUNCES SUCCESSFUL COMPLETION OF PIVOTAL PHASE 3 PNEUMONIA STUDY OF ITS MACROLIDE ANTIBIOTIC NAFITHROMYCIN WCK 4873

    WOCKPHARMA, 603.85 3.67
  • 11-Dec-2023 11:28:20

    SYNGENE INTERNATIONAL: Rs 36.69cr NSE Block Trade; for ~509924 shares, at Rs 719.5 (MULTIPLE BLOCKS)

    SYNGENE, 706.60 -0.32
  • 11-Dec-2023 10:10:47

    PIRAMAL PHARMA: Rs 32.04cr NSE Block Trade; for ~2513960 shares, at Rs 127.45

    PPLPHARMA, 131.75 1.19
  • 11-Dec-2023 10:09:50

    PIRAMAL PHARMA: PHARMA EXPORT DATA SEEN AT 24% GROWTH (MOM)

    PPLPHARMA, 131.75 1.19
  • 11-Dec-2023 10:09:21

    LAURUS LABS: PHARMA EXPORT DATA SEEN AT 24% GROWTH (MOM)

    LAURUSLABS, 407.00 0.48
  • 11-Dec-2023 10:09:02

    DIVIS LAB: PHARMA EXPORT DATA SEEN AT 23% GROWTH (MOM)

    DIVISLAB, 3,490.00 -0.81
  • 11-Dec-2023 10:06:17

    PIRAMAL PHARMA: Rs 45.94cr NSE Block Trade; for ~3645814 shares, at Rs 126

    PPLPHARMA, 131.75 1.19
  • 11-Dec-2023 09:20:34

    ZYDUS LIFESCIENCES: CO SAYS LEUPROLIDE ACETATE FOR DEPOT SUSPENSION HAD ANNUAL SALES OF APPROXIMATELY USD 671M IN THE U.S

    ZYDUSLIFE, 943.80 1.20
  • 11-Dec-2023 09:18:28

    ZYDUS LIFESCIENCES: CO AND DAEWOONG PHARMACEUTICAL INK EXCLUSIVE DEAL FOR LEUPROLIDE LONG-ACTING INJECTABLE IN THE U.S

    ZYDUSLIFE, 943.80 1.20
  • 11-Dec-2023 09:17:55

    DR. REDDYS: Rs 27.78cr NSE Block Trade; for ~50712 shares, at Rs 5477.65

    DRREDDY, 6,425.55 -0.04
08 Dec-2023
  • 08-Dec-2023 16:47:30

    NEULAND LABORATORIES: DAVULURI FAMILY DOES NOT PLAN TO SELL ANY FURTHER SHARES IN FORESEEABLE FUTURE

    NEULANDLAB, 7,149.90 0.67
  • 08-Dec-2023 16:47:19

    NEULAND LABORATORIES: DAVULURI RAMA MOHAN RAO, PROMOTER, SOLD 3.12 % STAKE THROUGH OPEN MARKET -- SALE AT AVERAGE PRICE OF 5,012.45 RUPEES PER SHR

    NEULANDLAB, 7,149.90 0.67
  • 08-Dec-2023 15:23:44

    MAX HEALTHCARE: CO SAYS CURRENT OPERATIONAL BED CAPACITY IS 250 BEDS, WITH FY24 REVENUE RUN RATE OF RUPEES 200 CR

    MAXHEALTH, 791.15 -7.09
  • 08-Dec-2023 15:23:12

    MAX HEALTHCARE: CO SAYS DEAL FOR ENTERPRISE VALUE OF 9.4B RUPEES

    MAXHEALTH, 791.15 -7.09
  • 08-Dec-2023 15:22:29

    MAX HEALTHCARE: CO ENTERS INTO A SHARE PURCHASE AGREEMENT FOR ACQUISITION OF 550 BEDDED SAHARA HOSPITAL, LUCKNOW

    MAXHEALTH, 791.15 -7.09
  • 08-Dec-2023 12:13:46

    SYNGENE INTERNATIONAL: Rs 21.72cr NSE Block Trade; for ~301405 shares, at Rs 720.75

    SYNGENE, 706.60 -0.32
  • 08-Dec-2023 09:17:45

    NEULAND: RS 200.4CR BSE BLOCK TRADE; FOR ~400003 SHARES, AT RS 5010

    NEULANDLAB, 7,149.90 0.67
07 Dec-2023
  • 07-Dec-2023 17:01:46

    GLAXOSMITHKLINE PHARMA: CO SAYS COMPLETED VOLUNTARY RETIREMENT SCHEME -- CO SPENT A SUM OF 1.57B RUPEES AS ONE-OFF COST OF VRS

    GLAXO, 2,176.10 1.02
  • 07-Dec-2023 17:01:36

    GLAXOSMITHKLINE PHARMA: CO HAS ESTABLISHED AN OMNICHANNEL TEAM TO EXPAND ITS REACH AND COVERAGE TO THE TARGET SEGMENTS BY LEVERAGING TECHNOLOGY AND IMPROVE PRODUCTIVITY

    GLAXO, 2,176.10 1.02
06 Dec-2023
  • 06-Dec-2023 09:49:12

    LUPIN: CO RECEIVES APPROVAL FROM U.S. FDA FOR VARENICLINE TABLETS -- TABLETS HAS US SALES OF 430M USD

    LUPIN, 1,622.05 0.35
  • 06-Dec-2023 09:36:18

    ZYDUS LIFESCIENCES: CO SAYS CUTX-101 HAS POTENTIAL TO BE THE FIRST FDA-APPROVED TREATMENT FOR MENKES DISEASE; ROLLING SUBMISSION OF NEW DRUG APPLICATION TO FDA IS ONGOING AND EXPECTED TO BE COMPLETED IN 2024

    ZYDUSLIFE, 943.80 1.20
  • 06-Dec-2023 09:35:21

    ZYDUS LIFESCIENCES: CO SAYS SENTYNL RECEIVES WORLDWIDE PROPRIETARY RIGHTS AND U.S. FDA DOCUMENTS PERTAINING TO CUTX-101 COPPER HISTIDINATE

    ZYDUSLIFE, 943.80 1.20
  • 06-Dec-2023 09:35:17

    ZYDUS LIFESCIENCES: CO SAYS SENTYNL THERAPEUTICS COMPLETES ASSET TRANSFER OF CUTX-101 COPPER HISTIDINATE PRODUCT CANDIDATE FOR TREATMENT OF MENKES DISEASE FROM CYPRIUM THERAPEUTICS

    ZYDUSLIFE, 943.80 1.20
  • 06-Dec-2023 06:44:13

    SUN PHARMA: CO SECURES USD 15M LICENSING DEAL WITH ACLARIS FOR DEURUXOLITINIB IN ALOPECIA TREATMENT

    SUNPHARMA, 1,579.75 0.37
04 Dec-2023
  • 04-Dec-2023 17:07:59

    UNICHEM LABORATORIES: CO SOLD BALANCE STAKE HELD IN OPTIMUS DRUGS TO SEKHMET FOR AGGREGATE CONSIDERATION OF 674.7 MLN RUPEES

    UNICHEMLAB, 517.95 0.21
  • 04-Dec-2023 13:59:02

    APOLLO HOSPITAL: Rs 84.48cr NSE Block Trade; for ~150313 shares, at Rs 5620

    APOLLOHOSP, 6,102.65 -4.08
  • 04-Dec-2023 10:10:45

    ASTER DM HEALTHCARE: CO ANNOUNCES STRATEGIC EXPANSION: INTERNAL ACCRUALS FUEL CAPEX PLAN FOR SIGNIFICANT BED CAPACITY INCREASE TO 6,334 BEDS FROM 4855 BEDS BY FY27 - INVESTOR PRESENTATION

    ASTERDM, 471.55 -2.74
  • 04-Dec-2023 06:48:28

    GRANULES: CO RECEIVED ANDA APPROVAL FOR SILDENAFIL FOR ORAL SUSPENSION -- IT HAS US SALES OF USD 43M

    GRANULES, 464.50 0.98
02 Dec-2023
  • 02-Dec-2023 18:53:39

    ASTRAZENECA PHARMA: CO RECEIVES PERMISSION TO IMPORT PHARMACEUTICAL OF NEW DRUG FOR SALE OR FOR DISTRIBUTION IN FORM CT-20 FROM CDSCO

    ASTRAZEN, 5,535.50 0.42
01 Dec-2023
  • 01-Dec-2023 21:10:42

    ALKEM LABORATORIES: NO DATA INTEGRITY OBSERVATION -- US FDA HAD CONDUCTED INSPECTION FROM 27 NOVEMBER TO 1 DECEMBER

    ALKEM, 5,138.55 2.97
  • 01-Dec-2023 21:10:35

    ALKEM LABORATORIES: US FDA INSPECTION AT COS API MANUFACTURING FACILITY LOCATED AT MANDVA -- CO RECEIVED FORM 483 WITH THREE OBSERVATIONS

    ALKEM, 5,138.55 2.97
  • 01-Dec-2023 19:04:33

    STRIDES PHARMA SCIENCE: CO LAUNCHES ICOSAPENT ETHYL ACID SOFT GEL CAPSULES IN PARTNERSHIP WITH AMNEAL

    STAR, 784.50 0.25
  • 01-Dec-2023 17:10:56

    BAJAJ HEALTHCARE: CO SAYS CFO RUPESH NIKAM RESIGNS

    BAJAJHCARE, 334.95 -6.48
  • 01-Dec-2023 15:24:46

    LUPIN: CO LAUNCHES TURQOZ (NORGESTREL AND ETHINYL ESTRADIOL) TABLETS USP IN THE UNITED STATES -- THIS TABLETS HAS US SALES OF USD 33M

    LUPIN, 1,622.05 0.35
  • 01-Dec-2023 12:09:40

    ZYDUS LIFESCIENCES: CO RECEIVES FINAL APPROVAL FROM THE USFDA FOR IVABRADINE TABLETS, 5 MG AND 7.5 MG -- THIS TABLES HAS US SALES OF USD 136.5M

    ZYDUSLIFE, 943.80 1.20
30 Nov-2023
  • 30-Nov-2023 20:56:49

    PFIZER: CO SAYS MILIND PATIL, CHIEF FINANCIAL OFFICER OF CO HAS RETIRED

    PFIZER, 4,601.45 0.89
  • 30-Nov-2023 19:50:07

    PIRAMAL PHARMA: CO SAYS VETDC INITIATED CIVIL SUIT MAKING CLAIMS IN RELATION TO BATCHES OF PRODUCT MANUFACTURED DURING 2018-2019 AGAINST UNIT -- VETDC ALLEGED IT SUFFERED DAMAGES TO EXTENT OF ABOUT $8.91M

    PPLPHARMA, 131.75 1.19
  • 30-Nov-2023 16:24:25

    BIOCON: BIOCON BIOLOGICS SUCCESSFULLY COMPLETES INTEGRATION OF VIATRIS BIOSIMILAR BUSINESS IN 31 COUNTRIES IN EUROPE

    BIOCON, 276.45 1.99
  • 30-Nov-2023 11:01:41

    AUROBINDO PHARMA: CO UNIT EUGIA PHARMA RECEIVES USFDA APPROVAL FOR BUDESONIDE INHALATION SUSPENSION, 0.5 MG/2 ML SINGLE-DOSE AMPULE -- THIS DRUG HAS US SALES USD 226M

    AUROPHARMA, 1,028.10 -0.04
29 Nov-2023
  • 29-Nov-2023 12:55:13

    LAURUS LABS: Rs 48.67cr NSE Block Trade; for ~1300386 shares, at Rs 374.3

    LAURUSLABS, 407.00 0.48
  • 29-Nov-2023 12:21:28

    GLAND PHARMA: Rs 36.72cr NSE Block Trade; for ~206631 shares, at Rs 1777

    GLAND, 1,764.45 -2.07
  • 29-Nov-2023 11:41:06

    AUROBINDO PHARMA: CO RECEIVES USFDA APPROVAL TO MANUFACTURE AND MARKET DARUNAVIR TABLETS -- US SALES IS USD 274.8M

    AUROPHARMA, 1,028.10 -0.04
28 Nov-2023
  • 28-Nov-2023 21:08:27

    ASTER DM HEALTHCARE: CO APPROVED SALE OF SHARES HELD BY AFFINITY IN ASTER DM HEALTHCARE FZC TO ALPHA GCC HOLDINGS -- CONSIDERATION RECEIVABLE FROM TRANSACTION IS USD 1B (CORRECTION)

    ASTERDM, 471.55 -2.74
  • 28-Nov-2023 21:06:48

    ASTER DM HEALTHCARE: ASTER TO SEPARATE ITS INDIA AND GCC BUSINESSES TO UNLOCK VALUE; ANNOUNCES AGREEMENT FOR FAJR CAPITAL-LED CONSORTIUM TO INVEST IN ASTER GCC

    ASTERDM, 471.55 -2.74
  • 28-Nov-2023 19:23:12

    ASTER DM HEALTHCARE: FUNDS TO BE MANAGED BY FAJR CAPITAL ADVISORS LTD -- BUYER WILL BE OWNED BY PROMOTER OF ASTER INDIA AND FUNDS MANAGED BY FAJR CAPITAL ADVISORS IN RATIO OF 35:65

    ASTERDM, 471.55 -2.74
  • 28-Nov-2023 19:23:04

    ASTER DM HEALTHCARE: AND UPTO $98.8M OF DEAL VALUE MAY BE RECEIVED SUBSEQUENTLY SUBJECT TO CERTAIN CONTINGENT EVENTS -- BUYER WILL BE OWNED BY PROMOTER/ PROMOTER GROUP OF ASTER INDIA

    ASTERDM, 471.55 -2.74
  • 28-Nov-2023 19:22:57

    ASTER DM HEALTHCARE: $903M OF DEAL VALUE IS PAYABLE AT CLOSING -- SALE IS ANTICIPATED TO COMPLETE IN QUARTER 4 OF FINANCIAL YEAR ENDING 2024

    ASTERDM, 471.55 -2.74
  • 28-Nov-2023 19:22:47

    ASTER DM HEALTHCARE: CO APPROVED SALE OF SHARES HELD BY AFFINITY IN ASTER DM HEALTHCARE FZC TO ALPHA GCC HOLDINGS -- CONSIDERATION RECEIVABLE FROM TRANSACTION IS USD 1.01B

    ASTERDM, 471.55 -2.74
  • 28-Nov-2023 16:28:22

    GLOBAL HEALTH: CO SAYS SANJEEV KUMAR, GROUP CHIEF FINANCIAL OFFICER RESIGNS

    MEDANTA, 1,357.70 -5.86
  • 28-Nov-2023 13:47:21

    ASTER DM: SALE OF COS GCC BUSINESS LIKELY TO BE ANNOUNCED SOON - CNBC TV18

    ASTERDM, 471.55 -2.74
  • 28-Nov-2023 12:34:35

    ALKEM LAB: Rs 18.26cr NSE Block Trade; for ~40144 shares, at Rs 4548.3

    ALKEM, 5,138.55 2.97
24 Nov-2023
  • 24-Nov-2023 16:26:55

    FORTIS HEALTHCARE: CO SAYS SALE OF OPS, LAND, BUILDING ASSETS OF FORTIS MALAR HOSPITAL ADYAR, CHENNAI TO MGM HEALTHCARE FOR 1.28B RUPEES

    FORTIS, 408.55 -3.07
  • 24-Nov-2023 16:26:49

    FORTIS HEALTHCARE: CO SAY FORTIS MALAR TO SELL OPD AND RADIOLOGY BUSINESS RELATED TO FORTIS MALAR HOSPITAL FOR 475.9M RUPEES

    FORTIS, 408.55 -3.07
  • 24-Nov-2023 10:47:39

    GLAND PHARMA: Rs 27.12cr NSE Block Trade; for ~150634 shares, at Rs 1800.1

    GLAND, 1,764.45 -2.07
  • 24-Nov-2023 10:23:35

    GLAND PHARMA: CO HAS RECEIVED EIR FROM THE US FDA INDICATING CLOSURE OF THE INSPECTION FOR PASHAMYLARAM FACILITY, HYDERABAD

    GLAND, 1,764.45 -2.07
23 Nov-2023
  • 23-Nov-2023 16:32:01

    CIPLA: CO SAYS IN PROCESS OF SUBMITTING REQUISITE RESPONSE TO WARNING LETTER WITHIN TIMELINES, WILL WORK CLOSELY WITH FDA TO ADDRESS CONCERNS -- CO SAYS REMAIN COMMITTED TO BE COMPLIANT WITH CGMP QUALITY STANDARDS

    CIPLA, 1,477.55 0.04
  • 23-Nov-2023 16:31:46

    CIPLA: CO CONFIRMS THAT WE DO NOT SEE MATERIAL RISK TO EXISTING COMMERCIAL PRODUCT PORTFOLIO FROM FDA WARNING LETTER -- CO IN PROCESS OF EXECUTING DE-RISKING PLAN FOR NEW PRODUCTS, SIMULTANEOUSLY ADDRESSING OBSERVATIONS EXPEDITIOUSLY

    CIPLA, 1,477.55 0.04
  • 23-Nov-2023 16:03:01

    LUPIN: CO RECEIVES TENTATIVE APPROVAL FROM U.S. FDA FOR CANAGLIFLOZIN TABLETS -- TABLETS HAS US SALES OF 561M USD

    LUPIN, 1,622.05 0.35
  • 23-Nov-2023 16:02:45

    LUPIN: CO RECEIVES APPROVAL FROM U.S. FDA FOR BROMFENAC OPHTHALMIC SOLUTION, 0.07% -- CO IS ELIGIBLE FOR 180-DAY EXCLUSIVITY PERIOD -- US SALES OF 185M USD

    LUPIN, 1,622.05 0.35
  • 23-Nov-2023 10:33:05

    LUPIN: CO LAUNCHES WORLD S FIRST FIXED-DOSE TRIPLE COMBINATION DRUG, VILFURO-G FOR COPD MANAGEMENT IN INDIA

    LUPIN, 1,622.05 0.35
  • 23-Nov-2023 08:47:41

    STRIDES PHARMA: CO RECEIVES USFDA APPROVAL FOR GENERIC SUPREP® BOWEL PREP KIT -- IT HAS US SALES OF $143M

    STAR, 784.50 0.25
  • 23-Nov-2023 07:49:01

    NARAYANA HRUDAYALAYA: CO ANNOUNCES RUPEES 1,000 CR INVESTMENT FOR STATE-OF-THE-ART SUPERSPECIALTY HOSPITAL

    NH, 1,350.00 -1.05
22 Nov-2023
  • 22-Nov-2023 19:30:56

    APOLLO HOSPITALS ENTERPRISE: AL TADAWI HEALTHCARE GROUP SIGNS MOU WITH APOLLO HOSPITALS GROUP OF INDIA TO ENHANCE HEALTHCARE SERVICES FOR CITIZENS AND RESIDENTS IN UAE - STATEMENT

    APOLLOHOSP, 6,102.65 -4.08
  • 22-Nov-2023 13:52:15

    GLAND PHARMA: Rs 34.44cr NSE Block Trade; for ~200533 shares, at Rs 1717.4

    GLAND, 1,764.45 -2.07
  • 22-Nov-2023 13:34:39

    AUROBINDO PHARMA: CO SAYS COMPLETION OF PURCHASE OF SHARES OF THERANYM

    AUROPHARMA, 1,028.10 -0.04
21 Nov-2023
  • 21-Nov-2023 15:28:59

    LUPIN: CO HAS RECEIVED APPROVAL FROM U.S. FDA FOR ITS ABBREVIATED NEW DRUG APPLICATION FOR PITAVASTATIN TABLETS -- PITAVASTATIN TABLETS HAD ESTIMATED ANNUAL SALES OF USD 298M IN THE U.S

    LUPIN, 1,622.05 0.35
  • 21-Nov-2023 15:22:13

    LUPIN: CO RECEIVES TENTATIVE APPROVAL FROM U.S. FDA FOR DAPAGLIFLOZIN TABLETS -- DAPAGLIFLOZIN TABLETS HAD ESTIMATED ANNUAL US SALES OF 7282M USD

    LUPIN, 1,622.05 0.35
  • 21-Nov-2023 14:20:21

    FORTIS HEALTHCARE: Rs 37cr NSE Block Trade; for ~1002206 shares, at Rs 369.15

    FORTIS, 408.55 -3.07
  • 21-Nov-2023 10:58:52

    STRIDES PHARMA: CO RECEIVES USFDA APPROVAL FOR LEVETIRACETAM ORAL SOLUTION -- DRUG HAS US SALES OF USD 55M

    STAR, 784.50 0.25
17 Nov-2023
  • 17-Nov-2023 19:24:16

    CIPLA: CO EXECUTED A FACILITY DEMAND GUARANTEE OF ZAR 945M IN FAVOUR OF FIRST RAND BANK, SOUTH AFRICA

    CIPLA, 1,477.55 0.04
  • 17-Nov-2023 16:26:44

    AUROBINDO PHARMA: CO SAYS COMPLETION OF US FDA INSPECTION AT UNIT I & III OF APL HEALTHCARE LTD -- INSPECTION CLOSED WITH ZERO OBSERVATIONS AND A CLASSIFICATION OF "NO ACTION INDICATED"

    AUROPHARMA, 1,028.10 -0.04
  • 17-Nov-2023 14:48:54

    LUPIN: CO RECEIVES APPROVAL FROM U.S. FDA FOR GANIRELIX ACETATE INJECTION -- INJECTION HAS US SALES OF 84M USD

    LUPIN, 1,622.05 0.35
  • 17-Nov-2023 14:09:25

    GUFIC BIOSCIENCES: CO SAYS REV IMPACT FROM PRODUCTION START AT INDORE FACILITY TO REFLECT Q3 FY24 ONWARDS

    GUFICBIO, 313.55 1.32
16 Nov-2023
  • 16-Nov-2023 18:33:32

    SHILPA MEDICARE: CO TO SELL 4% OF ITS STAKE HELD IN SRAVATHI ADVANCE PROCESS TECHNOLOGIES PVT LTD -- DEAL AT A CONSIDERATION OF 82.1M RUPEES

    SHILPAMED, 414.80 1.01
  • 16-Nov-2023 17:36:28

    GLAXOSMITHKLINE PHARMA: CO LAUNCHED VOLUNTARY RETIREMENT SCHEME FOR COMMERCIAL FUNCTION EMPLOYEES

    GLAXO, 2,176.10 1.02
  • 16-Nov-2023 17:36:18

    GLAXOSMITHKLINE PHARMA: CO APPROVED COMMERCIAL TRANSFORMATION INITIATIVE -- CO SAYS WILL EXPLORE NEW INNOVATIVE SOLUTIONS INCLUDING OMNICHANNEL STRATEGY TO EXPAND ITS REACH AND COVERAGE TO TARGET SEGMENTS

    GLAXO, 2,176.10 1.02
  • 16-Nov-2023 14:33:01

    ASTRAZENECA PHARMA: CO INTENDS TO EXIT MANUFACTURING SITE IN BANGALORE, IN DUE COURSE

    ASTRAZEN, 5,535.50 0.42
  • 16-Nov-2023 14:20:04

    WOCKHARDT: Rs 50.76cr NSE Block Trade; for ~1506562 shares, at Rs 336.95

    WOCKPHARMA, 603.85 3.67
  • 16-Nov-2023 13:58:00

    DR REDDYS: CO ROLLS OUT NERIVIO, A USFDA APPROVED DRUG-FREE NON-INVASIVE MIGRAINE MANAGEMENT DEVICE, IN INDIA

    DRREDDY, 6,425.55 -0.04
  • 16-Nov-2023 11:21:50

    DIVIS LAB: CO GETS INR 82 CRS GST DEMAND, PENALTY OF SAME AMOUNT FROM GST AUTHORITIES

    DIVISLAB, 3,490.00 -0.81
15 Nov-2023
  • 15-Nov-2023 13:22:02

    CIPLA: CO SAYS COMPLETED SALE OF ENTIRE 51.18% STAKE HELD IN CIPLA QUALITY CHEMICAL INDUSTRIES, UGANDA -- DEAL FOR FINAL CONSIDERATION AMOUNT OF USD 25M

    CIPLA, 1,477.55 0.04
  • 15-Nov-2023 11:41:23

    GLAND PHARMA: CO RECEIVES A TENTATIVE APPROVAL FROM THE US FDA FOR ANGIOTENSIN II FOR INJECTION -- INJECTION HAS US SALES OF 38M USD

    GLAND, 1,764.45 -2.07
  • 15-Nov-2023 09:32:28

    KIMS: Rs 16.78cr NSE Block Trade; for ~90235 shares, at Rs 1860

    KIMS, 2,254.35 -1.55
  • 15-Nov-2023 00:31:34

    WOCKHARDT: Q2 EBITDA 720M RUPEES VS 430M (YOY) -- Q2 EBITDA MARGIN 9.56% VS 6.33% (YOY)

    WOCKPHARMA, 603.85 3.67
  • 15-Nov-2023 00:31:26

    WOCKHARDT: Q2 CONS NET LOSS 770M RUPEES VS LOSS 1.9B (YOY); LOSS 1.34B (QOQ) -- Q2 REVENUE 7.53B RUPEES VS 6.79B (YOY); 6.44B (QOQ)

    WOCKPHARMA, 603.85 3.67
14 Nov-2023
  • 14-Nov-2023 23:07:33

    SOLARA ACTIVE PHARMA SCIENCES: Q2 EBITDA 372M RUPEES VS 280M (YOY) -- Q2 EBITDA MARGIN 8.74% VS 9.85% (YOY)

    SOLARA, 440.40 0.76
  • 14-Nov-2023 23:07:22

    SOLARA ACTIVE PHARMA SCIENCES: Q2 CONS NET LOSS 172M RUPEES VS LOSS 100M (YOY); LOSS 196M (QOQ) -- Q2 REVENUE 4.25B RUPEES VS 3.4B (YOY); 3.52B (QOQ)

    SOLARA, 440.40 0.76
  • 14-Nov-2023 20:06:58

    DR. REDDYS LAB: THERANICA - ENTERS INTO AGREEMENT WITH DR. REDDYS FOR COMMERCIALIZING NERIVIO IN EUROPE

    DRREDDY, 6,425.55 -0.04
  • 14-Nov-2023 16:41:24

    SOLARA ACTIVE PHARMA SCIENCES: CO APPROVED SALE OF LAND AND BUILDING BELONGING TO UNIT SEQUENT PENEMS

    SOLARA, 440.40 0.76
  • 14-Nov-2023 16:03:27

    SIGACHI INDUSTRIES: Q2 EBITDA 214M RUPEES VS 163M (YOY) -- Q2 EBITDA MARGIN 21.59% VS 19.73% (YOY)

    SIGACHI, 83.50 -0.77
  • 14-Nov-2023 16:02:41

    SIGACHI INDUSTRIES: Q2 CONS NET PROFIT 151.4M RUPEES VS 136M (YOY); 109M (QOQ) -- Q2 REVENUE 992M RUPEES VS 825M (YOY); 847M (QOQ)

    SIGACHI, 83.50 -0.77
  • 14-Nov-2023 14:15:33

    NATCO PHARMA: CO APPROVED DIVIDEND OF 1.25 RUPEES PER SHARE

    NATCOPHARM, 995.00 1.17
  • 14-Nov-2023 14:14:23

    NATCO PHARMA: Q2 EBITDA 4.58B RUPEES VS 953M (YOY) -- Q2 EBITDA MARGIN 44.41% VS 22.06% (YOY)

    NATCOPHARM, 995.00 1.17
  • 14-Nov-2023 14:14:06

    NATCO PHARMA: Q2 CONS NET PROFIT 3.69B RUPEES VS 570M (YOY); 4.2B (QOQ) -- Q2 REVENUE 10.3B RUPEES VS 4.32B (YOY); 11.4B (QOQ)

    NATCOPHARM, 995.00 1.17
13 Nov-2023
  • 13-Nov-2023 19:19:47

    NARAYANA HRUDAYALAYA: Q2 EBITDA 3.26B RUPEES VS 2.75B (YOY) -- Q2 EBITDA MARGIN 25.02% VS 24.08% (YOY)

    NH, 1,350.00 -1.05
  • 13-Nov-2023 19:19:41

    NARAYANA HRUDAYALAYA: Q2 CONS NET PROFIT 2.27B RUPEES VS 1.69B (YOY); 1.84B (QOQ) -- Q2 REVENUE 13.05B RUPEES VS 11.4B (YOY); 12.33B (QOQ)

    NH, 1,350.00 -1.05
  • 13-Nov-2023 16:20:29

    BIOCON: BIOCON BIOLOGICS RECEIVES MHRA, UK APPROVAL FOR YESAFILI, BIOSIMILAR AFLIBERCEPT

    BIOCON, 276.45 1.99
  • 13-Nov-2023 12:23:23

    BAJAJ HEALTHCARE: CO SAYS THE MANAGEMENT IS CONFIDENT OF CONTINUING THE INCREASE IN EBITDA MARGIN FOR THE SECOND HALF OF THE YEAR

    BAJAJHCARE, 334.95 -6.48
  • 13-Nov-2023 12:21:47

    BAJAJ HEALTHCARE: CO SAYS THE MANAGEMENT HAS SEEN THE IMPROVEMENT IN THE DOMESTIC AS WELL AS EXPORT MARKETS WHICH HELP TO ACHIEVE THE TARGETED SALES REVENUE FROM DOMESTIC AND EXPORT MARKETS

    BAJAJHCARE, 334.95 -6.48
11 Nov-2023
  • 11-Nov-2023 16:10:53

    TARSONS PRODUCTS: Q2 EBITDA 254M RUPEES VS 326M (YOY) -- Q2 EBITDA MARGIN 38.27% VS 45.79% (YOY)

    TARSONS, 467.00 -0.18
  • 11-Nov-2023 16:10:07

    TARSONS PRODUCTS: Q2 SL NET PROFIT 128M RUPEES VS 215M (YOY) -- Q2 REVENUE 663M RUPEES VS 712M (YOY)

    TARSONS, 467.00 -0.18
  • 11-Nov-2023 15:47:36

    JUBILANT PHARMOVA: COS RADIOPHARMA BUSINESS RECEIVES ANDA APPROVAL FOR TECHNETIUM SULFUR COLLOID INJECTION

    JUBLPHARMA, 568.00 1.44
10 Nov-2023
  • 10-Nov-2023 20:44:49

    GLENMARK PHARMA: CO HAS AN EXCEPTIONAL OF 3.25B RUPEES

    GLENMARK, 925.95 1.62
  • 10-Nov-2023 20:44:44

    GLENMARK PHARMA: Q2 EBITDA 4.6B RUPEES VS 6.22B (YOY); EST 6.48B -- Q2 EBITDA MARGIN 14.63% VS 18.42% (YOY); EST 18.5%

    GLENMARK, 925.95 1.62
  • 10-Nov-2023 20:44:39

    GLENMARK PHARMA: Q2 CONS NET LOSS 8.19B RUPEES VS PROFIT 2.6B (YOY); EST 2.44B - PROFIT 1.50B (QOQ) -- Q2 REVENUE 31.61B RUPEES VS 33.8B (YOY); EST 35B - 33.36B (QOQ)

    GLENMARK, 925.95 1.62
  • 10-Nov-2023 20:16:55

    SASTASUNDAR VENTURES: Q2 CONS NET LOSS 81M RUPEES VS LOSS 12M (YOY); PROFIT 13M (QOQ) -- Q2 REVENUE 3.58B RUPEES VS 2.5B (YOY); 3.36B (QOQ)

    SASTASUNDR, 345.80 -1.00
  • 10-Nov-2023 19:49:23

    FORTIS HEALTHCARE: Q2 EBITDA 3.3B RUPEES VS 3.2B (YOY) -- Q2 EBITDA MARGIN 18.65% VS 19.8% (YOY)

    FORTIS, 408.55 -3.07
  • 10-Nov-2023 19:49:17

    FORTIS HEALTHCARE: Q2 CONS NET PROFIT 1.74B RUPEES VS 2.2B (YOY); 1.24B (QOQ) -- Q2 REVENUE 17.70B RUPEES VS 16.1B (YOY); 16.57B (QOQ)

    FORTIS, 408.55 -3.07
  • 10-Nov-2023 19:32:20

    DR REDDYS LAB: CO HAS PRESENTLY INVESTED 4.3M RUPEES, EQUIVALENT TO 26% STAKE OF THE SPV -- CO ALSO INVESTED 7.3M RUPEES IN THE COMPULSORILY CONVERTIBLE DEBENTURES

    DRREDDY, 6,425.55 -0.04
  • 10-Nov-2023 19:32:09

    DR REDDYS LAB: CO SAYS ACQUISITION OF SECURITIES OF O2 RENEWABLE ENERGY IX PVT LTD -- CO ACQUIRED 26% OF THE PAID UP EQUITY SHARE CAPITAL OF THE SPV

    DRREDDY, 6,425.55 -0.04
  • 10-Nov-2023 17:20:32

    BIOCON: Q2 EBITDA 7.42B RUPEES VS 4.71B (YOY); EST 8.3B -- Q2 EBITDA MARGIN 21.42% VS 20.29% (YOY); EST 22.7%

    BIOCON, 276.45 1.99
  • 10-Nov-2023 17:20:27

    BIOCON: Q2 CONS NET PROFIT 1.26B RUPEES VS 469M (YOY); EST 1.38B - 1.01B (QOQ) -- Q2 REVENUE 34.62B RUPEES VS 23.19B (YOY); EST 36.53B - 34B (QOQ)

    BIOCON, 276.45 1.99
  • 10-Nov-2023 17:04:29

    NEULAND LABORATORIES: CO APPROVED CAPITAL EXPENDITURE OF 1.28B RUPEES FOR ENHANCING CAPACITY AT UNIT 3

    NEULANDLAB, 7,149.90 0.67
  • 10-Nov-2023 15:06:23

    THEMIS MEDICARE: CO LAUNCHES REMITHEM - REMIFENTANIL INJECTION, A NOVEL NARCOTIC ANALGESIC

    THEMISMED, 237.85 -0.19
  • 10-Nov-2023 15:00:13

    SHILPA MEDICARE: Q2 REVENUE 3.2B RUPEES VS 2.63B (YOY)

    SHILPAMED, 414.80 1.01
  • 10-Nov-2023 14:59:23

    SHILPA MEDICARE: Q2 EBITDA RUPEES 603M VS 122M (YOY) -- Q2 EBITDA MARGIN 19.27% VS 4.64% (YOY)

    SHILPAMED, 414.80 1.01
  • 10-Nov-2023 14:59:16

    SHILPA MEDICARE: Q2 CONS NET PROFIT 16M RUPEES VS LOSS 187M (YOY)

    SHILPAMED, 414.80 1.01
  • 10-Nov-2023 14:47:27

    ZYDUS LIFESCIENCES: CO AND TORRENT SIGN LICENSING AGREEMENT FOR CO-MARKETING SAROGLITAZAR MG, A CRITICAL TREATMENT FOR CHRONIC LIVER DISEASES IN INDIA

    ZYDUSLIFE, 943.80 1.20
  • 10-Nov-2023 13:48:22

    PANACEA: Q2 CONS NET LOSS 83M RUPEES VS PROFIT 157M (YOY) -- Q2 REVENUE 1.43B RUPEES VS 1B (YOY)

    PANACEABIO, 152.40 0.33
  • 10-Nov-2023 13:45:40

    IPCA LAB: CO DECLARED INTERIM DIVIDEND OF RUPEES 2 PER EQUITY SHARE

    IPCALAB, 1,191.35 0.26
  • 10-Nov-2023 13:38:08

    IPCA LABORATORIES: Q2 CONS NET PROFIT RUPEES 1.45B VS 1.46B (YOY) -- Q2 REVENUE RUPEES 20.4B VS 16B (YOY)

    IPCALAB, 1,191.35 0.26
  • 10-Nov-2023 13:37:59

    IPCA LABORATORIES: Q2 EBITDA 3.6B RUPEES VS 2.7B (YOY) -- Q2 EBITDA MARGIN 17.65% VS 16.3% (YOY)

    IPCALAB, 1,191.35 0.26
  • 10-Nov-2023 13:10:21

    SHILPA MEDICARE: CO SAYS HAD AN UNANNOUNCED USFDA INSPECTION FROM 30 OCT UNTIL 9 NOV

    SHILPAMED, 414.80 1.01
  • 10-Nov-2023 11:50:20

    APOLLO HOSPITAL: Rs 24.22cr NSE Block Trade; for ~46300 shares, at Rs 5230.75

    APOLLOHOSP, 6,102.65 -4.08
  • 10-Nov-2023 10:48:15

    LUPIN: CO AND AMMAN PHARMA SIGN EXCLUSIVE LICENSING AND SUPPLY AGREEMENT FORRANIBIZUMAB BIOSIMILAR

    LUPIN, 1,622.05 0.35
09 Nov-2023
  • 09-Nov-2023 18:59:03

    BAJAJ HEALTHCARE: Q2 EBITDA 189M RUPEES VS 333M (YOY) -- Q2 EBITDA MARGIN 18.71% VS 16.59% (YOY)

    BAJAJHCARE, 334.95 -6.48
  • 09-Nov-2023 18:58:57

    BAJAJ HEALTHCARE: Q2 SL NET LOSS 35M RUPEES VS PROFIT 164M (YOY); LOSS 482M (QOQ) -- Q2 REVENUE 1.01B RUPEES VS 2.01B (YOY); 1.30B (QOQ)

    BAJAJHCARE, 334.95 -6.48
  • 09-Nov-2023 18:24:35

    SUVEN PHARMA: Q2 EBITDA 980M RUPEES VS 999M (YOY) -- Q2 EBITDA MARGIN 42.40% VS 35.88% (YOY)

    SUVENPHAR, 631.05 -1.80
  • 09-Nov-2023 18:24:30

    SUVEN PHARMA: Q2 CONS NET PROFIT 796M RUPEES VS 721M (YOY); 1.06B (QOQ) -- Q2 REVENUE 2.31B RUPEES VS 2.78B (YOY); 3.47B (QOQ)

    SUVENPHAR, 631.05 -1.80
  • 09-Nov-2023 17:35:35

    ASTRAZENECA PHARMA: Q2 EBITDA 528M RUPEES VS 407M (YOY) -- Q2 EBITDA MARGIN 16.96% VS 17.24% (YOY)

    ASTRAZEN, 5,535.50 0.42
  • 09-Nov-2023 17:35:29

    ASTRAZENECA PHARMA: Q2 SL NET PROFIT 524M RUPEES VS 325M (YOY); 539M (QOQ) -- Q2 REVENUE 3.11B RUPEES VS 2.36B (YOY); 2.95B (QOQ)

    ASTRAZEN, 5,535.50 0.42
  • 09-Nov-2023 17:35:07

    HEALTHCARE GLOBAL ENTERPRISES: Q2 EBITDA 846M RUPEES VS 747M (YOY) -- Q2 EBITDA MARGIN 17.42% VS 17.82% (YOY)

    HCG, 361.75 -0.65
  • 09-Nov-2023 17:35:00

    HEALTHCARE GLOBAL ENTERPRISES: Q2 CONS NET PROFIT 136M RUPEES VS 74M (YOY); 76M (QOQ) -- Q2 REVENUE 4.86B RUPEES VS 4.2B (YOY); 4.60B (QOQ)

    HCG, 361.75 -0.65
  • 09-Nov-2023 17:00:40

    GLAXOSMITHKLINE PHARMA: Q2 EBITDA 2.89B RUPEES VS 2.6B (YOY) -- Q2 EBITDA MARGIN 30.25% VS 28.02% (YOY)

    GLAXO, 2,176.10 1.02
  • 09-Nov-2023 17:00:35

    GLAXOSMITHKLINE PHARMA: Q2 CONS NET PROFIT 2.17B RUPEES VS 1.93B (YOY); 1.3B (QOQ) -- Q2 REVENUE 9.57B RUPEES VS 9.2B (YOY); 7.6B (QOQ)

    GLAXO, 2,176.10 1.02
  • 09-Nov-2023 14:31:49

    APOLLO HOSPITALS ENTERPRISE: Q2 EBITDA RUPEES 6.28B VS 5.65B (YOY); EST 6B -- Q2 EBITDA MARGIN 13% VS 13.3% (YOY); EST 12.6%

    APOLLOHOSP, 6,102.65 -4.08
  • 09-Nov-2023 14:31:24

    APOLLO HOSPITALS: CO APPROVES RUPEES 34.4B CAPITAL OUTLAY FOR EXPANSION

    APOLLOHOSP, 6,102.65 -4.08
  • 09-Nov-2023 14:30:24

    APOLLO HOSPITALS ENTERPRISE: Q2 EBITDA RUPEES 6.28B VS 5.65B (YOY); EST 6B

    APOLLOHOSP, 6,102.65 -4.08
  • 09-Nov-2023 14:29:32

    APOLLO HOSPITALS ENTERPRISE: Q2 REVENUE 48.5B RUPEES VS 42.51B (YOY); EST 47.7B

    APOLLOHOSP, 6,102.65 -4.08
  • 09-Nov-2023 14:28:17

    APOLLO HOSPITALS ENTERPRISE: Q2 CONS NET PROFIT 2.33B RUPEES VS 2.04B (YOY); EST 2.93B

    APOLLOHOSP, 6,102.65 -4.08
  • 09-Nov-2023 13:13:53

    GRANULES INDIA: Q2 EBITDA RUPEES 2.13B VS 2.4B (YOY) -- Q2 EBITDA MARGIN 17.90% VS 21.11% (YOY)

    GRANULES, 464.50 0.98
  • 09-Nov-2023 13:13:48

    GRANULES INDIA: Q2 REVENUE 11.9B RUPEES VS 11.5B (YOY)

    GRANULES, 464.50 0.98
  • 09-Nov-2023 13:13:28

    GRANULES INDIA: Q2 CONS NET PROFIT 1B RUPEES VS 1.45B (YOY)

    GRANULES, 464.50 0.98
  • 09-Nov-2023 13:09:11

    MARKSANS PHARMA: Q2 EBITDA 1.1B RUPEES VS 802M (YOY) -- Q2 EBITDA MARGIN 21.46% VS 17.72% (YOY)

    MARKSANS, 151.95 -0.49
  • 09-Nov-2023 13:07:32

    MARKSANS PHARMA: Q2 CONS NET PROFIT RUPEES 835M VS 612M (YOY) -- Q2 REVENUE RUPEES 5.3B VS 4.52B (YOY)

    MARKSANS, 151.95 -0.49
  • 09-Nov-2023 12:44:09

    CAPLIN POINT LABORATORIES: Q2 EBITDA 1.38B RUPEES VS 1.06B (YOY) -- Q2 EBITDA MARGIN 33.71% VS 29.57% (YOY)

    CAPLIPOINT, 1,479.90 1.91
  • 09-Nov-2023 12:43:50

    CAPLIN POINT LABORATORIES: Q2 CONS NET PROFIT RUPEES 1.15B VS 917M (YOY) -- Q2 REVENUE RUPEES 4.1B VS 3.59B (YOY)

    CAPLIPOINT, 1,479.90 1.91
  • 09-Nov-2023 12:29:09

    GLOBAL HEALTH: Q2 REVENUE 8.4B RUPEES VS 6.79B (YOY)

    MEDANTA, 1,357.70 -5.86
  • 09-Nov-2023 12:29:06

    GLOBAL HEALTH: Q2 EBITDA 2.1B RUPEES VS 1.60B (YOY) -- Q2 EBITDA MARGIN 25.22% VS 23.04% (YOY)

    MEDANTA, 1,357.70 -5.86
  • 09-Nov-2023 12:28:32

    GLOBAL HEALTH: Q2 CONS NET PROFIT 1.25B RUPEES VS 856M (YOY)

    MEDANTA, 1,357.70 -5.86
  • 09-Nov-2023 11:35:19

    PIRAMAL PHARMA: CO SAYS US FDA HAS ISSUED AN EIR AND THE INSPECTION HAS NOW BEEN SUCCESSFULLY CLOSED BY THE US FDA

    PPLPHARMA, 131.75 1.19
08 Nov-2023
  • 08-Nov-2023 23:35:38

    LUPIN: Q2 EBITDA 8.59B RUPEES VS 4.14B (YOY); EST 7.76B -- Q2 EBITDA MARGIN 17.39% VS 10.11% (YOY); EST 16.1%

    LUPIN, 1,622.05 0.35
  • 08-Nov-2023 23:35:26

    LUPIN: Q2 CONS NET PROFIT 4.9B RUPEES VS 1.29B (YOY); EST 3.67B - 4.5B (QOQ) -- Q2 REVENUE 50.4B RUPEES VS 41.46B (YOY); EST 48.14B - 48.1B (QOQ)

    LUPIN, 1,622.05 0.35
  • 08-Nov-2023 23:31:34

    AMI ORGANICS: CO HAS EXCEPTIONAL ITEM GAIN OF 317.5M RUPEES

    AMIORG, 1,112.30 -1.35
  • 08-Nov-2023 23:31:27

    AMI ORGANICS: Q2 EBITDA 186.2M RUPEES VS 281M (YOY) -- Q2 EBITDA MARGIN 11.38% VS 19.13% (YOY)

    AMIORG, 1,112.30 -1.35
  • 08-Nov-2023 23:31:19

    AMI ORGANICS: Q2 SL NET LOSS 209.6M RUPEES VS PROFIT 190M (YOY); PROFIT 169M (QOQ) -- Q2 REVENUE 1.64B RUPEES VS 1.46B (YOY); 1.4B (QOQ)

    AMIORG, 1,112.30 -1.35
  • 08-Nov-2023 22:02:36

    DISHMAN CARBOGEN AMCIS: Q2 EBITDA 610M RUPEES VS 786M (YOY) -- Q2 EBITDA MARGIN 10.4% VS 12.8% (YOY)

    DCAL, 255.60 2.40
  • 08-Nov-2023 22:02:09

    DISHMAN CARBOGEN AMCIS: Q2 CONS NET LOSS 409M RUPEES VS LOSS 101M (YOY); 170M (QOQ) -- Q2 REVENUE 5.8B RUPEES VS 6B (YOY); 7.23B (QOQ)

    DCAL, 255.60 2.40
  • 08-Nov-2023 21:24:20

    SANOFI INDIA: CO SAYS RACHID AYARI NAMED AS CHIEF FINANCIAL OFFICER

    SANOFI, 8,611.25 -2.64
  • 08-Nov-2023 21:24:14

    SANOFI INDIA: CO SAYS VAIBHAV KARANDIKAR CHIEF FINANCIAL OFFICER MOVING INTO ANOTHER ROLE -- KARANDIKAR TO CEASE TO BE CFO AND WHOLE-TIME DIRECTOR OF CO

    SANOFI, 8,611.25 -2.64
  • 08-Nov-2023 21:00:12

    FDC: Q2 EBITDA 787M RUPEES VS 673M (YOY) -- Q2 EBITDA MARGIN 16.41% VS 15.13% (YOY)

    FDC, 434.85 -2.36
  • 08-Nov-2023 21:00:10

    FDC: Q2 EBITDA 787M RUPEES VS 673M (YOY) -- Q2 EBITDA MARGIN 16.41% VS 15.13% (YOY)

    FDC, 434.85 -2.36
  • 08-Nov-2023 20:59:23

    FDC: Q2 CONS NET PROFIT 720M RUPEES VS 513M (YOY); 1B (QOQ) -- Q2 REVENUE 4.8B RUPEES VS 4.45B (YOY); 5.3B (QOQ)

    FDC, 434.85 -2.36
  • 08-Nov-2023 20:08:44

    SANOFI INDIA: Q2 EBITDA 2b RUPEES VS 1.82B (YOY) -- Q2 EBITDA MARGIN 29.2% VS 26.29% (YOY)

    SANOFI, 8,611.25 -2.64
  • 08-Nov-2023 20:08:12

    SANOFI INDIA: Q2 sl NET PROFIT 1.52b RUPEES VS 1.30B (YOY); 1.23B (QOQ) -- Q2 REVENUE 7.14b RUPEES VS 6.9B (YOY); 7.06B (QOQ)

    SANOFI, 8,611.25 -2.64
  • 08-Nov-2023 18:53:01

    HEALTHCARE GLOBAL ENTERPRISES: CO DECIDED NOT TO PURSUE BTA ARRANGEMENT WITH RADIANT HOSPITAL SERVICES -- CO EXPLORING OTHER FEASIBLE OPTIONS, FOR OPERATING CANCER CENTRE IN SAMBALPUR

    HCG, 361.75 -0.65
  • 08-Nov-2023 18:13:17

    IOL CHEM AND PHARMA: Q2 EBITDA 644M RUPEES VS 309M (YOY) -- Q2 EBITDA MARGIN 11.8% VS 5.71% (YOY)

    IOLCP, 402.80 1.10
  • 08-Nov-2023 18:10:31

    IOL CHEM AND PHARMA: Q2 SL NET PROFIT 378M RUPEES VS 157M (YOY); 462M (QOQ) -- Q2 REVENUE 5.45B RUPEES VS 5.41B (YOY); 5.63B (QOQ)

    IOLCP, 402.80 1.10
  • 08-Nov-2023 17:44:29

    BIOCON: UNIT ENTERED INTO DEAL WITH ERIS LIFESCIENCES FOR DIVESTURE OF DERMATOLOGY, NEPHROLOGY BRANDED FORMULATIONS BUSINESS UNITS IN INDIA

    BIOCON, 276.45 1.99
  • 08-Nov-2023 17:44:22

    BIOCON: CO SAYS POST DEAL CLOSE, OVER 120 EMPLOYEES OF TWO BUSINESS UNITS EXPECTED TO TRANSITION TO ERIS -- DIVESTITURE IS EXPECTED TO CLOSE BY END OF NOV 2023

    BIOCON, 276.45 1.99
  • 08-Nov-2023 17:44:16

    BIOCON: BIOCON BIOLOGICS ANNOUNCES DIVESTMENT OF TWO NON-CORE BRANDED FORMULATIONS - INDIA BUSINESS UNITS -- TOTAL TRANSACTION VALUE OF DIVESTMENT IS 3.66B RUPEES

    BIOCON, 276.45 1.99
  • 08-Nov-2023 14:19:27

    ERIS LIFESCIENCES: Q2 REVENUE 5B RUPEES VS 4.6B (YOY)

    ERIS, 883.75 1.31
  • 08-Nov-2023 14:18:54

    ERIS LIFESCIENCES: Q2 EBITDA RUPEES 1.8B VS 1.5B (YOY) -- Q2 EBITDA MARGIN 35.85% VS 32.88% (YOY)

    ERIS, 883.75 1.31
  • 08-Nov-2023 14:18:50

    ERIS LIFESCIENCES: Q2 CONS NET PROFIT 1.23B RUPEES VS 1.2B (YOY)

    ERIS, 883.75 1.31
  • 08-Nov-2023 13:07:49

    SMS PHARMA: Q2 EBITDA RUPEES 278M VS 136M (YOY) -- Q2 EBITDA MARGIN 16.70% VS 8.54% (YOY)

    SMSPHARMA, 149.80 -3.01
  • 08-Nov-2023 13:06:58

    SMS PHARMA: Q2 REVENUE 1.66B RUPEES VS 1.59B (YOY)

    SMSPHARMA, 149.80 -3.01
  • 08-Nov-2023 13:06:09

    SMS PHARMA: Q2 SL NET PROFIT 120M RUPEES VS 7.8M (YOY)

    SMSPHARMA, 149.80 -3.01
  • 08-Nov-2023 10:55:06

    GLAND PHARMA: CO HAS RECEIVED ESTABLISHMENT INSPECTION REPORT (EIR) FROM THE US FDA INDICATING CLOSURE OF THE INSPECTION FOR VISAKHAPATNAM PLANT

    GLAND, 1,764.45 -2.07
  • 08-Nov-2023 10:43:22

    LUPIN: CO SAYS ROCURONIUM INJECTION HAD ESTIMATED ANNUAL SALES OF USD 54M IN THE UNITED STATES

    LUPIN, 1,622.05 0.35
  • 08-Nov-2023 10:41:21

    LUPIN: CO LAUNCHES ROCURONIUM BROMIDE INJECTION IN THE UNITED STATES

    LUPIN, 1,622.05 0.35
  • 08-Nov-2023 09:55:42

    GLOBAL HEALTH: Rs 53.32cr NSE Block Trade; for ~637133 shares, at Rs 836.85

    MEDANTA, 1,357.70 -5.86
07 Nov-2023
  • 07-Nov-2023 21:03:56

    KRISHNA INSTITUTE OF MEDICAL SCIENCES: CO HYDERABAD ORDERS RADIATION THERAPY SYSTEMS FOR USD 40M FROM ELEKTA -- ELEKTA AB - ORDER WAS BOOKED IN Q2 OF ELEKTAS 2023/24 FISCAL YEAR

    KIMS, 2,254.35 -1.55
  • 07-Nov-2023 19:38:07

    KRISHNA INSTITUTE OF MEDICAL SCIENCES: Q2 EBITDA 177M RUPEES VS 1.52B (YOY) -- Q2 EBITDA MARGIN 27.16% VS 27.02% (YOY)

    KIMS, 2,254.35 -1.55
  • 07-Nov-2023 19:38:02

    KRISHNA INSTITUTE OF MEDICAL SCIENCES: Q2 CONS NET PROFIT 960M RUPEES VS 971M (YOY); 808M (QOQ) -- Q2 REVENUE 6.52B RUPEES VS 5.6B (YOY); 6.06B (QOQ)

    KIMS, 2,254.35 -1.55
  • 07-Nov-2023 19:37:12

    SUPRIYA LIFESCIENCE: Q2 EBITDA 318M RUPEES VS 286M (YOY) -- Q2 EBITDA MARGIN 22.70% VS 25.49% (YOY)

    SUPRIYA, 344.00 0.85
  • 07-Nov-2023 19:37:05

    SUPRIYA LIFESCIENCE: Q2 SL NET PROFIT 239M RUPEES VS 169M (YOY); 285M (QOQ) -- Q2 REVENUE 1.40B RUPEES VS 1.12B (YOY); 1.32B (QOQ)

    SUPRIYA, 344.00 0.85
  • 07-Nov-2023 17:02:27

    LUPIN: CO RECEIVES TENTATIVE APPROVAL FROM U.S. FDA FOR CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS -- CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS (RLD INVOKAMET XR®) HAD ESTIMATED ANNUAL SALES OF USD 28M IN THE U.S. (IQVIA MAT JULY 2023)

    LUPIN, 1,622.05 0.35
  • 07-Nov-2023 15:31:56

    J.B.CHEMICALS & PHARMACEUTICALS: Q2 REVENUE 8.8B RUPEES VS 8.1B (YOY)

    JBCHEPHARM, 1,564.45 -2.23
  • 07-Nov-2023 15:31:42

    J.B.CHEMICALS & PHARMACEUTICALS: Q2 CONS NET PROFIT 1.5B RUPEES VS 1.1B (YOY)

    JBCHEPHARM, 1,564.45 -2.23
  • 07-Nov-2023 15:31:17

    J.B.CHEMICALS & PHARMACEUTICALS: Q2 EBITDA RUPEES 2.43B VS 1.85B (YOY) -- Q2 EBITDA MARGIN 27.62% VS 22.8% (YOY)

    JBCHEPHARM, 1,564.45 -2.23
  • 07-Nov-2023 14:36:33

    NEULAND LABORATORIES: Q2 EBITDA RUPEES 1.37B VS 693M (YOY) -- Q2 EBITDA MARGIN 32.91% VS 23.59% (YOY)

    NEULANDLAB, 7,149.90 0.67
  • 07-Nov-2023 14:35:46

    NEULAND LABORATORIES: Q2 REVENUE 4.2B RUPEES VS 2.9B (YOY)

    NEULANDLAB, 7,149.90 0.67
  • 07-Nov-2023 14:35:20

    NEULAND LABORATORIES: Q2 CONS NET PROFIT 892M RUPEES VS 385M (YOY)

    NEULANDLAB, 7,149.90 0.67
  • 07-Nov-2023 14:02:09

    ALKEM LABORATORIES: Q2 REVENUE 34.4B RUPEES VS 30.8B (YOY)

    ALKEM, 5,138.55 2.97
  • 07-Nov-2023 13:56:16

    ALEMBIC PHARMA: Q2 REVENUE 15.9B RUPEES VS 14.75B (YOY)

    APLLTD, 1,017.90 -1.05
  • 07-Nov-2023 13:54:25

    VIJAYA DIAGNOSTIC CENTRE: Q2 REVENUE 1.4B RUPEES VS 1.2B (YOY)

    VIJAYA, 643.90 -1.92
  • 07-Nov-2023 13:54:08

    VIJAYA DIAGNOSTIC: Q2 EBITDA RUPEES 574M VS 487M (YOY) -- Q2 EBITDA MARGIN 41.31% VS 40.36% (YOY)

    VIJAYA, 643.90 -1.92
  • 07-Nov-2023 13:53:39

    VIJAYA DIAGNOSTIC CENTRE: Q2 CONS NET PROFIT 333M RUPEES VS 233M (YOY)

    VIJAYA, 643.90 -1.92
  • 07-Nov-2023 13:49:43

    ALKEM LABORATORIES: Q2 EBITDA RUPEES 7.47B VS 4.5B (YOY) -- Q2 EBITDA MARGIN 21.71% VS 14.74% (YOY)

    ALKEM, 5,138.55 2.97
  • 07-Nov-2023 13:39:40

    ALEMBIC PHARMA: Q2 EBITDA RUPEES 2.1B VS 2.3B (YOY) -- Q2 EBITDA MARGIN 13.06% VS 15.8% (YOY)

    APLLTD, 1,017.90 -1.05
  • 07-Nov-2023 13:39:16

    ALEMBIC PHARMA: Q2 CONS NET PROFIT 1.37B RUPEES VS 1.3B (YOY)

    APLLTD, 1,017.90 -1.05
  • 07-Nov-2023 13:28:20

    KOPRAN: Q2 EBITDA RUPEES 228M VS 101M (YOY) -- Q2 EBITDA MARGIN 14.96% VS 8.67% (YOY)

    KOPRAN, 245.70 -0.73
  • 07-Nov-2023 13:28:05

    KOPRAN: Q2 REVENUE 1.5B RUPEES VS 1.17B (YOY)

    KOPRAN, 245.70 -0.73
  • 07-Nov-2023 13:27:28

    KOPRAN: Q2 CONS NET PROFIT 138M RUPEES VS 46M (YOY)

    KOPRAN, 245.70 -0.73
  • 07-Nov-2023 12:29:14

    HESTER BIOSCIENCES: Q2 EBITDA 132M RUPEES VS 127M (YOY) -- Q2 EBITDA MARGIN 18.72% VS 17.35% (YOY)

    HESTERBIO, 1,394.95 -0.58
  • 07-Nov-2023 12:28:52

    HESTER BIOSCIENCES: Q2 CONS NET PROFIT 41M RUPEES VS 69M (YOY) -- Q2 REVENUE 705M RUPEES VS 731M (YOY)

    HESTERBIO, 1,394.95 -0.58
  • 07-Nov-2023 12:15:38

    ADVANCED ENZYME TECH: Q2 EBITDA 513M RUPEES VS 396M (YOY) -- Q2 EBITDA MARGIN 32.51% VS 28.55% (YOY)

    ADVENZYMES, 385.95 0.39
  • 07-Nov-2023 12:15:27

    ADVANCED ENZYME TECH: Q2 REVENUE 1.6B RUPEES VS 1.4B (YOY)

    ADVENZYMES, 385.95 0.39
  • 07-Nov-2023 12:14:45

    ADVANCED ENZYME TECH: Q2 CONS NET PROFIT 344M RUPEES VS 262M (YOY)

    ADVENZYMES, 385.95 0.39
  • 07-Nov-2023 12:04:01

    ZYDUS LIFESCIENCES: Q2 EBITDA RUPEES 11.46B VS 8.2B (YOY) -- Q2 EBITDA MARGIN 26.23% VS 20.35% (YOY)

    ZYDUSLIFE, 943.80 1.20
  • 07-Nov-2023 12:03:16

    ZYDUS LIFESCIENCES: Q2 REVENUE 43.7B RUPEES VS 41.3B (YOY)

    ZYDUSLIFE, 943.80 1.20
  • 07-Nov-2023 12:02:28

    ZYDUS LIFESCIENCES: Q2 CONS NET PROFIT 8B RUPEES VS 5.23B (YOY)

    ZYDUSLIFE, 943.80 1.20
  • 07-Nov-2023 09:21:20

    GLENMARK PHARMA: CO RECEIVES ANDA APPROVAL FOR FLUPHENAZINE HYDROCHLORIDE TABLETS USP -- TABLETS US SALES IS USD 18M

    GLENMARK, 925.95 1.62
  • 07-Nov-2023 09:10:40

    GLAND PHARMA: SHARES UP 4.5% IN PRE-OPEN TRADE AFTER REPORTING QTRLY RESULTS

    GLAND, 1,764.45 -2.07
06 Nov-2023
  • 06-Nov-2023 22:44:32

    SEQUENT SCIENTIFIC: CO HAS AN EXCEPTIONAL ITEM LOSS OF 80.7M RUPEES

    SEQUENT, 128.70 -2.76
  • 06-Nov-2023 22:44:23

    SEQUENT SCIENTIFIC: Q2 EBITDA 232M RUPEES VS 28.7M (YOY) -- Q2 EBITDA MARGIN 6.71% VS 0.85% (YOY)

    SEQUENT, 128.70 -2.76
  • 06-Nov-2023 22:43:55

    SEQUENT SCIENTIFIC: Q2 CONS NET LOSS 83.8M RUPEES VS LOSS 37.5M (YOY); LOSS 348.5M (QOQ) -- Q2 REVENUE 3.46B RUPEES VS 3.38B (YOY); 3.33B (QOQ)

    SEQUENT, 128.70 -2.76
  • 06-Nov-2023 18:03:44

    GLAND PHARMA: Q2 EBITDA 3.20B RUPEES VS 2.97B (YOY) -- Q2 EBITDA MARGIN 23% VS 28.42% (YOY)

    GLAND, 1,764.45 -2.07
  • 06-Nov-2023 18:03:38

    GLAND PHARMA: Q2 CONS NET PROFIT 1.94B RUPEES VS 2.4B (YOY); 1.94B (QOQ) -- Q2 REVENUE 13.73B RUPEES VS 10.4B (YOY); 12.09B (QOQ)

    GLAND, 1,764.45 -2.07
  • 06-Nov-2023 17:29:19

    CIPLA: CO APPROVED TRANSFER OF GENERICS BUSINESS UNDERTAKING AS A GOING CONCERN ON A SLUMP SALE BASIS TO CIPLA PHARMA AND LIFE SCIENCES -- GENERICS BUSINESS UNDERTAKING DEAL FOR 3.5B RUPEES

    CIPLA, 1,477.55 0.04
  • 06-Nov-2023 14:52:59

    MAX HEALTHCARE INSTITUTE: Q2 EBITDA RUPEES 3.87B VS 3.2B (YOY) -- Q2 EBITDA MARGIN 28.42% VS 28.05% (YOY)

    MAXHEALTH, 791.15 -7.09
  • 06-Nov-2023 14:52:42

    MAX HEALTHCARE INSTITUTE: Q2 REVENUE 13.6B RUPEES VS 11.37B (YOY)

    MAXHEALTH, 791.15 -7.09
  • 06-Nov-2023 14:52:12

    MAX HEALTHCARE INSTITUTE: Q2 CONS NET PROFIT 2.77B RUPEES VS 4.57B (YOY)

    MAXHEALTH, 791.15 -7.09
  • 06-Nov-2023 12:31:21

    DIVIS LABORATORIES: Q2 EBITDA 4.8B RUPEES VS 6.2B (YOY); EST 5.71B -- Q2 EBITDA MARGIN 25.09% VS 33.49% (YOY); EST 30.3% - CORRECTION

    DIVISLAB, 3,490.00 -0.81
  • 06-Nov-2023 12:29:26

    DIVIS LABORATORIES: Q2 EBITDA 4.8B RUPEES VS 6.2B (YOY); EST 5.71B -- Q2 EBITDA MARGIN 25.09% VS 33.49% (YOY); EST 13.3%

    DIVISLAB, 3,490.00 -0.81
  • 06-Nov-2023 12:29:22

    DIVIS LABORATORIES: Q2 REVENUE 19.1B RUPEES VS 18.5B (YOY)

    DIVISLAB, 3,490.00 -0.81
  • 06-Nov-2023 12:28:52

    DIVIS LABORATORIES: Q2 CONS NET PROFIT 3.5B RUPEES VS 4.9B (YOY);EST 4.1B

    DIVISLAB, 3,490.00 -0.81
  • 06-Nov-2023 11:27:40

    MARKSANS PHARMA: CO UNIT HAS RECEIVED MARKETING AUTHORISATION FOR THE PRODUCT CYANOCOBALAMIN 50MG FILM COATED TABLETS FROM UK MHRA

    MARKSANS, 151.95 -0.49
  • 06-Nov-2023 11:27:25

    MANKIND PHARMA: Rs 21.65cr NSE Block Trade; for ~124433 shares, at Rs 1740

    MANKIND, 2,138.50 4.14
  • 06-Nov-2023 10:32:58

    NARAYANA HRUDAYALAYA: Rs 15.54cr NSE Block Trade; for ~150894 shares, at Rs 1030

    NH, 1,350.00 -1.05
  • 06-Nov-2023 09:00:43

    STRIDES PHARMA: Rs 44.6cr BSE Block Trade; for ~949000 shares, at Rs 469.97 (PRE-OPEN BLOCK)

    STAR, 784.50 0.25
03 Nov-2023
  • 03-Nov-2023 19:54:57

    INDRAPRASTHA MEDICAL CORP: Q2 EBITDA 505M RUPEES VS 436M (YOY) -- Q2 EBITDA MARGIN 15.93% VS 15.33% (YOY)

    INDRAMEDCO, 180.00 -2.99
  • 03-Nov-2023 19:54:38

    INDRAPRASTHA MEDICAL CORP: Q2 SL NET PROFIT 328M RUPEES VS 251.3M (YOY); 305M (QOQ) -- Q2 REVENUE 3.17B RUPEES VS 2.84B (YOY); 3.06B (QOQ)

    INDRAMEDCO, 180.00 -2.99
  • 03-Nov-2023 14:22:00

    ZYDUS LIFESCIENCES: CO AND LUPIN SIGN LICENSING AGREEMENT FOR CO-MARKETING OF SAROGLITAZAR MG, A CRITICAL TREATMENT FOR CHRONIC LIVER DISEASES IN INDIA

    ZYDUSLIFE, 943.80 1.20
  • 03-Nov-2023 13:55:14

    JAGSONPAL PHARMA: Q2 REVENUE 578M RUPEES VS 605M (YOY)

    JAGSNPHARM, 305.05 0.74
  • 03-Nov-2023 13:54:52

    JAGSONPAL PHARMA: Q2 EBITDA RUPEES 84M VS 129M (YOY) -- Q2 EBITDA MARGIN 14.47% VS 21.32% (YOY)

    JAGSNPHARM, 305.05 0.74
  • 03-Nov-2023 13:54:23

    JAGSONPAL PHARMA: Q2 SL NET PROFIT 75M RUPEES VS 104M (YOY)

    JAGSNPHARM, 305.05 0.74
  • 03-Nov-2023 10:51:04

    MARKSANS PHARMA: CO UNIT RECEIVES ESTABLISHMENT INSPECTION REPORT FROM US FDA -- NO 483 S WERE ISSUED DURING THE AUDIT

    MARKSANS, 151.95 -0.49
02 Nov-2023
  • 02-Nov-2023 19:47:41

    SHILPA MEDICARE: CO ACQUIRED "PILNOVA PHARMA, INC" IN UNITED STATES

    SHILPAMED, 414.80 1.01
  • 02-Nov-2023 16:09:49

    LUPIN: DIAZEPAM RECTAL GEL (RLD DIASTAT® ACUDIALTM) HAD ESTIMATED ANNUAL SALES OF USD 37M IN THE U.S. (IQVIA MAT SEPTEMBER 2023)

    LUPIN, 1,622.05 0.35
  • 02-Nov-2023 16:09:43

    LUPIN: LUPIN LAUNCHES DIAZEPAM RECTAL GEL IN UNITED STATES -- CO SAYS LAUNCH AFTER UNIT RECEIVED APPROVAL FOR ANDA FROM UNITED STATES FOOD AND DRUG ADMINISTRATION

    LUPIN, 1,622.05 0.35
  • 02-Nov-2023 15:20:31

    HIKAL: Q2 REVENUE 4.34B RUPEES VS 5.6B (YOY)

    HIKAL, 281.45 0.43
  • 02-Nov-2023 14:55:09

    HIKAL: Q2 EBITDA 575M RUPEES VS 697M (YOY) -- Q2 EBITDA MARGIN 13.23% VS 12.48% (YOY)

    HIKAL, 281.45 0.43
  • 02-Nov-2023 14:53:35

    HIKAL: Q2 CONS NET PROFIT 126M RUPEES VS 248M (YOY)

    HIKAL, 281.45 0.43
  • 02-Nov-2023 14:27:00

    MOREPEN LABORATORIES: CO APPROVED DIVIDEND OF 3 RUPEES PER SHARE

    MOREPENLAB, 49.45 0.92
  • 02-Nov-2023 14:25:43

    MOREPEN LABORATORIES: Q2 REVENUE 4.2B RUPEES VS 4.02B (YOY)

    MOREPENLAB, 49.45 0.92
  • 02-Nov-2023 14:25:38

    MOREPEN LABORATORIES: Q2 EBITDA 335M RUPEES VS 289M (YOY) -- Q2 EBITDA MARGIN 7.96% VS 7.18% (YOY)

    MOREPENLAB, 49.45 0.92
  • 02-Nov-2023 14:25:15

    MOREPEN LABORATORIES: Q2 CONS NET PROFIT 213M RUPEES VS 158M (YOY)

    MOREPENLAB, 49.45 0.92
  • 02-Nov-2023 13:37:18

    DR. LAL PATH LABS: Q2 EBITDA 1.8B RUPEES VS 1.4B (YOY); EST: 1.55B -- Q2 EBITDA MARGIN 29.57% VS 26.94% (YOY); EST: 26.5%

    LALPATHLAB, 2,350.60 1.62
  • 02-Nov-2023 13:37:16

    DR. LAL PATH LABS: Q2 REVENUE 6B RUPEES VS 5.3B (YOY); EST 5.8B

    LALPATHLAB, 2,350.60 1.62
  • 02-Nov-2023 13:36:53

    DR. LAL PATH LABS: Q2 CONS NET PROFIT 1.1B RUPEES VS 717M (YOY); EST 885M

    LALPATHLAB, 2,350.60 1.62
  • 02-Nov-2023 12:44:15

    LUPIN: CO RECEIVES TENTATIVE APPROVAL FROM U.S. FDA FOR SELEXIPAG FOR INJECTION -- INJECTION HAS US SALES USD 1.1M

    LUPIN, 1,622.05 0.35
  • 02-Nov-2023 12:26:43

    LINCOLN PHARMA: CO MD SAYS CO EXPECT BETTER GROWTH IN Q3 AND Q4, DRIVEN BY NEW PRODUCT LAUNCHES IN BOTH THE DOMESTIC AND EXPORT MARKETS

    LINCOLN, 685.50 -0.33
  • 02-Nov-2023 12:25:12

    LINCOLN PHARMA: CO MD SAYS CO HAS CONTINUED TO EXPERIENCE ROBUST GROWTH ACROSS ALL BUSINESS VERTICALS IN Q2 AND HI FY24, ALL WHILE MAINTAINING NET DEBT-FREE STATUS

    LINCOLN, 685.50 -0.33
  • 02-Nov-2023 12:25:12

    LINCOLN PHARMA: Q2 EBITDA 398M RUPEES VS 346M (YOY) (AS PER CO STATEMENT)

    LINCOLN, 685.50 -0.33
  • 02-Nov-2023 12:22:22

    LINCOLN PHARMA: Q2 EBITDA 311M RUPEES VS 290M (YOY) -- Q2 EBITDA MARGIN 19.96% VS 20.56% (YOY)

    LINCOLN, 685.50 -0.33
  • 02-Nov-2023 12:22:20

    LINCOLN PHARMA: Q2 REVENUE 1.56B RUPEES VS 1.4B (YOY)

    LINCOLN, 685.50 -0.33
  • 02-Nov-2023 12:21:46

    LINCOLN PHARMA: Q2 SL NET PROFIT 276M RUPEES VS 237M (YOY)

    LINCOLN, 685.50 -0.33
  • 02-Nov-2023 10:45:19

    SUNPHARMA: Rs 33.44cr NSE Block Trade; for ~297429 shares, at Rs 1124.45

    SUNPHARMA, 1,579.75 0.37
  • 02-Nov-2023 09:56:16

    ZYDUS LIFESCIENCES: CO AND GUARDANT HEALTH TO JOINTLY PROMOTE THE GUARDANT360 PORTFOLIO OF NEXT-GENERATION GENOMIC TESTS FOR ADVANCED SOLID CANCERS IN INDIA AND NEPAL

    ZYDUSLIFE, 943.80 1.20
  • 02-Nov-2023 09:25:31

    SUN PHARMA ADVANCED: CO IN EXCLUSIVE LICENSE PACT WITH JHU AND IOCB

    SPARC, 365.05 2.96
  • 02-Nov-2023 09:00:44

    NATCO PHARMA: CO ACHIEVES ZERO-OBSERVATION COMPLIANCE IN USFDA PHARMACOVIGILANCE INSPECTION

    NATCOPHARM, 995.00 1.17
01 Nov-2023
  • 01-Nov-2023 20:43:12

    BLISS GVS PHARMA: Q2 EBITDA 544M RUPEES VS 245M (YOY) -- Q2 EBITDA MARGIN 25.66% VS 14.23% (YOY)

    BLISSGVS, 126.45 2.47
  • 01-Nov-2023 20:43:07

    BLISS GVS PHARMA: Q2 CONS NET PROFIT 420M RUPEES VS 138M (YOY); 147M (QOQ) -- Q2 REVENUE 2.12B RUPEES VS 1.72B (YOY); 1.59B (QOQ)

    BLISSGVS, 126.45 2.47
  • 01-Nov-2023 17:52:31

    PFIZER: CO ENTERED INTO AN AGREEMENT TO ASSIGN AND ASSUME LEASE OF MIDC LAND AND SALE OF BUILDING -- LAND ADMEASURING APPROX. 82,000 SQ. MTRS IN THANE, DEAL FOR 2.64B RUPEES

    PFIZER, 4,601.45 0.89
  • 01-Nov-2023 17:49:37

    PFIZER: CO HAS ENTERED INTO AN AGREEMENT TO ASSIGN AND ASSUME THE LEASE OF MIDC LAND

    PFIZER, 4,601.45 0.89
  • 01-Nov-2023 13:46:20

    SUN PHARMA: CO SAYS FORMULATION SALES IN THE US WERE USD 430M RECORDING A GROWTH OF 4.2% OVER Q2 LAST YEAR ACCOUNTING FOR OVER 30% OF TOTAL CONSOLIDATED SALES

    SUNPHARMA, 1,579.75 0.37
  • 01-Nov-2023 13:26:26

    UNICHEM LAB: Q2 REVENUE 4.2B RUPEES VS 3.29B (YOY)

    UNICHEMLAB, 517.95 0.21
  • 01-Nov-2023 13:25:32

    SUN PHARMA INDUSTRIES: Q2 REVENUE 122B RUPEES VS 109B (YOY);EST 120B

    SUNPHARMA, 1,579.75 0.37
  • 01-Nov-2023 13:25:28

    SUN PHARMA INDUSTRIES: Q2 EBITDA RUPEES 31.79B VS 29.5B (YOY); EST 31.47B -- Q2 EBITDA MARGIN 26.08% VS 26.99% (YOY); EST 26.2%

    SUNPHARMA, 1,579.75 0.37
  • 01-Nov-2023 13:24:02

    SUN PHARMA INDUSTRIES: Q2 CONS NET PROFIT 23.8B RUPEES VS 22.6B (YOY); EST 21.87B

    SUNPHARMA, 1,579.75 0.37
  • 01-Nov-2023 13:23:40

    UNICHEM LAB: Q2 EBITDA GAIN RUPEES 87M VS EBITDA LOSS 183M (YOY) -- Q2 EBITDA MARGIN 2.11%

    UNICHEMLAB, 517.95 0.21
  • 01-Nov-2023 13:23:08

    UNICHEM LAB: Q2 CONS NET LOSS 245M RUPEES VS LOSS 707M (YOY)

    UNICHEMLAB, 517.95 0.21
  • 01-Nov-2023 12:51:38

    FORTIS HEALTHCARE: Rs 16.55cr NSE Block Trade; for ~504693 shares, at Rs 327.9

    FORTIS, 408.55 -3.07
  • 01-Nov-2023 11:12:16

    MARKSANS PHARMA: COS NEWLY ACQUIRED MANUFACTURING FACILITY IN VERNA, GOA, HAS PASSED INSPECTION BY GERMAN HEALTH AUTHORITIES WITH NO MAJOR ISSUES, ONLY MINOR RECOMMENDATIONS FOR IMPLEMENTATION

    MARKSANS, 151.95 -0.49
  • 01-Nov-2023 09:29:27

    FORTIS HEALTHCARE: Rs 32.42cr NSE Block Trade; for ~1001385 shares, at Rs 323.75

    FORTIS, 408.55 -3.07
31 Oct-2023
  • 31-Oct-2023 21:15:50

    LUPIN: CO SAYS INSPECTION CLOSED WITH FACILITY RECEIVING AN INSPECTION CLASSIFICATION OF "NO ACTION INDICATED" -- EIR WAS ISSUED POST LAST INSPECTION OF FACILITY CONDUCTED FROM AUGUST 7 TO AUGUST 11, 2023

    LUPIN, 1,622.05 0.35
  • 31-Oct-2023 21:15:42

    LUPIN: CO SAYS RECEIVED ESTABLISHMENT INSPECTION REPORT FROM U.S. FDA FOR COS MANDIDEEP UNIT-2 MANUFACTURING FACILITY

    LUPIN, 1,622.05 0.35
  • 31-Oct-2023 19:13:27

    MANKIND PHARMA: CO APPROVED SCHEME OF AMALGAMATION BETWEEN SHREE JEE LABORATORY, JPR LABS, JASPACK INDUSTRIES WITH CO

    MANKIND, 2,138.50 4.14
  • 31-Oct-2023 19:13:21

    MANKIND PHARMA: Q2 EBITDA 6.83B RUPEES VS 5.91B (YOY) -- Q2 EBITDA MARGIN 25.21% VS 24.35% (YOY)

    MANKIND, 2,138.50 4.14
  • 31-Oct-2023 19:13:13

    MANKIND PHARMA: Q2 CONS NET PROFIT 5.01B RUPEES VS 4.2B (YOY); 4.87B (QOQ) -- Q2 REVENUE 27.1B RUPEES VS 24.3B (YOY); 25.79B (QOQ)

    MANKIND, 2,138.50 4.14
  • 31-Oct-2023 17:39:21

    THYROCARE TECHNOLOGIES: Q2 EBITDA 375.2M RUPEES VS 315.8M (YOY) -- Q2 EBITDA MARGIN 25.35% VS 23.4% (YOY)

    THYROCARE, 696.25 2.24
  • 31-Oct-2023 17:39:08

    THYROCARE TECHNOLOGIES: Q2 CONS NET PROFIT 203.4M RUPEES VS 154M (YOY); 173M (QOQ) -- Q2 REVENUE 1.48B RUPEES VS 1.35B (YOY); 1.35B (QOQ)

    THYROCARE, 696.25 2.24
  • 31-Oct-2023 16:36:02

    KRISHNA INSTITUTE OF MEDICAL SCIENCES: CO ACQUIRED ADDITIONAL EQUITY STAKE OF 6.86% IN UNIT SPANV MEDISEARCH LIFESCIENCES -- CO NOW HOLDS 69.30% STAKE IN SPANV MEDISEARCH LIFESCIENCES

    KIMS, 2,254.35 -1.55
  • 31-Oct-2023 14:19:44

    ZYDUS LIFE: CO TO ACQUIRE LIQMEDS GROUP FOR EURO 68M OR 689 CR RUPEES

    ZYDUSLIFE, 943.80 1.20
  • 31-Oct-2023 14:19:31

    PIRAMAL PHARMA: RS 351.12CR BSE BLOCK TRADE; FOR ~33600000 SHARES, AT RS 104.5 (AVG PRICE)

    PPLPHARMA, 131.75 1.19
  • 31-Oct-2023 13:41:17

    AJANTA PHARMA: Q2 REVENUE 10.28B RUPEES VS 9.38B (YOY)

    AJANTPHARM, 2,232.70 7.08
  • 31-Oct-2023 13:41:11

    AJANTA PHARMA: Q2 CONS NET PROFIT 1.95B RUPEES VS 1.57B (YOY)

    AJANTPHARM, 2,232.70 7.08
  • 31-Oct-2023 13:41:10

    AJANTA PHARMA: Q2 EBITDA RUPEES 2.9B VS 1.96B (YOY) -- Q2 EBITDA MARGIN 28.26% VS 20.9% (YOY)

    AJANTPHARM, 2,232.70 7.08
  • 31-Oct-2023 13:38:43

    MANKIND PHARMA: Rs 18.78cr NSE Block Trade; for ~107337 shares, at Rs 1750

    MANKIND, 2,138.50 4.14
  • 31-Oct-2023 08:53:03

    IPCA LAB: CO SAYS FACILITY CONSIDERED TO BE IN MINIMALLY ACCEPTABLE STATE OF COMPLIANCE WITH REGARD TO CGMP

    IPCALAB, 1,191.35 0.26
  • 31-Oct-2023 08:52:25

    IPCA LAB: COS MANUFACTURING FACILITY AT SEZ INDORE, PITHAMPUR RECEIVED ESTABLISHMENT INSPECTION REPORT -- CO SAYS ESTABLISHMENT INSPECTION REPORT CLASSIFYING MANUFACTURING FACILITY AS VAI

    IPCALAB, 1,191.35 0.26
28 Oct-2023
  • 28-Oct-2023 15:33:01

    PFIZER: Q2 EBITDA 1.8B RUPEES VS 2.31B (YOY) -- Q2 EBITDA MARGIN 31.61% VS 36.26% (YOY)

    PFIZER, 4,601.45 0.89
  • 28-Oct-2023 15:31:20

    PFIZER: Q2 REVENUE 5.75B RUPEES VS 6.37B (YOY); 5.31B (QOQ)

    PFIZER, 4,601.45 0.89
  • 28-Oct-2023 15:30:09

    PFIZER: Q2 SL NET PROFIT 1.48B RUPEES VS 3.11B (YOY); 935M (QOQ)

    PFIZER, 4,601.45 0.89
27 Oct-2023
  • 27-Oct-2023 22:17:27

    PIRAMAL PHARMA: Q2 EBITDA 2.66B RUPEES VS 1.73B (YOY) -- Q2 EBITDA MARGIN 13.9% VS 10.03% (YOY)

    PPLPHARMA, 131.75 1.19
  • 27-Oct-2023 22:17:18

    PIRAMAL PHARMA: Q2 CONS NET PROFIT 50.2M RUPEES VS LOSS 373.4M (YOY); LOSS 985.8M (QOQ) -- Q2 REVENUE 19.11B RUPEES VS 17.2B (YOY); 17.5B (QOQ)

    PPLPHARMA, 131.75 1.19
  • 27-Oct-2023 21:42:10

    SANOFI INDIA: CO ANNOUNCES INTENTION TO SEPARATE THE CONSUMER HEALTHCARE BUSINESS AT THE EARLIEST IN Q4 2024 VIA THE CREATION OF A PUBLICLY LISTED ENTITY HEADQUARTERED IN FRANCE -- CO REITERATES CAPITAL ALLOCATION POLICY AND 2023 BUSINESS EPS GROWTH TARGET, AND PROVIDES PRELIMINARY 2024 AND 2025 OUTLOOK

    SANOFI, 8,611.25 -2.64
  • 27-Oct-2023 21:42:04

    SANOFI INDIA: CO SAYS INCREASES INVESTMENTS IN ITS PIPELINE TO FULLY REALIZE LONG-TERM GROWTH POTENTIAL, BOLSTERED BY SUCCESSFUL LAUNCHES AND R&D PROGRESS -- CO SAYS LAUNCHES STRATEGIC COST INITIATIVES, WITH MOST OF THE SAVINGS TO BE REALLOCATED TO FUND INNOVATION AND GROWTH DRIVERS

    SANOFI, 8,611.25 -2.64
  • 27-Oct-2023 19:03:46

    STRIDES PHARMA SCIENCE: STRIDES ANNOUNCES SALE OF MANUFACTURING FACILITY IN SINGAPORE FOR CONSIDERATION OF $15 MLN

    STAR, 784.50 0.25
  • 27-Oct-2023 15:29:16

    DR.REDDYS LAB: Q2 EBITDA RUPEES 21.8B -- EBITDA MARGIN 31.7% ( AS PER CO STATEMENT)

    DRREDDY, 6,425.55 -0.04
  • 27-Oct-2023 15:27:41

    DR.REDDYS LAB: Q2 EBITDA RUPEES 20.08B VS 1.90B (YOY); EST 19.32B -- Q2 EBITDA MARGIN 29.09% VS 29.99% (YOY); EST 28.3%

    DRREDDY, 6,425.55 -0.04
  • 27-Oct-2023 15:26:15

    DR.REDDYS LAB: Q2 CONS NET PROFIT 14.8B RUPEES VS 11.1B (YOY); EST 12.72B -- Q2 REVENUE 69B RUPEES VS 63.1B (YOY); EST 68.20B

    DRREDDY, 6,425.55 -0.04
  • 27-Oct-2023 14:25:19

    JUBILANT PHARMOVA: Q2 EBITDA RUPEES 2.4B VS 2.2B (YOY) -- Q2 EBITDA MARGIN 14.39% VS 13.68% (YOY)

    JUBLPHARMA, 568.00 1.44
  • 27-Oct-2023 14:24:29

    JUBILANT PHARMOVA: Q2 CONS NET PROFIT 625M RUPEES VS 55M (YOY) -- Q2 REVENUE 16.8B RUPEES VS 15.84B (YOY)

    JUBLPHARMA, 568.00 1.44
  • 27-Oct-2023 13:48:55

    CIPLA: Q2 EBITDA 17.34B RUPEES VS 13.02B (YOY); EST 14.86B -- Q2 EBITDA MARGIN 25.97% VS 22.34% (YOY); EST 23.2%

    CIPLA, 1,477.55 0.04
  • 27-Oct-2023 13:47:57

    CIPLA: Q2 REVENUE RUPEES 67B VS 57.7B (YOY); EST 64.05B

    CIPLA, 1,477.55 0.04
  • 27-Oct-2023 13:47:32

    CIPLA: Q2 CONS NET PROFIT RUPEES 11.3B VS 7.9B (YOY); EST 9.81B

    CIPLA, 1,477.55 0.04
  • 27-Oct-2023 12:28:36

    SHALBY: Q2 EBITDA 527M RUPEES VS 371M (YOY) -- Q2 EBITDA MARGIN 22.14% VS 18.38% (YOY)

    SHALBY, 269.25 -3.67
  • 27-Oct-2023 12:28:11

    SHALBY: Q2 CONS NET PROFIT 276M RUPEES VS 184M (YOY) -- Q2 REVENUE 2.4B RUPEES VS 2B (YOY)

    SHALBY, 269.25 -3.67
  • 27-Oct-2023 12:26:46

    GRANULES: CO TO CONSIDER Q2 RESULTS ON NOV 9

    GRANULES, 464.50 0.98
26 Oct-2023
  • 26-Oct-2023 17:28:04

    KRISHNA INSTITUTE OF MEDICAL SCIENCES: CO ACQUIRED ADDITIONAL EQUITY STAKE OF 5.72% IN SPANV MEDISEARCH LIFESCIENCES -- SPANV MEDISEARCH LIFESCIENCES DEAL FOR 222M RUPEES

    KIMS, 2,254.35 -1.55
  • 26-Oct-2023 15:00:33

    LAURUS LABS: Rs 21.63cr NSE Block Trade; for ~600007 shares, at Rs 360.5

    LAURUSLABS, 407.00 0.48
  • 26-Oct-2023 14:26:02

    LAURUS LABS: Rs 21.47cr NSE Block Trade; for ~604193 shares, at Rs 355.35

    LAURUSLABS, 407.00 0.48
  • 26-Oct-2023 14:20:29

    CIPLA: CO SAYS USFDA INSPECTION AT INVAGEN MANUFACTURING FACILITY IN HAUPPAUGE, NEW YORK CONCLUDED WITH ZERO FORM 483 OBSERVATIONS

    CIPLA, 1,477.55 0.04
  • 26-Oct-2023 14:08:26

    FORTIS HEALTHCARE: Rs 19.65cr NSE Block Trade; for ~614792 shares, at Rs 319.55

    FORTIS, 408.55 -3.07
  • 26-Oct-2023 11:44:10

    J B CHEMICALS: CO SAYS GST DEPARTMENT COMMENCED INSPECTION ON OCT 25 AT CO PREMISES -- CO SAYS BUSINESS OPERATIONS OF CO CONTINUE AS USUAL, OPERATIONS ARE NOT IMPACTED

    JBCHEPHARM, 1,564.45 -2.23
  • 26-Oct-2023 10:44:55

    SYNGENE INTERNATIONAL: Rs 20.41cr NSE Block Trade; for ~301095 shares, at Rs 677.8

    SYNGENE, 706.60 -0.32
  • 26-Oct-2023 10:23:31

    APOLLO HOSPITAL: Rs 15.04cr NSE Block Trade; for ~31327 shares, at Rs 4801

    APOLLOHOSP, 6,102.65 -4.08
  • 26-Oct-2023 10:18:21

    FORTIS HEALTHCARE: Rs 16.7cr NSE Block Trade; for ~519410 shares, at Rs 321.45

    FORTIS, 408.55 -3.07
25 Oct-2023
  • 25-Oct-2023 10:28:45

    LUPIN: CO TO CONSIDER Q2 RESULTS ON NOV.8

    LUPIN, 1,622.05 0.35
  • 25-Oct-2023 09:45:41

    ZYDUS LIFESCIENCES: CO INITIATES PHASE II CLINICAL TRIAL OF ZYIL1, A NOVEL ORAL NLRP3 INFLAMMASOME INHIBITOR IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)

    ZYDUSLIFE, 943.80 1.20
23 Oct-2023
  • 23-Oct-2023 18:20:52

    TORRENT PHARMACEUTICALS: Q2 EBITDA 8.25B RUPEES VS 6.94B (YOY) -- Q2 EBITDA MARGIN 31.02% VS 30.69% (YOY)

    TORNTPHARM, 2,668.55 2.12
  • 23-Oct-2023 18:20:45

    TORRENT PHARMACEUTICALS: Q2 CONS NET PROFIT 3.86B RUPEES VS 3.12B (YOY); 3.78B (QOQ) -- Q2 REVENUE 26.60B RUPEES VS 22.9B (YOY); 25.91B (QOQ)

    TORNTPHARM, 2,668.55 2.12
  • 23-Oct-2023 16:25:25

    LUPIN: CO RECEIVES APPROVAL FROM U.S. FDA FOR FLUCONAZOLE TABLETS, USP -- FLUCONAZOLE TABLETS USP (RLD DIFLUCAN®) HAD ESTIMATED ANNUAL SALES OF USD 43M IN THE U.S. (IQVIA MAT JULY 2023)

    LUPIN, 1,622.05 0.35
  • 23-Oct-2023 16:21:49

    KRISHNA INSTITUTE OF MEDICAL SCIENCES: CO UNIT BUYS ADDITIONAL STAKE OF 12.09% IN KONDAPUR HEALTHCARE -- CO UNIT HOLDS TOTAL 37.18% STAKE IN KONDAPUR HEALTHCARE

    KIMS, 2,254.35 -1.55
  • 23-Oct-2023 13:34:41

    NATCO PHARMA: Rs 40.33cr NSE Block Trade; for ~496837 shares, at Rs 811.65

    NATCOPHARM, 995.00 1.17
  • 23-Oct-2023 12:49:05

    AUROBINDO PHARMA: CO SAYS EUGIA PHARMA RECEIVES USFDA APPROVAL FOR TESTOSTERONE CYPIONATE INJECTION -- INJECTION HAS US SALES OF 227M USD

    AUROPHARMA, 1,028.10 -0.04
  • 23-Oct-2023 12:28:10

    SUPRIYA LIFESCIENCE: CO SIGNS AGREEMENT WITH KALINGA INSTITUTE OF TECHNOLOGY FOR DEVELOPMENT OF NOVEL ORAL CANCER DETECTION KIT

    SUPRIYA, 344.00 0.85
  • 23-Oct-2023 10:02:26

    LAURUS LABS: Rs 15.3cr NSE Block Trade; for ~402395 shares, at Rs 380.3

    LAURUSLABS, 407.00 0.48
  • 23-Oct-2023 09:13:01

    LAURUS LABS: SHARES DOWN 3.2% IN PRE-OPEN TRADE AFTER SEPT-QTR PROFIT FALLS

    LAURUSLABS, 407.00 0.48
20 Oct-2023
  • 20-Oct-2023 18:06:11

    ZYDUS LIFESCIENCES: ZYDUS GETS USFDA APPROVAL FOR ZITUVIO TO TREAT ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS -- CO RECEIVED FINAL APPROVAL FROM THE USFDA FOR ITS NEW DRUG APPLICATION (NDA) FOR ZITUVIOTM (SITAGLIPTIN) TABLETS, 25 MG, 50 MG, AND 100 MG

    ZYDUSLIFE, 943.80 1.20
  • 20-Oct-2023 15:19:08

    LAURUS LABS: CO SAYS IN H1, CO INVESTED A TOTAL OF RUPEES 385 CR CAPEX AND WE ARE ON TRACK TO EXECUTE ON OUR FUTURE CAPEX

    LAURUSLABS, 407.00 0.48
  • 20-Oct-2023 15:16:45

    LAURUS LABS: CO BECAME FIRST STRATEGIC COLLABORATION TO WIN MARKETING APPROVAL FOR INDIA’S FIRST CAR-T THERAPY, NEXCAR19, WHICH IS INNOVATIVE BREAKTHROUGH IN TREATING BLOOD CANCER

    LAURUSLABS, 407.00 0.48
  • 20-Oct-2023 14:57:55

    LAURUS LABS: Q2 CONS NET PROFIT 370M RUPEES VS 2.33B (YOY); EST 1.27B -- Q2 REVENUE 12.2B RUPEES VS 15.8B (YOY); EST 13.72

    LAURUSLABS, 407.00 0.48
  • 20-Oct-2023 14:57:30

    LAURUS LABS: Q2 EBITDA 1.87B RUPEES VS 4.5B (YOY); EST 2.9B -- Q2 EBITDA MARGIN 15.34% VS 28.49% (YOY); EST 21.3%

    LAURUSLABS, 407.00 0.48
  • 20-Oct-2023 14:44:58

    NATCO PHARMA: Rs 73.69cr NSE Block Trade; for ~893122 shares, at Rs 825.1

    NATCOPHARM, 995.00 1.17
  • 20-Oct-2023 13:25:18

    GLENMARK LIFE SCIENCES: CO MD SAYS CONTINUE TO DELIVER REMARKABLE GROWTH, PROPELLED BY A ROBUST GPL BUSINESS AND STEADY EXTERNAL API BUSINESS

    GLS, 869.45 -0.84
  • 20-Oct-2023 13:24:57

    GLENMARK LIFE: CO MD SAYS ENHANCED VISIBILITY TOWARDS THE H2FY24 DEMAND FOR OUR GENERIC API AND CDMO BUSINESS BOLSTERS OUR CONFIDENCE OF DELIVERING GROWTH IN FY24

    GLS, 869.45 -0.84
  • 20-Oct-2023 13:14:10

    GLENMARK LIFE SCIENCES: Q2 SL NET PROFIT 1.2B RUPEES VS 1.1B (YOY) -- Q2 REVENUE 6B RUPEES VS 5.1B (YOY)

    GLS, 869.45 -0.84
  • 20-Oct-2023 13:13:14

    GLENMARK LIFE SCIENCES: Q2 EBITDA 1.67B RUPEES VS 1.4B (YOY) -- Q2 EBITDA MARGIN 28.06% VS 28.2% (YOY)

    GLS, 869.45 -0.84
  • 20-Oct-2023 09:04:47

    METROPOLIS: RS 171.15CR BSE BLOCK TRADE; FOR ~1133537 SHARES, AT RS 1509.88

    METROPOLIS, 1,602.35 -0.19
  • 20-Oct-2023 08:59:11

    AJANTA PHARMA: RS 116.97CR BSE BLOCK TRADE; FOR ~661004 SHARES, AT RS 1769.58

    AJANTPHARM, 2,232.70 7.08
19 Oct-2023
  • 19-Oct-2023 21:55:18

    AMI ORGANICS: INVESTOR ASHISH KACHOLIA DECREASED STAKE FROM 2.13% TO 2.11% IN CO DURING Q2

    AMIORG, 1,112.30 -1.35
  • 19-Oct-2023 20:43:18

    SIGACHI INDUSTRIES: CO SAYS MANUFACTURING FACILITY PLANNED TO BE SET UP IN RIYADH IN ABOUT 3 YEARS

    SIGACHI, 83.50 -0.77
  • 19-Oct-2023 20:43:11

    SIGACHI INDUSTRIES: CO UNIT SIGACHI MENA FZCO FORMS JOINT VENTURE WITH SAUDI NATIONAL PROJECTS INVESTMENT -- SIGACHI MENA FZCO WILL HOLD 75% OF STAKE IN JV WHILE SNP WILL HOLD 25% STAKE

    SIGACHI, 83.50 -0.77
  • 19-Oct-2023 18:18:35

    BAJAJ HEALTHCARE: CO SIGNED MEMORANDUM OF UNDERSTANDING FOR EFFECTING SALE OR DISPOSAL OF VACANT INDUSTRIAL LAND -- CONSIDERATION FOR LAND WILL BE AROUND 95.2M RUPEES

    BAJAJHCARE, 334.95 -6.48
  • 19-Oct-2023 18:14:25

    AARTI DRUGS: CO SAYS CAPEX EXPECTED TO BE IN RANGE OF 2.50B RUPEES TO 3B RUPEES FOR FY24 -- CO SAYS EXPECT GUJARAT SAYAKHA PROJECT, TARAPUR CAPEX ON DERMATOLOGY, SPECIALTY CHEMICAL TO GET COMPLETED BY MID H2 FY24

    AARTIDRUGS, 497.90 -0.56
  • 19-Oct-2023 16:56:33

    NATCO PHARMA: CO SAYS COMPLETION OF AN INSPECTION BY USFDA FOR ITS PHARMA DIVISION LOCATED IN KOTHUR HYDERABAD, INDIA -- FACILITY RECEIVED EIGHT (8) OBSERVATIONS

    NATCOPHARM, 995.00 1.17
  • 19-Oct-2023 16:24:43

    AARTI DRUGS: Q2 EBITDA 764M RUPEES VS 743M (YOY) -- Q2 EBITDA MARGIN 11.92% VS 10.8% (YOY)

    AARTIDRUGS, 497.90 -0.56
  • 19-Oct-2023 16:24:37

    AARTI DRUGS: Q2 CONS NET PROFIT 396M RUPEES VS 388M (YOY) -- Q2 REVENUE 6.41B RUPEES VS 6.88B (YOY)

    AARTIDRUGS, 497.90 -0.56
  • 19-Oct-2023 16:09:30

    INDOCO REMEDIES: CO SAYS PRE-APPROVAL INSPECTION WAS CONDUCTED FOR TWO DRUG PRODUCT APPLICATIONS (ANDAS) FILED FROM FACILITY -- USFDA HAS ISSUED ‘FOUR OBSERVATIONS’ IN FORM 483 AT END OF PRE-APPROVAL INSPECTION

    INDOCO, 349.00 -0.60
  • 19-Oct-2023 16:09:20

    INDOCO REMEDIES: CO SAYS A PRE-APPROVAL INSPECTION WAS CONDUCTED BY USFDA AT CO’S SOLID ORAL FORMULATION FACILITY (PLANT I) LOCATED AT GOA

    INDOCO, 349.00 -0.60
  • 19-Oct-2023 15:23:00

    SOLARA ACTIVE PHARMA: CO APPOINTED MR. P V RAGHAVENDRA RAO AS CFO -- HE COMES FROM SEQUENT SCIENTIFIC LTD & BEFORE THIS, HE WAS AT MACLEODS PHARMACEUTICALS LTD AND DR. REDDYS LABORATORIES LTD

    SOLARA, 440.40 0.76
  • 19-Oct-2023 15:08:10

    BIOCON: KEDAR UPADHYE HAS OVER 23 YEARS OF EXPERIENCE IN SENIOR GLOBAL LEADERSHIP ROLES AT LEADING PHARMA, ENERGY AND FMCG PLAYERS SUCH AS CIPLA, DR. REDDY’S, PEPSICO, AND THERMAX

    BIOCON, 276.45 1.99
  • 19-Oct-2023 15:06:05

    BIOCON : CO APPOINTED KEDAR UPADHYE AS NEW CFO OF BIOCON BIOLOGICS

    BIOCON, 276.45 1.99
  • 19-Oct-2023 12:10:09

    INDOCO REMEDIES: Q2 EBITDA RUPEES 714M VS 879M (YOY) -- Q2 EBITDA MARGIN 14.82% VS 20.29% (YOY)

    INDOCO, 349.00 -0.60
  • 19-Oct-2023 12:09:30

    INDOCO REMEDIES: Q2 CONS NET PROFIT 351M RUPEES VS 497M (YOY) -- Q2 REVENUE 4.8B RUPEES VS 4.3B (YOY)

    INDOCO, 349.00 -0.60
  • 19-Oct-2023 10:49:46

    GRANULES INDIA: CO RECEIVED ANDA APPROVAL FOR ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES -- CAPSULES HAS US SALES OF USD 168M

    GRANULES, 464.50 0.98
  • 19-Oct-2023 10:35:16

    SPARC: CO TO PROVIDE UPDATE ON CLINICAL PROGRAMS AND R&D PIPELINE

    SPARC, 365.05 2.96
  • 19-Oct-2023 10:20:57

    SUNPHARMA: Rs 28.19cr NSE Block Trade; for ~246433 shares, at Rs 1144

    SUNPHARMA, 1,579.75 0.37
  • 19-Oct-2023 09:33:22

    METROPOLIS: Rs 24.91cr NSE Block Trade; for ~168263 shares, at Rs 1480.5

    METROPOLIS, 1,602.35 -0.19
  • 19-Oct-2023 09:16:05

    RPG LIFE SCIENCES: SHARES UP 3.26% IN EARLY TRADE; Q2 NET PROFIT HITS 259 MILLION RUPEES, A 30% INCREASE (YOY) AND 18% (QOQ)

    RPGLIFE, 1,513.95 -1.78
18 Oct-2023
  • 18-Oct-2023 20:58:09

    RPG LIFE SCIENCES: CO SAYS EXECUTION OF POWER DELIVERY AGREEMENT WITH SUNPOUND SOLAR FOR SUPPLY OF ELECTRICITY BY POWER PRODUCER TO CO -- AGREED TO INVEST UPTO 11M RUPEES TO SUBSCRIBE SHARES OF SUNPOUND

    RPGLIFE, 1,513.95 -1.78
  • 18-Oct-2023 20:43:30

    BAJAJ HEALTHCARE LTD - SUCCESSFUL COMMISSIONING OF ALKALOID EXTRACTION PLANT IN VADODARA -- WITH THE COMMISSIONING OF THIS PLANT, CO HAS EXPANDED THE CAPACITY ALMOST THREE TIMES AND IS POISED FOR A NEW PHASE OF GROWTH AND COMMITTED TO DELIVERING TOP-QUALITY PRODUCTS

    BAJAJHCARE, 334.95 -6.48
  • 18-Oct-2023 20:40:12

    RPG LIFE SCIENCES: Q2 EBITDA 373M RUPEES VS 297M (YOY) -- Q2 EBITDA MARGIN 24.28% VS 22.06% (YOY)

    RPGLIFE, 1,513.95 -1.78
  • 18-Oct-2023 20:40:07

    RPG LIFE SCIENCES: Q2 SL NET PROFIT 259M RUPEES VS 199M (YOY); 221M (QOQ) -- Q2 REVENUE 1.54B RUPEES VS 1.34B (YOY); 1.48B (QOQ)

    RPGLIFE, 1,513.95 -1.78
  • 18-Oct-2023 10:28:17

    PFIZER: Rs 40.27cr NSE Block Trade; for ~100685 shares, at Rs 4000

    PFIZER, 4,601.45 0.89
  • 18-Oct-2023 09:29:48

    CIPLA: Rs 39.66cr NSE Block Trade; for ~332468 shares, at Rs 1193

    CIPLA, 1,477.55 0.04
  • 18-Oct-2023 09:02:46

    GLENMARK PHARMA: CO IS FIRST TO LAUNCH A TRIPLE-DRUG FDC OF TENELIGLIPTIN + DAPAGLIFLOZIN + METFORMIN IN INDIA FOR TYPE 2 DIABETES IN ADULTS WITH CO-MORBIDITIES

    GLENMARK, 925.95 1.62
  • 18-Oct-2023 08:59:07

    BIOCON: U.S. FDA INSPECTION AT BIOCON BIOLOGICS’ MANUFACTURING FACILITY IN JOHOR, MALAYSIA -- THE FDA HAS DETERMINED THE INSPECTION CLASSIFICATION AS “OAI” (OFFICIAL ACTION INDICATED)

    BIOCON, 276.45 1.99
17 Oct-2023
  • 17-Oct-2023 20:11:46

    TORRENT PHARMA: SEBI EXEMPTS FAMILY TRUSTS LINKED TO TORRENT POWER, TORRENT PHARMA, GUJARAT LEASE FINANCING FROM OPEN OFFER REQUIREMENTS - MONEY CONTROL

    TORNTPHARM, 2,668.55 2.12
  • 17-Oct-2023 19:45:58

    SYNGENE INTERNATIONAL: Q2 EBITDA 2.54B RUPEES VS 2.2B (YOY) -- Q2 EBITDA MARGIN 27.92% VS 28.19% (YOY)

    SYNGENE, 706.60 -0.32
  • 17-Oct-2023 19:45:52

    SYNGENE INTERNATIONAL: Q2 CONS NET PROFIT 1.16B RUPEES VS 1B (YOY); 934M (QOQ) -- Q2 REVENUE 9.10B RUPEES VS 7.7B (YOY); 7.16B (QOQ)

    SYNGENE, 706.60 -0.32
  • 17-Oct-2023 13:46:35

    SHILPA MEDICARE: CO SAYS CO TO REGISTER AND MARKET ITS PRODUCTS IN AUSTRALIA AND OTHER REST OF WORLD MARKETS WHICH RECOGNIZE AUSTRALIAN GMP

    SHILPAMED, 414.80 1.01
  • 17-Oct-2023 13:45:39

    SHILPA MEDICARE: CO UNIT IV JEDCHERLA, TELANGANA HAS CLEARED TGA AUSTRALIA GMP INSPECTION

    SHILPAMED, 414.80 1.01
  • 17-Oct-2023 12:46:49

    GLAND PHARMA: Rs 45.23cr NSE Block Trade; for ~285539 shares, at Rs 1584

    GLAND, 1,764.45 -2.07
  • 17-Oct-2023 10:35:58

    SYNGENE INTERNATIONAL: Rs 27.12cr NSE Block Trade; for ~348194 shares, at Rs 779

    SYNGENE, 706.60 -0.32
  • 17-Oct-2023 10:22:48

    FORTIS HEALTHCARE: Rs 16.92cr NSE Block Trade; for ~503361 shares, at Rs 336.05

    FORTIS, 408.55 -3.07
  • 17-Oct-2023 09:07:33

    GLENMARK PHARMA: CO RECEIVES ANDA APPROVAL FOR APREMILAST TABLETS -- TABLETS HAS US SALES OF 3.7B USD

    GLENMARK, 925.95 1.62
16 Oct-2023
  • 16-Oct-2023 19:54:57

    LUPIN: CO SIGNS BUSINESS TRANSFER AGREEMENT WITH UNIT TO CARVE OUT TWO API MANUFACTURING SITES

    LUPIN, 1,622.05 0.35
  • 16-Oct-2023 16:52:50

    PIRAMAL PHARMA: PIRAMAL PHARMA SOLUTIONS LAUNCHES IN-VITRO BIOLOGY CAPABILITIES AT AHMEDABAD DISCOVERY SERVICES SITE

    PPLPHARMA, 131.75 1.19
  • 16-Oct-2023 11:51:15

    AUROBINDO PHARMA: CO INAUGURATED GREEN-FIELD MANUFACTURING UNIT OF EUGIA STERILES PRIVATE LIMITED

    AUROPHARMA, 1,028.10 -0.04
  • 16-Oct-2023 11:09:01

    SUN PHARMA: CO SAYS POSITIVE RESULTS FROM THE PHASE III PIVOTAL TRIAL IN PATIENTS WITH LOCALLY ADVANCED FULLY RESECTABLE MELANOMA

    SUNPHARMA, 1,579.75 0.37
  • 16-Oct-2023 10:14:09

    SYNGENE INTERNATIONAL: Rs 7.79cr NSE Block Trade; for ~100000 shares, at Rs 778.6

    SYNGENE, 706.60 -0.32
13 Oct-2023
  • 13-Oct-2023 20:33:51

    ZYDUS LIFESCIENCES: ZYDUS UNIT RECALLS 7,248 BOTTLES OF OXYBUTYNIN CHLORIDE TABLETS IN U.S.- BQ PRIME

    ZYDUSLIFE, 943.80 1.20
  • 13-Oct-2023 19:17:15

    BAJAJ HEALTHCARE: CO ANNOUNCES THE SUCCESSFULLY COMPLETION OF CONSTRUCTION OF ALKALOID EXTRACTION PLANT AT VADODARA, GUJARAT UNIT

    BAJAJHCARE, 334.95 -6.48
  • 13-Oct-2023 18:49:12

    SUN PHARMACEUTICAL INDUSTRIES: BOARD MEETING ON NOV 1 TO CONSIDER Q2 RESULTS

    SUNPHARMA, 1,579.75 0.37
  • 13-Oct-2023 18:38:28

    GLENMARK LIFE SCIENCES: BOARD MEETING ON OCT 20 TO CONSIDER Q2 RESULTS

    GLS, 869.45 -0.84
  • 13-Oct-2023 16:54:33

    MANKIND PHARMA: CO SAYS RESUMPTION OF OPERATIONS AT COMPANYS MANUFACTURING FACILITY AT SIKKIM -- CO SAYS NO MAJOR DISRUPTION IN SUPPLY CHAIN DUE TO SIKKIM PLANT CLOSURE; MANUFACTURING OF PRODUCTS HAD BEEN DIVERTED TO OTHER PLANTS

    MANKIND, 2,138.50 4.14
  • 13-Oct-2023 16:46:22

    LAURUS LABS: CO SAYS GOT APPROVAL FOR NEXCAR19, FOR TREATMENT OF R/R B-CELL LYMPHOMAS, LEUKEMIA

    LAURUSLABS, 407.00 0.48
  • 13-Oct-2023 16:45:53

    LAURUS LABS: CO SAYS ASSOCIATE CO RECEIVED APPROVAL OF CAR-T CELL THERAPY, NEXCAR19 FROM CENTRAL DRUGS STANDARD CONTROL ORGANIZATION

    LAURUSLABS, 407.00 0.48
  • 13-Oct-2023 15:17:08

    LUPIN: CO RECEIVES TENTATIVE APPROVAL FROM U.S. FDA FOR APALUTAMIDE TABLETS -- TABLETS HAS US SALES OF USD 1185.5M

    LUPIN, 1,622.05 0.35
  • 13-Oct-2023 15:08:09

    LAURUS LABS: CO TO CONSIDER Q2 RESULT ON OCT. 20

    LAURUSLABS, 407.00 0.48
  • 13-Oct-2023 13:34:59

    FORTIS HEALTHCARE: Rs 51.03cr NSE Block Trade; for ~1509210 shares, at Rs 338.1

    FORTIS, 408.55 -3.07
12 Oct-2023
  • 12-Oct-2023 22:29:08

    ASTRAZENECA PHARMA INDIA: KARNATAKA GOVT SIGNS MOU WITH ASTRAZENECA INDIA TO ACCELERATE LUNG CANCER TESTING

    ASTRAZEN, 5,535.50 0.42
  • 12-Oct-2023 21:48:06

    PANACEA BIOTEC: CO UNIT PBPL WAS ISSUED A ‘FDA FORM 483’ WITH NINE (9) OBSERVATIONS WHICH ARE RELATED TO IMPROVEMENTS IN EXISTING PROCEDURES AND ARE ADDRESSABLE -- CO UNIT PBPL WILL RESPOND TO THE US FDA WITHIN THE STIPULATED TIME AND WORK CLOSELY WITH US FDA TO CLOSE THE SAID OBSERVATIONS

    PANACEABIO, 152.40 0.33
  • 12-Oct-2023 21:47:55

    PANACEA BIOTEC: USFDA CONDUCTED AN INSPECTION OF THE CO UNIT PANACEA BIOTEC PHARMA LTD (PBPL) AT BADDI, HIMACHAL PRADESH, BETWEEN OCT 03, 2023 AND OCT 12, 2023

    PANACEABIO, 152.40 0.33
  • 12-Oct-2023 21:41:45

    LUPIN: CO SAYS NET PRODUCT SALES FOR CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES ORAL SOLUTION (RLD XYWAV®) WERE USD 958.4M FOR THE YEAR ENDING DEC 2022 AND USD 604.3M FOR THE FIRST SIX MONTHS OF 2023

    LUPIN, 1,622.05 0.35
  • 12-Oct-2023 21:41:18

    LUPIN: CO RECEIVES TENTATIVE APPROVAL FROM U.S. FDA FOR CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES ORAL SOLUTION

    LUPIN, 1,622.05 0.35
  • 12-Oct-2023 21:05:35

    NEULAND LABORATORIES: INVESTOR MUKUL MAHAVIR AGRAWAL DECREASED STAKE FROM 3.29% TO 3.12% IN CO DURING Q2

    NEULANDLAB, 7,149.90 0.67
  • 12-Oct-2023 18:57:36

    DR REDDYS LABORATORIES: CO ISSUED A FORM 483 WITH NINE OBSERVATIONS, WHICH WE WILL ADDRESS WITHIN STIPULATED TIMELINE -- US FDA COMPLETED PRODUCT- SPECIFIC PRE-APPROVAL INSPECTION AT BACHUPALLY FACILITY

    DRREDDY, 6,425.55 -0.04
  • 12-Oct-2023 18:19:17

    AARTI DRUGS: BOARD MEETING ON OCT 19 TO CONSIDER Q2 RESULTS

    AARTIDRUGS, 497.90 -0.56
  • 12-Oct-2023 16:36:45

    SUN PHARMA: CEQUA® (CYCLOSPORINE OPHTHALMIC SOLUTION) 0.09% PHASE 4 DATA SHOWED SUSTAINED IMPROVEMENT IN DRY EYE DISEASE SIGNS AND SYMPTOMS IN PATIENTS SWITCHED FROM RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION) 0.05%

    SUNPHARMA, 1,579.75 0.37
  • 12-Oct-2023 14:24:11

    FORTIS HEALTHCARE: Rs 37.11cr NSE Block Trade; for ~1107663 shares, at Rs 335

    FORTIS, 408.55 -3.07
  • 12-Oct-2023 12:34:53

    HIKAL: Rs 17cr BSE Block Trade; for ~600566 shares, at Rs 283

    HIKAL, 281.45 0.43
  • 12-Oct-2023 09:16:09

    CIPLA: SHARES UP 1.03% IN EARLY TRADE; CO. RECEIVES EIR FROM USFDA FOR VOLUNTARY ACTION INDICATED CLASSIFICATION AT INVAGEN MANUFACTURING FACILITY IN LONG ISLAND, NY, USA

    CIPLA, 1,477.55 0.04
  • 12-Oct-2023 09:15:21

    SHILPA MEDICARE: SHARES UP 2.18% IN EARLY TRADE; CO. RECEIVES APPROVAL TO MANUFACTURE AND SELL ORAL MUCOSITIS SPRAY FROM THE DIRECTORATE OF AYURVEDA AND UNANI SERVICES

    SHILPAMED, 414.80 1.01
  • 12-Oct-2023 09:04:49

    GLENMARK PHARMA: ICHNOS SCIENCES ENTERS LICENSING AGREEMENT FOR OX40 ANTAGONIST MONOCLONAL ANTIBODY PORTFOLIO WITH ASTRIA THERAPEUTICS

    GLENMARK, 925.95 1.62
11 Oct-2023
  • 11-Oct-2023 21:54:55

    SUVEN PHARMA: BERHYANDA TO BUY 26% STAKE IN SUVEN PHARMACEUTICALS THROUGH OPEN OFFER -- PRICE DETERMINED FOR THE OPEN OFFER IS RS 495 APIECE, WHICH AGGREGATES TO RS 3,276.3 CRORE (CORRECTION)

    SUVENPHAR, 631.05 -1.80
  • 11-Oct-2023 21:27:25

    RPG LIFE SCIENCES: BOARD MEETING ON OCT 18 TO CONSIDER Q2 RESULT

    RPGLIFE, 1,513.95 -1.78
  • 11-Oct-2023 21:27:06

    NEULAND LABORATORIES: BOARD MEETING ON NOV 7 TO CONSIDER Q2 RESULT

    NEULANDLAB, 7,149.90 0.67
  • 11-Oct-2023 20:47:43

    SUVEN PHARMA: BERHYANDA TO BUY 26% STAKE IN SUVEN PHARMACEUTICALS THROUGH OPEN OFFER -- PRICE DETERMINED FOR THE OPEN OFFER IS RS 495 APIECE, WHICH AGGREGATES TO RS 32,763 CRORE - BQ PRIME

    SUVENPHAR, 631.05 -1.80
  • 11-Oct-2023 19:21:09

    SHILPA MEDICARE: CO SAYS RECEIVED APPROVAL FROM OFFICE OF DIRECTORATE OF AYURVEDA AND UNANI SERVICES -- RECEIVED APPROVAL FOR MANUFACTURE AND SALE OF ORAL MUCOSITIS SPRAY

    SHILPAMED, 414.80 1.01
  • 11-Oct-2023 17:53:35

    AUROBINDO PHARMA: CO UNIT CURATEQ BIOLOGICS AND ITS UNITS IN DISCUSSIONS WITH MERCK SHARP & DOHME SINGAPORE TRADING, ITS AFFILIATES FOR CMO OPERATIONS

    AUROPHARMA, 1,028.10 -0.04
  • 11-Oct-2023 17:50:34

    CIPLA: CO SAYS UPDATE ON USFDA INSPECTION AT INVAGEN MANUFACTURING FACILITY IN CENTRAL ISLIP, LONG ISLAND, NY, USA -- CO RECEIVED EIR FROM USFDA ON CLASSIFICATION OF INSPECTION AS VOLUNTARY ACTION INDICATED

    CIPLA, 1,477.55 0.04
  • 11-Oct-2023 16:35:25

    ASTER DM HEALTHCARE: BLACKSTONE, KKR ALSO EYEING ASTER’S INDIA ASSETS, DEAL OPTIONS -- POTENTIAL SUITORS COULD ALSO CONSIDER BUYING ENTIRE COMPANY - BBG

    ASTERDM, 471.55 -2.74
  • 11-Oct-2023 16:29:22

    ASTER DM HEALTHCARE: ASTER’S INDIA UNIT DRAWS SUITORS VALUING BUSINESS AT $1.5B - BBG

    ASTERDM, 471.55 -2.74
  • 11-Oct-2023 14:00:31

    SUN PHARMA: Rs 31.1cr NSE Block Trade; for ~276883 shares, at Rs 1123.05

    SUNPHARMA, 1,579.75 0.37
  • 11-Oct-2023 10:25:19

    ALKEM LAB: Rs 26.98cr NSE Block Trade; for ~75048 shares, at Rs 3595

    ALKEM, 5,138.55 2.97
  • 11-Oct-2023 09:49:48

    GLAND PHARMA: Rs 88.53cr NSE Block Trade; for ~541468 shares, at Rs 1635

    GLAND, 1,764.45 -2.07
10 Oct-2023
  • 10-Oct-2023 15:29:41

    MAX HEALTHCARE: Rs 59.23cr NSE Block Trade; for ~1068299 shares, at Rs 554.4

    MAXHEALTH, 791.15 -7.09
  • 10-Oct-2023 09:11:54

    AARTI DRUGS: ANTI-DUMPING INVESTIGATION CONCERNING IMPORTS OF " METRONIDAZOLE” ORIGINATING IN OR EXPORTED FROM CHINA PR

    AARTIDRUGS, 497.90 -0.56
09 Oct-2023
  • 09-Oct-2023 20:24:17

    DR REDDYS LABORATORIES: COMPLAINT FILED BY MAYO CLINIC AND LIFEPOINT CORPORATE SERVICES -- DEFENDANTS IMPROPERLY RESTRAINED COMPETITION, MAINTAINED SHARED MONOPOLY IN BRAND, GENERIC REVLIMID SALES

    DRREDDY, 6,425.55 -0.04
  • 09-Oct-2023 20:24:01

    DR REDDYS LABORATORIES: CO MAINTAINS THAT ALLEGATIONS AGAINST IT LACK MERIT AND WILL VIGOROUSLY DEFEND THE LITIGATION

    DRREDDY, 6,425.55 -0.04
  • 09-Oct-2023 20:23:54

    DR REDDYS LABORATORIES: COMPLAINT ALLEGES IMPROPERLY LIMITED GENERIC COMPETITION THROUGH 2026 -- COMPLAINT SEEKS DAMAGES FOR PURPORTED OVERPAYMENTS, EQUITABLE RELIEF

    DRREDDY, 6,425.55 -0.04
  • 09-Oct-2023 20:23:47

    DR REDDYS LABORATORIES: COS UNIT NAMED AS DEFENDANT IN COMPLAINT IN US DISTRICT COURT FOR NORTHERN DISTRICT OF CALIFORNIA -- COMPLAINT ALLEGES THAT CHALLENGED AGREEMENTS IMPROPERLY DELAYED GENERIC ENTRY ENTIRELY UNTIL 2022

    DRREDDY, 6,425.55 -0.04
  • 09-Oct-2023 18:11:09

    GLENMARK LIFE SCIENCES: CO SAYS RECORD DATE FOR THE SAID INTERIM DIVIDEND HAS BEEN FIXED ON OCT 17, 2023 -- SHAREHOLDERS OF CO WILL RECEIVE THE AFOREMENTIONED INTERIM DIVIDEND FOR FY24 ON OR AFTER OCT 23, 2023

    GLS, 869.45 -0.84
  • 09-Oct-2023 16:36:22

    GLENMARK LIFE SCIENCES: CO SAYS INTERIM EQUITY DIVIDEND FOR FY 2023-24 OF 22.50 RUPEES PER SHARE

    GLS, 869.45 -0.84
  • 09-Oct-2023 14:01:52

    DIVIS LAB: Rs 44.38cr NSE Block Trade; for ~119979 shares, at Rs 3699

    DIVISLAB, 3,490.00 -0.81
  • 09-Oct-2023 10:41:10

    AMI ORGANICS: CO DECLARED FINAL DIVIDEND OF RUPEES 3 PER SHARE

    AMIORG, 1,112.30 -1.35
  • 09-Oct-2023 09:19:02

    SUN PHARMA: SHARES DOWN 1.05% IN EARLY TRADE; CO. OWNS A SIGNIFICANT STAKE IN ISRAELS TARO PHARMACEUTICAL

    SUNPHARMA, 1,579.75 0.37
  • 09-Oct-2023 09:07:49

    BIOCON: CO SAYS DECISION HAS NO IMPACT ON MANUFACTURING OR DISTRIBUTION OF COMPANYS EXISTING COMMERCIAL PORTFOLIO

    BIOCON, 276.45 1.99
  • 09-Oct-2023 09:06:29

    BIOCON: CO SAYS FDA DIDNT IDENTIFY ANY OUTSTANDING SCIENTIFIC ISSUES

    BIOCON, 276.45 1.99
  • 09-Oct-2023 09:05:47

    BIOCON: CO UNIT RECEIVES COMPLETE RESPONSE LETTER FROM US FDA FOR BIOSIMILAR INSULIN ASPART

    BIOCON, 276.45 1.99
07 Oct-2023
  • 07-Oct-2023 14:22:20

    FORTIS HEALTHCARE: CO SAYS MR. JOERG AYRLE STEPS DOWN AS NON-EXECUTIVE DIRECTOR

    FORTIS, 408.55 -3.07
06 Oct-2023
  • 06-Oct-2023 20:14:53

    ASTER DM HEALTHCARE: CO UNIT ENTERED INTO LEASE AGREEMENT FOR SETTING UP OF HOSPITAL BLOCK, EXPAND ASTER WHITEFIELD HOSPITAL, BENGALURU

    ASTERDM, 471.55 -2.74
  • 06-Oct-2023 19:39:32

    METROPOLIS HEALTHCARE: CO SAYS SEPT QTR CORE BUSINESS REVENUE GREW BY 13% (YOY)

    METROPOLIS, 1,602.35 -0.19
  • 06-Oct-2023 16:25:52

    BIOCON: CO WILL BE RESPONSIBLE FOR OBTAINING REGULATORY NOD FOR LIRAGLUTIDE AND FOR MANUFACTURE AND SUPPLY OF PRODUCT IN CANADIAN MARKET

    BIOCON, 276.45 1.99
  • 06-Oct-2023 16:25:45

    BIOCON: CO SIGNS COMMERCIALIZATION AGREEMENT WITH JUNO PHARMACEUTICALS IN CANADA -- DEAL FOR COMMERCIALIZATION OF ITS VERTICALLY INTEGRATED, COMPLEX FORMULATION, LIRAGLUTIDE

    BIOCON, 276.45 1.99
  • 06-Oct-2023 14:59:39

    SYNGENE INT: CO TO CONSIDER Q2 RESULT ON OCT 17

    SYNGENE, 706.60 -0.32
  • 06-Oct-2023 14:39:23

    ZYDUS LIFESCIENCES: CO RECEIVES FINAL APPROVAL FORM THE USFDA FOR SUGAMMADEX INJECTION -- IT HAS US SALES USD 986 M

    ZYDUSLIFE, 943.80 1.20
  • 06-Oct-2023 13:14:58

    MAX HEALTHCARE: Rs 30.88cr NSE Block Trade; for ~551956 shares, at Rs 559.4

    MAXHEALTH, 791.15 -7.09
  • 06-Oct-2023 12:08:56

    ALEMBIC PHARMA: Rs 42.65cr NSE Block Trade; for ~550222 shares, at Rs 775.15

    APLLTD, 1,017.90 -1.05
  • 06-Oct-2023 11:35:26

    ALKEM LAB: Rs 18.5cr NSE Block Trade; for ~52847 shares, at Rs 3500

    ALKEM, 5,138.55 2.97
  • 06-Oct-2023 11:29:18

    APOLLO HOSPITAL: Rs 25.63cr NSE Block Trade; for ~50739 shares, at Rs 5051.2

    APOLLOHOSP, 6,102.65 -4.08
  • 06-Oct-2023 10:30:21

    APOLLO HOSPITAL: Rs 17.8cr NSE Block Trade; for ~35367 shares, at Rs 5034.15

    APOLLOHOSP, 6,102.65 -4.08
  • 06-Oct-2023 09:24:56

    STRIDES PHARMA: Rs 52.88cr BSE Block Trade; for ~1050223 shares, at Rs 503.55

    STAR, 784.50 0.25
  • 06-Oct-2023 09:23:30

    STRIDES PHARMA: Rs 18.96cr BSE Block Trade; for ~378839 shares, at Rs 500.5

    STAR, 784.50 0.25
  • 06-Oct-2023 09:07:48

    SUN PHARMA: CO ANNOUNCES US FDA FILING ACCEPTANCE OF NDA FOR DEURUXOLITINIB

    SUNPHARMA, 1,579.75 0.37
05 Oct-2023
  • 05-Oct-2023 20:59:38

    PANACEA BIOTEC: CO SAYS REQUEST FOR ARBITRATION FILED BY APOTEX, BASED OUT OF CANADA -- ARBITRATION FOR DISPUTE BETWEEN THE PARTIES

    PANACEABIO, 152.40 0.33
  • 05-Oct-2023 20:59:30

    PANACEA BIOTEC: CO GOT NOTIFICATION FROM INTERNATIONAL COURT OF ARBITRATION, PARIS -- NOTIFICATION ABOUT ARBITRATION PROCEEDING BEING COMMENCED

    PANACEABIO, 152.40 0.33
  • 05-Oct-2023 19:53:40

    SUN PHARMA: CO EXECUTED AN ADDITIONAL AGREEMENT TO ACQUIRE FURTHER 4.04% EQUITY SHARES OF AGATSA SOFTWARE -- EZERX DEAL FOR 286.9M RUPEES

    SUNPHARMA, 1,579.75 0.37
  • 05-Oct-2023 19:53:29

    SUN PHARMA: CO TO ACQUIRE EQUITY SHARES OF EZERX HEALTH TECH -- CO ENTERED INTO AN AGREEMENT TO ACQUIRE 37.76% EQUITY SHAREHOLDING OF EZERX

    SUNPHARMA, 1,579.75 0.37
  • 05-Oct-2023 17:53:13

    GLENMARK PHARMACEUTICALS: CO TO SEEK SHAREHOLDERS NOD FOR SALE OF EQUITY SHARES OF GLENMARK LIFE SCIENCES

    GLENMARK, 925.95 1.62
  • 05-Oct-2023 17:12:23

    LUPIN: CO RECEIVES TENTATIVE APPROVAL FROM U.S. FDA FOR TOLVAPTAN TABLETS -- TOLVAPTAN TABLETS (RLD JYNARQUE®) HAD ESTIMATED ANNUAL SALES OF USD 287M IN THE U.S. (IQVIA MAT AUGUST 2023)

    LUPIN, 1,622.05 0.35
  • 05-Oct-2023 13:23:33

    FORTIS HEALTHARE: Rs 22.71cr NSE Block Trade; for ~683085 shares, at Rs 332.4

    FORTIS, 408.55 -3.07
  • 05-Oct-2023 10:26:41

    CIPLA: Rs 20.64cr NSE Block Trade; for ~177015 shares, at Rs 1165.8

    CIPLA, 1,477.55 0.04
  • 05-Oct-2023 10:26:00

    TORRENT PHARMA: Rs 27.78cr NSE Block Trade; for ~150383 shares, at Rs 1847.55

    TORNTPHARM, 2,668.55 2.12
04 Oct-2023
  • 04-Oct-2023 20:09:10

    GLENMARK LIFE SCIENCES: BOARD MEETING ON OCT 9 TO CONSIDER AND APPROVE DECLARATION OF INTERIM DIVIDEND, IF ANY

    GLS, 869.45 -0.84
  • 04-Oct-2023 18:02:59

    LUPIN: HARMONY BIOSCIENCES - ON SEPT 28, RECEIVED NOTICE FROM NOVUGEN PHARMA & LUPIN SEEKING APPROVAL TO MANUFACTURE, SELL A GENERIC VERSION OF WAKIX IN US -- HARMONY BIOSCIENCES HOLDINGS INC - CURRENTLY REVIEWING NOTICES & INTENDS TO VIGOROUSLY DEFEND ITS INTELLECTUAL PROPERTY RIGHTS PROTECTING WAKIX

    LUPIN, 1,622.05 0.35
  • 04-Oct-2023 16:58:08

    HEALTHCARE GLOBAL ENTERPRISES: CO SAYS COMPLETION OF ACQUISITION OF ONCOLOGY AND RADIATION BUSINESS FROM SRJ HEALTH CARE PVT LTD, AND AMRISH ONCOLOGY SERVICES PVT LTD, INDORE, BY THE CO, ON A SLUMP SALE BASIS

    HCG, 361.75 -0.65
  • 04-Oct-2023 15:19:00

    STRIDES PHARMA: CO RECIEVES USFDA APPROVAL FOR EFAVIRENZ, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMURATE TABLET -- IT HAS US SALES OF USD 7.5M

    STAR, 784.50 0.25
  • 04-Oct-2023 14:36:22

    AJANTA PHARMA: Rs 20.92cr NSE Block Trade; for ~119385 shares, at Rs 1752.1

    AJANTPHARM, 2,232.70 7.08
  • 04-Oct-2023 11:08:57

    JB CHEMICAL: Rs 17.34cr NSE Block Trade; for ~115191 shares, at Rs 1505.7

    JBCHEPHARM, 1,564.45 -2.23
  • 04-Oct-2023 11:06:21

    GLENMARK PHARMA: FITCH AFFIRMS CO AT BB; OUTLOOK STABLE

    GLENMARK, 925.95 1.62
  • 04-Oct-2023 03:02:54

    Azurity Pharms., Inc. v. Alkem Labs. Ltd. Firvanq® (Vancomycin) - JD Supra

    ALKEM, 5,138.55 2.97
03 Oct-2023
  • 03-Oct-2023 19:51:25

    Strides Pharma arm gets USFDA nod for triglyceride tamer icosapent ethyl capsules - CNBCTV18

    STAR, 784.50 0.25
  • 03-Oct-2023 18:10:07

    Strides Pharma arms gains USFDA nod for triglyceride tamer icosapent ethyl capsules - CNBCTV18

    STAR, 784.50 0.25
  • 03-Oct-2023 17:57:08

    Strides Pharma Science gets USFDA nod for generic capsule to control triglyceride level - ETHealthWorld

    STAR, 784.50 0.25
  • 03-Oct-2023 16:18:53

    Strides Pharma Science gets USFDA nod for generic capsule to control triglyceride level - NewsDrum

    STAR, 784.50 0.25
  • 03-Oct-2023 16:13:55

    STRIDES PHARMA SCIENCE: CO RECEIVES USFDA APPROVAL FOR ICOSAPENT ETHYL CAPSULES -- ICOSAPENT ETHYL CAPSULES HAS A MARKET SIZE OF ~USD 1.3B PER IQVIA

    STAR, 784.50 0.25
  • 03-Oct-2023 16:01:09

    Khaitan advises Menarini in the divestment of 5 legacy brands to Lupin - Bar & Bench - Indian Legal News

    LUPIN, 1,622.05 0.35
  • 03-Oct-2023 16:00:31

    Why Glenmark Pharma Share Price is Rising - Equitymaster

    GLENMARK, 925.95 1.62
  • 03-Oct-2023 15:17:01

    LUPIN: CO LAUNCHES HUMRAHI - UNIQUE PATIENT SUPPORT PROGRAM FOR DIABETES MANAGEMENT

    LUPIN, 1,622.05 0.35
  • 03-Oct-2023 15:09:31

    JB CHEMICAL: Rs 19.52cr NSE Block Trade; for ~130059 shares, at Rs 1501.1

    JBCHEPHARM, 1,564.45 -2.23
  • 03-Oct-2023 14:20:00

    Following a USFDA inspection of a Telangana unit, Aurobindo Pharma is down 2% - Indiainfoline

    AUROPHARMA, 1,028.10 -0.04
  • 03-Oct-2023 12:18:02

    CIPLA: Rs 35.56cr NSE Block Trade; for ~300283 shares, at Rs 1184.3

    CIPLA, 1,477.55 0.04
  • 03-Oct-2023 11:11:12

    MARKSANS PHARMA: CO GETS US FDA APPROVAL FOR ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES

    MARKSANS, 151.95 -0.49
  • 03-Oct-2023 10:35:00

    Fortis Healthcare subsidiary files IPO, boosting parent company ... - Investing.com

    FORTIS, 408.55 -3.07
  • 03-Oct-2023 10:23:39

    AstraZeneca India falls 0.6% despite a new CFO and nod to drug imports - Moneycontrol

    ASTRAZEN, 5,535.50 0.42
  • 03-Oct-2023 10:05:36

    Fortis Healthcare shares gain as after subsidiary files draft IPO papers - Moneycontrol

    FORTIS, 408.55 -3.07
  • 03-Oct-2023 09:38:14

    Granules India gets USFDA approval for hypertension drug; share price gains - Moneycontrol

    GRANULES, 464.50 0.98
  • 03-Oct-2023 09:04:56

    Stocks to Watch: Auto stocks, Cipla, Fortis, Aurobindo, JSW Infra ... - Share Price India News

    FORTIS, 408.55 -3.07
02 Oct-2023
  • 02-Oct-2023 18:00:32

    ALEMBIC PHARMA: CO SAYS HAS RECEIVED VARIOUS US FOOD & DRUG ADMINISTRATION (USFDA) PRODUCT APPROVALS DURING THE QUARTER ENDED 30TH SEPT, 2023

    APLLTD, 1,017.90 -1.05
  • 02-Oct-2023 15:27:56

    Breakout Stocks: How are Eris Lifesciences, Aurobindo Pharma and ... - msnNOW

    ERIS, 883.75 1.31

Download Our App On: